Original Article
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
N Engl J Med 2006; 355:2408-2417December 7, 2006
- Abstract
Background
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.
Methods
We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.
Results
The median follow-up was 60 months. Kaplan–Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events.
Conclusions
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343.)
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Cumulative Best Response to Initial Imatinib Therapy.Figure 2
Kaplan–Meier Estimates of the Rates of Event-free Survival and Progression to the Accelerated Phase or Blast Crisis of CML for Patients Receiving Imatinib.Article Activity
- Article
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the expansion of a clone of hematopoietic cells that carries the Philadelphia chromosome (Ph).1 The Ph chromosome results from a reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11).2 The molecular consequence of this translocation is a novel fusion gene, BCR-ABL, which encodes a constitutively active protein, tyrosine kinase.3-5 Imatinib (Gleevec, Novartis; formerly called STI571) is a relatively specific inhibitor of the BCR-ABL tyrosine kinase and has efficacy in CML.6-11
Before the availability of imatinib, interferon alfa plus cytarabine was considered standard therapy for patients with CML who were not planning to undergo allogeneic hematopoietic stem-cell transplantation.12,13 A randomized trial that compared imatinib with interferon alfa plus cytarabine in the chronic phase of CML demonstrated the significant superiority of imatinib in all standard indicators of the disease within a median follow-up of 19 months.14 The trial was designed as a crossover study, and given the superior results with imatinib, a large proportion of patients in the interferon group switched to imatinib. In addition, at the time of Food and Drug Administration approval of imatinib, many patients who were assigned to receive interferon alfa plus cytarabine left the study. Consequently, the trial has evolved into a long-term study of the result of treating newly diagnosed patients in the chronic phase of CML with imatinib. We now report 60 months of follow-up data and focus on patients who received imatinib as a primary treatment.
Methods
Study Design
The design of the study has been described previously.14 The International Randomized Study of Interferon and STI571 (IRIS) was a multicenter, international, open-label, phase III randomized study. Eligible patients had to be between 18 and 70 years of age, must have been diagnosed with Ph-positive CML in chronic phase within 6 months before study entry, and must not have received treatment for CML, except for hydroxyurea or anagrelide.
Patients were recruited from June 2000 through January 2001 and were randomly assigned to receive imatinib at a dose of 400 mg orally per day or subcutaneous interferon alfa at a daily target dose of 5 million U per square meter of body-surface area, plus 10-day cycles of cytarabine at a daily dose of 20 mg per square meter every month. Patients receiving imatinib who did not have a complete hematologic response within 3 months or whose bone marrow contained more than 65% Ph-positive cells at 12 months could have a stepwise increase in the dose of imatinib to 400 mg orally twice daily as long as there were no dose-limiting adverse events. Patients were allowed to cross over to the other treatment group if they did not achieve either a complete hematologic response after 6 months of therapy or a major cytogenetic response after 12 months or if they had a relapse or an increase in white-cell count or could not tolerate treatment. All crossover requests were made anonymously and considered weekly by the study management committee (see the Appendix).
End Points
The primary end point was event-free survival, which was referred to in previous presentations and articles as the time to progression, or progression-free survival. Events were defined by the first occurrence of any of the following: death from any cause during treatment, progression to the accelerated phase or blast crisis of CML, or loss of a complete hematologic or major cytogenetic response. Secondary end points were the rate of complete hematologic response (defined as a leukocyte count <10×109 per liter, a platelet count of <450×109 per liter, <5% myelocytes plus metamyelocytes, no blasts or promyelocytes, no extramedullary involvement, and no signs of the accelerated phase or blast crisis of CML); a cytogenetic response in marrow cells, categorized as complete (no Ph-positive metaphases), partial (1 to 35% Ph-positive metaphases), or major (complete plus partial responses) on the basis of G-banding in at least 20 cells in metaphase per sample; progression to the accelerated phase or blast crisis; overall survival; safety; and tolerability. Signs of a molecular response were sought every 3 months after a complete cytogenetic response was obtained with the use of real-time quantitative polymerase chain reaction to measure the ratio of BCR-ABL transcripts to BCR transcripts. Results were expressed as “log reductions” below a standardized baseline derived from a median ratio of BCR-ABL to BCR obtained from 30 untreated patients with chronic-phase CML.15
Ethics and Study Management
The study was conducted in accordance with the Declaration of Helsinki. The study protocol was reviewed by the ethics committee or institutional review board at each participating center. All patients gave written informed consent, according to institutional regulations. The academic investigators and representatives of the sponsor, Novartis, designed the study. Data-management and statistical-support staff at a contract research organization collected the data, which were analyzed and interpreted by a biostatistician from Novartis in close collaboration with the investigators. The study management committee and all academic investigators had access to the raw data. The study management committee, composed of four academic investigators, served as the writing committee. Along with the Novartis biostatistician, they vouch for the accuracy and completeness of the data.
Statistical Analysis
The study is ongoing, but January 31, 2006, was the cutoff date for this analysis. This date marked 5 to 5.5 years after patients started to receive imatinib treatment. We followed all 553 patients who were assigned to receive imatinib for an analysis of safety and efficacy until they stopped taking imatinib, and we have continued to follow all patients until death, loss to follow-up, or withdrawal of consent. Survival data were also collected on patients who underwent bone marrow transplantation after imatinib treatment. We performed analyses of survival and event-free survival, using the Kaplan–Meier method according to the intention-to-treat principle and using all data available, regardless of whether crossover occurred. Differences between subgroups of patients receiving imatinib were calculated by the log-rank test. Cumulative rates of complete hematologic and cytogenetic responses were estimated according to the Kaplan–Meier method, in which data from patients receiving imatinib who did not have an adequate response, who had switched to interferon alfa plus cytarabine, or who had discontinued treatment for reasons other than progression of CML were censored at the last follow-up visit. For the estimation of cumulative response rates, we censored data from patients with progressive CML at maximum follow-up. We used the life-table method to determine yearly event probabilities. The safety of imatinib was analyzed for 551 patients who received at least one dose of the study drug during the trial. For the 553 patients assigned to receive interferon alfa plus cytarabine, disposition and overall survival were summarized.
Results
Patients
Five years after the last of 1106 patients had started treatment, and with a median of 60 months of follow-up, 382 of 553 patients (69%) in the imatinib group and 16 of 553 patients (3%) in the group given interferon alfa plus cytarabine continued with their initially assigned treatment (Table 1Table 1
Enrollment, Outcomes, and Reasons for Crossover and Discontinuation.). Of the patients given interferon plus cytarabine, 359 (65%) had crossed over to imatinib, whereas 14 patients (3%) in the imatinib group had switched to the alternative treatment. The most common reason for crossover among patients given interferon plus cytarabine was intolerance of treatment (26%). Of these patients, 90 (16%) switched because they did not achieve a complete hematologic or major cytogenetic response by the designated target dates, as did 77 patients (14%) with disease progression. An additional 178 patients (32%) given interferon alfa plus cytarabine discontinued therapy. The reasons most commonly reported were withdrawal of consent (14%) and adverse events (6%). In the imatinib group, 23 patients (4%) discontinued therapy owing to an adverse event, and 25 patients (5%) withdrew consent (Table 1).Since few patients were still receiving interferon alfa plus cytarabine at 60 months, the remainder of this report focuses on the long-term follow-up of patients who received imatinib as the initial therapy for CML. They had been treated with imatinib for a mean (±SD) of 50±19 months (median, 60 months). Among the 382 patients who continued receiving imatinib, the mean daily dose during this reporting period was 382±50 mg. In 82% of these patients, the last reported daily dose was 400 mg; 6% were receiving 600 mg, 4% were receiving 800 mg, and 8% were receiving less than 400 mg.
Adverse Events
After a median follow-up of 60 months, the adverse events reported were similar to those reported previously.14 The most commonly reported adverse events were edema (including peripheral and periorbital edema) (60%), muscle cramps (49%), diarrhea (45%), nausea (50%), musculoskeletal pain (47%), rash and other skin problems (40%), abdominal pain (37%), fatigue (39%), joint pain (31%), and headache (37%). Grade 3 or 4 adverse events consisted of neutropenia (17%), thrombocytopenia (9%), anemia (4%), elevated liver enzymes (5%), and other drug-related adverse events (17%). Congestive heart failure was reported as being drug-related in one patient (<1%). Newly occurring or worsening grade 3 or 4 hematologic or biochemical adverse events were infrequent after both 2 and 4 years of therapy (Table 2Table 2
Proportion of Patients Receiving First-Line Imatinib Therapy with Grade 3 or Grade 4 Adverse Events.).Efficacy
Figure 1Figure 1
Kaplan–Meier Estimates of the Cumulative Best Response to Initial Imatinib Therapy. shows the estimated cumulative rates of complete hematologic remission: 96% at 12 months and 98% at 60 months. The best observed rate of complete hematologic response was 97%. At 12 months, the estimated rate of major cytogenic response was 85% and that of complete cytogenetic response was 69%. At 60 months, the estimated rates were 92% and 87%, respectively. With a median follow-up of 60 months, the best observed rate of major cytogenetic response was 89%, and the best rate of complete cytogenetic response was 82%. Of the 382 patients who still received imatinib at 60 months, 368 (96%) had a complete cytogenetic response.There were significant differences in the rates of cytogenetic response, according to a scoring system devised by Sokal and colleagues,16 which divides patients with CML into low-risk, intermediate-risk, and high-risk groups. In patients who were deemed to be at low risk on the Sokal scoring system, the rate of complete cytogenetic response was 89%; the rate among patients at intermediate risk was 82%; and for those at high risk, the rate was 69% (P<0.001).
Among 124 patients who had a complete cytogenetic response and whose blood samples taken at 1 and 4 years were available, BCR-ABL transcripts in the blood samples were measured. After 1 year, levels of BCR-ABL transcripts had fallen by at least 3 log in 66 of 124 patients (53%); after 4 years, levels had fallen in 99 of 124 patients (80%) (P<0.001). The proportion of patients with a reduction of at least 4 log in transcript levels increased from 22 to 41% between 1 and 4 years (P<0.001). The median log reduction of BCR-ABL transcripts was 3.08 at 1 year and 3.78 at 4 years (P<0.001).
Long-Term Outcomes
At 60 months, the estimated rate of event-free survival was 83% (95% confidence interval [CI], 79 to 87), and an estimated 93% of patients (95% CI, 90 to 96) had not progressed to the accelerated phase or blast crisis (Figure 2Figure 2
Kaplan–Meier Estimates of the Rates of Event-free Survival and Progression to the Accelerated Phase or Blast Crisis of CML for Patients Receiving Imatinib.). Of the 553 patients receiving imatinib, 35 (6%) progressed to the accelerated phase or blast crisis, 14 (3%) had a hematologic relapse, 28 (5%) had a loss of major cytogenetic response, and 9 (2%) died from a cause unrelated to CML. The estimated annual rate of treatment failure after the start of imatinib therapy was 3.3% in the first year, 7.5% in the second year, 4.8% in the third year, 1.5% in the fourth year, and 0.9% in the fifth year. The corresponding annual rates of progression to the accelerated phase or blast crisis were 1.5%, 2.8%, 1.6%, 0.9%, and 0.6%, respectively. In the 454 patients who had a complete cytogenetic response, the annual rates of treatment failure were 5.5% in the first year, 2.3% in the second year, 1.1% in the third year, and 0.4% in the fourth year after a response was achieved. The corresponding annual rates of progression to the accelerated phase or blast crisis were 2.1%, 0.8%, 0.3%, and 0%, respectively, in these patients.Effect of Response on Outcome
Cytogenetic and molecular responses had significant associations with event-free survival and deterrence against progression to the accelerated phase or blast crisis (Figure 3Figure 3
Rate of Progression to the Accelerated Phase or Blast Crisis on the Basis of Cytogenetic Response after 12 Months or Molecular Response after 18 Months of Imatinib Therapy.). A landmark analysis of the 350 patients who had had a complete cytogenetic response at 12 months after the initiation of imatinib treatment revealed that at 60 months, 97% of the patients (95% CI, 94 to 99) had not progressed to the accelerated phase or blast crisis. For the 86 patients with a partial cytogenetic response, the estimate was 93% (95% CI, 87 to 99); for the 73 patients who did not have a major cytogenetic response within 12 months, the estimate was 81% (95% CI, 70 to 92) (overall, P<0.001; P<0.001 for the comparison between patients with a complete response and those without a complete response, and P=0.20 for the comparison between patients with a complete response and those with a partial response) (Figure 3A).At 60 months, the estimated risk of disease progression was significantly higher for the high-risk group of patients, according to the Sokal scoring system (P=0.002); the estimated rates for patients in the high-risk, intermediate-risk, and low-risk groups were 17%, 8%, and 3%, respectively. However, the Sokal score was not associated with disease progression in patients who had a complete cytogenetic response (95%, 95%, and 99% in the high-risk, intermediate-risk, and low-risk groups, respectively) (P=0.20 overall; P=0.92 for the comparison between the intermediate-risk group and the high-risk group, and P=0.16 for the comparison between the low-risk group and the high-risk group).
The molecular responses at 12 and 18 months were also associated with long-term outcomes. At 60 months, the patients who had a complete cytogenetic response and a reduction of at least 3 log in levels of BCR-ABL transcripts in bone marrow cells after 18 months of treatment had an estimated rate of survival without progression of CML of 100%. In the group with a reduction of less than 3 log in levels of BCR-ABL transcripts, the estimated rate was 98% (P=0.11). However, in the absence of a complete cytogenetic response, the rate was 87% (P<0.001) (Figure 3B). No patient who had a complete cytogenetic response and reduction of at least 3 log in levels of Bcr-Abl transcripts at 12 months had progressed to the accelerated phase or blast crisis at 60 months.
Overall Survival
By the cutoff date for this analysis, 57 patients (10%) who received imatinib had died; 5 of these patients had switched to interferon alfa plus cytarabine. The estimated overall survival rate at 60 months was 89% (95% CI, 86 to 92) (Figure 4Figure 4
Overall Survival among Patients Treated with Imatinib Based on an Intention-to-Treat Analysis.). Allogeneic hematopoietic stem-cell transplantation was carried out in 44 patients who discontinued imatinib: 11 had progressed to the accelerated phase or blast crisis, 15 had had a hematologic or cytogenetic relapse, and 18 had stopped therapy for other reasons (including safety and withdrawal of consent). Of the 44 patients who underwent transplantation, 14 (32%) died. At 60 months, with data censored at the time of transplantation, the estimated overall survival rate was 92% (95% CI, 89 to 95). After data were censored for patients who had died from causes unrelated to CML or transplantation, the overall estimated survival rate was 95% (95% CI, 93 to 98) at 60 months (Figure 4).Discussion
The initial analysis of this study, performed at a median follow-up of 19 months, showed a high rate of response and an acceptable rate of side effects of imatinib as initial therapy for newly diagnosed chronic-phase CML.14 The present analysis, with a median follow-up of 60 months, showed an estimated relapse rate of 17% at 60 months, and an estimated 7% of all patients progressed to the accelerated phase or blast crisis. The 5-year estimated overall survival rate for patients who received imatinib as initial therapy (89%) is higher than that reported in any previously published prospective study of the treatment of CML.17
This trial allowed patients to cross over to the alternate treatment, and most patients in the interferon group either switched to imatinib or discontinued interferon. On the basis of an intention-to-treat analysis, there was no significant difference in overall survival between the group of patients who began their treatment with interferon and those who began their treatment with imatinib (data not shown). Previous randomized studies of interferon alfa plus cytarabine, performed before the availability of imatinib, showed a 5-year overall survival of 68 to 70%.12,13 With the use of historical comparisons, a survival advantage for initial therapy with imatinib over interferon alfa can be demonstrated.18
In a landmark analysis, 97% of patients with a complete cytogenetic response within 12 months after starting imatinib did not progress to the accelerated phase or blast crisis by 60 months. Notably, patients who were deemed to be at high risk on the basis of Sokal scores had a lower rate of complete cytogenetic response (69%) than did patients who were at low risk or intermediate risk (89% and 82%, respectively). However, the risk of relapse in patients who had a cytogenetic response was not associated with the Sokal score. With interferon treatment, by contrast, the Sokal score was important even among patients with a complete cytogenetic response.19
Remarkably, no patient who had a complete cytogenetic response and a reduction in levels of BCR-ABL transcripts of at least 3 log at 12 or 18 months after starting imatinib had progression of CML by 60 months. Only 2% of patients who had a complete cytogenetic response and a reduction in levels of BCR-ABL transcripts of less than 3 log at 18 months had progressed to the accelerated phase or blast crisis at 60 months.
It is currently recommended that imatinib therapy be continued indefinitely. Anecdotal reports suggest that the discontinuation of imatinib, even in patients with undectectable levels of BCR-ABL transcripts, results in relapse.20-24 Although it is not known why imatinib is not able to eradicate the malignant clone, potential mechanisms include drug efflux25 and amplification or mutation of the BCR-ABL gene.26 It is also possible that imatinib cannot completely inhibit BCR-ABL kinase activity; low levels of activity would allow cells to survive but not proliferate. As an alternative, the malignant clone could persist through mechanisms that are independent of the BCR-ABL kinase.27
Initial studies of two new inhibitors of the BCR-ABL kinase that are more potent than imatinib — dasatinib and nilotinib — showed high response rates in patients who had had a relapse during imatinib therapy.28,29 Despite their potency, these inhibitors cannot eradicate all CML cells in vitro.30 As was the case in patients in our study, it is assumed that in patients receiving these drugs a durable response can be achieved even without disease eradication if there is a reduction in levels of BCR-ABL transcripts of at least 3 log.
Notably, the rate of disease progression in patients in our study is apparently trending downward, although the trend has not reached statistical significance. If it persists, such a trend would be consistent with the findings that mutations in the BCR-ABL gene are the major cause of relapse in patients treated with imatinib.31 If we presume that mutations precede imatinib therapy (as the data suggest),32,33 the emergence of resistance to the drug would depend on the size of the mutant clone at the start of therapy and its doubling time. Since most mutated and unmutated BCR-ABL clones have similar doubling times,34 a patient with a mutant clone should be at highest risk for relapse during the first several years of therapy. This prediction is in line with the apparent downward trend in the risk of disease progression observed in our study.
Dr. Druker's institution is the site of clinical trials sponsored by Novartis, but neither he nor his laboratory reports receiving funds from Novartis. Dr. Guilhot reports receiving consulting and lecture fees from Novartis; Dr. O'Brien, consulting fees from Novartis and Bristol-Myers Squibb and lecture fees from Novartis; Ms. Gathmann, being an employee of and having equity ownership in Novartis; Dr. Kantarjian, consulting fees from Novartis, Bristol-Myers Squibb, and MGI Pharma; Dr. Gattermann, consulting and lecture fees from Novartis and Pharmion; Dr. Deininger, consulting and lecture fees from Novartis and Bristol-Myers Squibb; Dr. Silver, consulting fees from Novartis; Dr. Goldman, lecture fees from Novartis; Dr. Stone, consulting and lecture fees and grant support from Novartis and Bristol-Myers Squibb; Dr. Cervantes, consulting fees from Novartis and lecture fees from Novartis and Bristol-Myers Squibb; Dr. Hochhaus, consulting and lecture fees from Novartis and Bristol-Myers Squibb; Dr. Powell, lecture fees from Pharmion; Dr. Gabrilove, consulting fees from Novartis; Dr. Rousselot, lecture fees from Novartis Oncology; Dr. Cornelissen, consulting fees from Novartis Oncology; Dr. Hughes, consulting and lecture fees from Novartis; Dr. Fischer, consulting fees from LymphoSign and Novartis and lecture fees from Novartis; Dr. Saglio, consulting and lecture fees from Novartis; Dr. Gratwohl, consulting fees from Novartis, Pfizer, and Amgen and lecture fees from Novartis; Dr. Radich, consulting fees from Novartis and Bristol-Myers Squibb and lecture fees from Novartis; Dr. Simonsson, consulting fees from Novartis and Bristol-Myers Squibb; Dr. Taylor, consulting fees from Amgen, Novartis, Bristol-Myers Squibb, and Celgene and lecture fees from Novartis; Dr. Baccarani, consulting fees from Novartis, Bristol-Myers Squibb, Merck, and Pfizer and lecture fees from Novartis, Bristol-Myers Squibb, Schering, and Pfizer; Dr. So, being an employee of Novartis and having equity ownership in Novartis and Pfizer; Dr. Letvak, being an employee of and having equity ownership in Novartis; and Dr. Larson, consulting and lecture fees from Novartis. No other potential conflict of interest relevant to this article was reported.
We thank the coinvestigators; the members of the medical, nursing, and research staff at the trial centers; the clinical trial monitors and the data managers and programmers at Novartis for their contributions; and Tillman Krahnke and Manisha Mone for their invaluable collaboration.
Source Information
From the Oregon Health and Science University Cancer Institute, Portland (B.J.D.); Centre Hospitalier Universitaire, Poitiers, France (F.G.); University of Newcastle, Newcastle, United Kingdom (S.G.O.); Novartis, Basel, Switzerland (I.G.); M.D. Anderson Cancer Center, Houston (H.K.); Heinrich Heine University, Dusseldorf, Germany (N.G.); Universität Leipzig, Leipzig, Germany (M.W.N.D.); Weill–Cornell Medical Center, New York (R.T.S.); National Heart, Lung, and Blood Institute, Bethesda, MD (J.M.G.); Dana–Farber Cancer Institute, Boston (R.M.S.); Hospital Clinic I Provincial, Barcelona (F.C.); University of Heidelberg, Mannheim, Germany (A.H.); Wake Forest University Baptist Medical Center, Winston-Salem, NC (B.L.P.); Mount Sinai School of Medicine, New York (J.L.G.); Hôpital Saint Louis, Paris (P.R.); Centre Hospitalier Universitaire de Bordeaux, Pessac, France (J.R.); Erasmus Medical Center, Rotterdam, the Netherlands (J.J.C.); Royal Adelaide Hospital, Adelaide, Australia (T.H.); Universitätsklinik für Innere Medizin I, Vienna (H.A.); Johannes Gutenberg Universität, Mainz, Germany (T.F.); University Hospital Gasthuisberg, Leuven, Belgium (G.V.); Vancouver Hospital, Vancouver, BC, Canada (J.S.); Azienda Ospedaliera S. Luigi Gonzaga, Orbassano, Italy (G.S.); University Hospital Basel, Switzerland (A.G.); Aarhus Amtssygehus, Aarhus, Denmark (J.L.N.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Akademiska Sjukhuset, Uppsala, Sweden (B.S.); Mater Hospital, Brisbane, Australia (K.T.); Policlinico S. Orsola–Malpighi, Bologna, Italy (M.B.); Novartis, Florham Park, NJ (C.S., L.L.); and University of Chicago, Chicago (R.A.L.).
Address reprint requests to Dr. Druker at the Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, or at drukerb@ohsu.edu.
Investigators in the International Randomized Study of Interferon and STI571 (IRIS) are listed in the Appendix.
Appendix
The following investigators participated in IRIS: Australia — Royal Brisbane Hospital, Herston: S. Durrant; Monash Medical Centre, Melbourne: A. Schwarer; Sir Charles Gairdner Hospital, Perth: D. Joske; Australian Leukemia and Lymphoma Group, Melbourne: J. Seymour; Royal Melbourne Hospital, Parkville: A. Grigg; St. Vincent's Hospital, Darlinghurst: D. Ma; Royal North Shore Hospital, St. Leonards: C. Arthur; Westmead Hospital, Westmead: K. Bradstock; Royal Prince Alfred Hospital, Sydney: D. Joshua. Belgium — A.Z. Sint-Jan, Brugge: A. Louwagie; Institut Jules Bordet, Brussels: P. Martiat; Cliniques Universitaires, Yvoir: A. Bosly. Canada — McGill University, Montreal: C. Shustik; Princess Margaret Hospital, Toronto: J. Lipton; Queen Elizabeth II Health Sciences Centre, Halifax, NS: D. Forrest; McMaster University Medical Centre, West Hamilton, ON: I. Walker; Université de Montréal, Montreal: D.-C. Roy; CancerCare Manitoba, Winnipeg: M. Rubinger; Ottawa Hospital Regional Cancer Centre, Ottawa: I. Bence-Bruckler; University of Calgary and Tom Baker Cancer Centre, Calgary, AB: D. Stewart; London Regional Cancer Centre, London, ON: M. Kovacs; Cross Cancer Center, Edmonton, AB: A.R. Turner. Denmark — Kobenhavns Amts Sygehus i Gentofte, Hellerup: H. Birgens; Danish University of Pharmaceutical Sciences and University of Southern Denmark, Copenhagen: O. Bjerrum. France — Hôpital Claude Huriez, Lille: T. Facon; Hôtel Dieu Hospital, Nantes: J.-L. Harousseau; Henri Mondor Hospital, Creteil: M. Tulliez; Centre Hospitalier Universitaire (CHU) Brabois, Vandoeuvre-les-Nancy: A. Guerci; Institut Paoli-Calmettes, Marseille: D. Blaise; Hopital Civil, Strasbourg: F. Maloisel; CHU la Milétrie, Poitiers: M. Michallet. Germany — University of Regensburg, Regensburg: R. Andreesen; Krankenhaus Muenchen Schwabing, Munich: C. Nerl; Universitätsklinikum Rostock, Rostock: M. Freund; Heinrich Heine University, Düsseldorf: N. Gattermann; Carl-Gustav Carus Universität, Dresden: G. Ehninger; Leipzig University Hospital, Leipzig: M. Deininger; Medizinische Klinik III, Frankfurt: O. Ottmann; Clinical Center Rechts der Isar, Munich: C. Peschel; University of Heidelberg, Heidelberg: S. Fruehauf; Philipps-Universität Marburg, Baldingerstraße, Marburg: A. Neubauer; Humboldt Universität, Berlin: P. Le Coutre; Robert Bosch Hospital, Stuttgart: W. Aulitzky. Italy — University Hospital, Udine: R. Fanin; San Orsola Hospital, Bologna: G. Rosti; Università La Sapienza, Rome: F. Mandelli; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia: M. Lazzarino; Niguarda Ca' Granda Hospital, Milan: E. Morra; Azienda Ospedaliera e Cliniche Universitarie San Martino, Largo R Benzi, Genoa: A. Carella; University of Pisa, Pisa: M. Petrini; Azienda Ospedaliera Bianchi-Malacrino-Morelli, Reggio Calabria: F. Nobile; University of Bari, Policlinico, Bari: V. Liso; Cardarelli Hospital, Naples: F. Ferrara; University of Parma, Parma: V. Rizzoli; Ospedale Civile, Pescara: G. Fioritoni; Institute of Hematology and Medical Oncology Seragnoli, Bologna: G. Martinelli; Università degli Studi di Firenze, Florence: V. Santini. the Netherlands — Vrije Universiteit Academic Medical Center, Amsterdam: G. Ossenkoppele. New Zealand — University of Auckland, Auckland: P. Browett. Norway — Medisinsk Avdeling, Rikshospitalet, Oslo: T. Gedde-Dahl; Ullevål Sykehus, Oslo: J.-M. Tangen; Hvidovre Hospital, Betalende: I. Dahl. Spain — Hospital Clinic, Villarroel, Barcelona: J. Odriozola; University of Barcelona, Barcelona: J.C. Hernández Boluda; Hospital Universitario de la Princesa, Madrid: J.L. Steegman; Hospital Universitario de Salamanca, Salamanca: C. Cañizo; San Carlos Clinical Hospital, Madrid: J. Diaz; Institut Català d'Oncología, Barcelona: A. Granena; Hospital Lluis Alcanyis, Cta Xativa-Silla: M.N. Fernández. Sweden — Karolinska Hospital, Stockholm: L. Stenke; Huddinge Sjukhus, Huddinge: C. Paul; Medicinkliniken Universitetssjukhuset, Örebro: M. Bjoreman; Regionsjukhuset, Linköping: C. Malm; Sahlgrenska Hospital, Göteborg: H. Wadenvik; Endokrinsekt/Medklin Universitetssjukhuset, Lund: P.-G. Nilsson; Universitetssjukhuset Malmo University Hospital, Malmo: I. Turesson. Switzerland — Kantonsspital, St. Gallen: U. Hess; University of Bern, Bern: M. Solenthaler. United Kingdom — University of Nottingham and Nottingham City Hospital, Nottingham: N. Russell; Kings College, London: G. Mufti; St. George's Hospital, Medical School, London: J. Cavenagh; Royal Liverpool University Hospital, Liverpool: R.E. Clark; Cambridge Institute for Medical Research, Cambridge: A.R. Green; Glasgow Royal Infirmary, Glasgow: T.L. Holyoake; Manchester Royal Infirmary, Manchester: G.S. Lucas; Leeds General Infirmary, Leeds: G. Smith; Queen Elizabeth Hospital, Edgbaston, Birmingham: D.W. Milligan; Derriford Hospital, Plymouth: S.J. Rule; University Hospital of Wales, Cardiff: A.K. Burnett; United States — Walt Disney Memorial Cancer Institute, Orlando, FL: R. Moroose; Roswell Park Cancer Center, Buffalo, NY: M. Wetzler; Gibbs Cancer Center, Spartanburg, SC: J. Bearden; Ohio State University School of Medicine, Columbus: S. Cataland; University of New Mexico Health Sciences Center, Albuquerque: I. Rabinowitz; University of Maryland Cancer Center, Baltimore: B. Meisenberg; Montgomery Cancer Center, Montgomery, AL: K. Thompson; State University of New York Upstate Medical Center, Syracuse: S. Graziano; University of Alabama at Birmingham, Birmingham: P. Emanuel; Hematology and Oncology, Inc., Dayton, OH: H. Gross; Billings Oncology Associates, Billings, MT: P. Cobb; City of Hope National Medical Center, Duarte, CA: R. Bhatia; Cancer Center of Kansas, Wichita: S. Dakhil; Alta Bates Comprehensive Cancer Center, Berkeley, CA: D. Irwin; Cancer Research Center of Hawaii, Honolulu: B. Issell; University of Nebraska Medical Center, Omaha: S. Pavletic; Columbus Community Clinical Oncology Program, Columbus, OH: P. Kuebler; Michigan State University Hematology/Oncology, Lansing: E. Layhe; Brown University School of Medicine, Providence, RI: P. Butera; Loyola University Medical Center, Shreveport, LA: J. Glass; Duke University Medical Center, Durham, NC: J. Moore; University of Vermont, Burlington: B. Grant; University of Tennessee, Memphis: H. Niell; University of Louisville Hospital, Louisville, KY: R. Herzig; Sarah Cannon Cancer Center, Nashville: H. Burris; University of Minnesota, Minneapolis: B. Peterson; Cleveland Clinic Foundation, Cleveland: M. Kalaycio; Fred Hutchinson Cancer Research Center, Seattle: D. Stirewalt; University of Utah, Salt Lake City: W. Samlowski; Memorial Sloan-Kettering Cancer Center, New York: E. Berman; University of North Carolina School of Medicine, Charlotte: S. Limentani; Atlanta Cancer Center, Atlanta: T. Seay; University of North Carolina School of Medicine, Chapel Hill: T. Shea; Indiana Blood and Marrow Institute, Beech Grove: L. Akard; San Juan Regional Cancer Center, Farmington, NM: G. Smith; University of Massachusetts Memorial Medical Center, Worcester: P. Becker; Washington University School of Medicine, St. Louis: S. Devine; Veterans Affairs Medical Center, Milwaukee: R. Hart; Louisiana State University Medical Center, New Orleans: R. Veith; Decatur Memorial Hospital, Decatur, IL: J. Wade; Rocky Mountain Cancer Centers, Denver: M. Brunvand; Oncology-Hematology Group of South Florida, Miami: L. Kalman; Memphis Cancer Center, Memphis, TN: D. Strickland; Henry Ford Hospital, Detroit: M. Shurafa; University of California, San Diego, Medical Center, La Jolla: A. Bashey; Western Pennsylvania Cancer Institute, Pittsburgh: R. Shadduck; Tulane Cancer Center, New Orleans: H. Safah; Southbay Oncology Hematology Partners, Campbell, CA: M. Rubenstein; University of Texas Southwest Medical Center, Dallas: R. Collins; Cancer Care Associates, Tulsa, OK: A. Keller; Robert H. Lurie Comprehensive Cancer Center, Chicago: M. Tallman; Northern New Jersey Cancer Center, Hackensack: A. Pecora; University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh: M. Agha; Texas Oncology, Dallas: H. Holmes; and New Mexico Oncology Hematology Consultants, Albuquerque: R. Guidice. Study Management Committee: Oregon Health and Science University Cancer Institute Research and Patient Care, Portland: B.J. Druker; University Hospital, Poitier, France: F. Guilhot; University of Chicago, Chicago: R.A. Larson; University of Newcastle upon Tyne, Newcastle upon Tyne, UK: S.G. O'Brien. Independent Data Monitoring Board: Rambam Medical Center, Haifa, Israel: J. Rowe; Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit: C.A. Schiffer; International Drug Development Institute, Brussels: M. Buyse. Protocol Working Group: Policlinico San Orsola–Malpighi, Bologna, Italy: M. Baccarani; Hospital Clinic, Barcelona: F. Cervantes; Erasmus Medical Center, Rotterdam, the Netherlands: J. Cornelissen; Johannes Gutenberg Universität, Mainz, Germany: T. Fischer; Universität Heidelberg, Mannheim, Germany: A. Hochhaus; Hanson Institute Centre for Cancer, Adelaide, Australia: T. Hughes; Medical University of Vienna, Vienna: K. Lechner; Aarhus Amtssygehus, Aarhus, Denmark: J.L. Nielsen; CHU de Bordeaux, Pessac, France: J. Reiffers; Hôpital Saint Louis, Paris: P. Rousselot; San Luigi Gonzaga Hospital, Turin, Italy: G. Saglio; Vancouver Hospital, Vancouver, BC, Canada: J. Shepherd; Akademiska Sjukhuset, Uppsala, Sweden: B. Simonsson; University Hospital, Basel, Switzerland: A. Gratwohl; Imperial College, London: J.M. Goldman; University of Michigan Health System, Ann Arbor: M. Talpaz; Mater Misericordiae Public Hospital, Brisbane, Australia: K. Taylor; and University Hospital Gasthuisberg, Leuven, Belgium: G. Verhoef.
- References
References
1
Nowell PC ,Hungerford DA . A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-1497
Web of Science2
Rowley JD . A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293
CrossRef | Web of Science | Medline3
Heisterkamp N ,Stam K ,Groffen J ,de Klein A ,Grosveld G . Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315:758-761
CrossRef | Web of Science | Medline4
Konopka JB ,Watanabe SM ,Witte ON . An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-1042
CrossRef | Web of Science | Medline5
Shtivelman E ,Lifshitz B ,Gale RP ,Canaani E . Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554
CrossRef | Web of Science | Medline6
Druker BJ ,Tamura S ,Buchdunger E , et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566
CrossRef | Web of Science | Medline7
Druker BJ ,Sawyers CL ,Kantarjian H , et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042[Erratum, N Engl J Med 2001;345:232.]
Full Text | Web of Science | Medline8
Druker BJ ,Talpaz M ,Resta DJ , et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
Full Text | Web of Science | Medline9
Kantarjian H ,Sawyers C ,Hochhaus A , et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652[Erratum, N Engl J Med 2002;346:1923.]
Full Text | Web of Science | Medline10
Sawyers CL ,Hochhaus A ,Feldman E , et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-3539
CrossRef | Web of Science | Medline11
Talpaz M ,Silver RT ,Druker BJ , et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-1937
CrossRef | Web of Science | Medline12
Baccarani M ,Rosti G ,de Vivo A , et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-1535
CrossRef | Web of Science | Medline13
Guilhot F ,Chastang C ,Michallet M , et al. Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229
Full Text | Web of Science | Medline14
O'Brien SG ,Guilhot F ,Larson RA , et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
Full Text | Web of Science | Medline15
Hughes TP ,Kaeda J ,Branford S , et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432
Full Text | Web of Science | Medline16
Sokal JE ,Cox EB ,Baccarani M , et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789-799
Web of Science | Medline17
Silver RT ,Woolf SH ,Hehlmann R , et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-1536
Web of Science | Medline18
Roy L ,Guilhot J ,Krahnke T , et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484
CrossRef | Web of Science | Medline19
Bonifazi F ,de Vivo A ,Rosti G , et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-3081
CrossRef | Web of Science | Medline20
Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood (in press).
21
Breccia M ,Diverio D ,Pane F , et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006;30:1577-1579
CrossRef | Web of Science | Medline22
Mauro MJ ,Druker BJ ,Maziarz RT . Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28:Suppl 1:S71-S73
CrossRef | Web of Science | Medline23
Merante S ,Orlandi E ,Bernasconi P ,Calatroni S ,Boni M ,Lazzarino M . Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005;90:979-981
Web of Science | Medline24
Cortes J ,O'Brien S ,Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-2205
CrossRef | Web of Science | Medline25
Thomas J ,Wang L ,Clark RE ,Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745
CrossRef | Web of Science | Medline26
Chu S ,Xu H ,Shah NP , et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-2098
CrossRef | Web of Science | Medline27
Graham SM ,Jorgensen HG ,Allan E , et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325
CrossRef | Web of Science | Medline28
Talpaz M ,Shah NP ,Kantarjian H , et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541
Full Text | Web of Science | Medline29
Kantarjian H ,Giles F ,Wunderle L , et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551
Full Text | Web of Science | Medline30
Copland M ,Hamilton A ,Elrick LJ , et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-4539
CrossRef | Web of Science | Medline31
Shah NP ,Sawyers CL . Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003;22:7389-7395
CrossRef | Web of Science | Medline32
Willis SG ,Lange T ,Demehri S , et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-2137
CrossRef | Web of Science | Medline33
Roche-Lestienne C ,Preudhomme C . Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003;40:Suppl 2:80-82
CrossRef | Web of Science | Medline34
Griswold IJ ,MacPartlin M ,Bumm T , et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26:6082-6093
CrossRef | Web of Science | Medline
- Citing Articles (771)
Citing Articles
1
Simone Cardaci, Enrico Desideri, Maria Rosa Ciriolo. (2012) Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. Journal of Bioenergetics and Biomembranes
CrossRef2
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef3
Antonio D’Avolio, Marco Simiele, Silvia De Francia, Alessandra Ariaudo, Lorena Baietto, Jessica Cusato, Carmen Fava, Giuseppe Saglio, Francesco Di Carlo, Giovanni Di Perri. (2012) HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). Journal of Pharmaceutical and Biomedical Analysis 59, 109-116
CrossRef4
Vicent Guillem, Paula Amat, Francisco Cervantes, Alberto Alvarez-Larrán, Jose Cervera, Margherita Maffioli, Beatriz Bellosillo, María Collado, Isabel Marugán, Francisco Martínez-Ruiz, Juan-Carlos Hernández-Boluda. (2012) Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leukemia Research 36:2, 174-181
CrossRef5
Izhar Hardan, Anfisa Stanevsky, Yuliya Volchek, Tali Tohami, Ninette Amariglio, Luba Trakhtenbrot, Maya Koren-Michowitz, Avichai Shimoni, Arnon Nagler. (2012) Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia. Cytokine 57:2, 290-293
CrossRef6
Jennifer F T Teng, Vincent H Mabasa, Mary H H Ensom. (2012) The Role of Therapeutic Drug Monitoring of Imatinib in Patients with Chronic Myeloid Leukemia and Metastatic or Unresectable Gastrointestinal Stromal Tumors. Therapeutic Drug Monitoring 34:1, 85-97
CrossRef7
Seung-Tae Lee, Yongick Ji, Hee-Jin Kim, Chang-Seok Ki, Chul Won Jung, Jong-Won Kim, Sun-Hee Kim. (2012) Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia. Leukemia Research
CrossRef8
Mathew J. Garnett, Ultan McDermott. (2012) Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discovery Today
CrossRef9
Michele De Palma, Douglas Hanahan. (2012) The Biology of Personalized Cancer Medicine: Facing Individual Complexities Underlying Hallmark Capabilities. Molecular Oncology
CrossRef10
Oliver Hantschel, Wolfgang Warsch, Eva Eckelhart, Ines Kaupe, Florian Grebien, Kay-Uwe Wagner, Giulio Superti-Furga, Veronika Sexl. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature Chemical Biology
CrossRef11
Hidehiro Itonaga, Hideki Tsushima, Tomoko Hata, Emi Matsuo, Daisuke Imanishi, Yoshitaka Imaizumi, Yasuhisa Kawaguchi, Takuya Fukushima, Yuko Doi, Sayaka Mori, Shimeru Kamihira, Masao Tomonaga, Yasushi Miyazaki. (2012) Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. International Journal of Hematology
CrossRef12
Jerald P. Radich. (2012) Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer 118:2, 300-311
CrossRef13
T Klag, N Härtel, P Erben, J Schwaab, U Schnetzke, T Schenk, A Hochhaus, P La Rosée. (2012) Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors. Leukemia
CrossRef14
Marianne Ulcickas Yood, Susan A. Oliveria, Mark Cziraky, Ishan Hirji, Muhammad Hamdan, Catherine Davis. (2012) Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Current Medical Research and Opinion1-7
CrossRef15
Wendy Osborne, Gail L Jones, Graham H Jackson, Helen Marr. (2012) Myeloproliferative disorders in older people. Reviews in Clinical Gerontology1-11
CrossRef16
Nóra Meggyesi, András Kozma, Gabriella Halm, Sarolta Nahajevszky, Árpád Bátai, Sándor Fekete, Anikó Barta, György Ujj, Sándor Lueff, Andrea Sipos, Emma Ádám, András Bors, Péter Reményi, Tamás Masszi, Attila Tordai, Hajnalka Andrikovics. (2012) Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients. Acta Haematologica 127:1, 34-42
CrossRef17
Michael T. Furlong, Shruti Agrawal, Dara Hawthorne, Michael Lago, Steve Unger, Linda Krueger, Bruce Stouffer. (2012) A validated LC–MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 58, 130-135
CrossRef18
Lawrence J Jennings, Frederick A Smith, Kevin C Halling, Diane L Persons, Suzanne Kamel-Reid. (2012) Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease. Archives of Pathology & Laboratory Medicine 136:1, 33-40
CrossRef19
Juliann Chmielecki, Martin Peifer, Agnes Viale, Katherine Hutchinson, Jennifer Giltnane, Nicholas D. Socci, Clayton J. Hollis, Rebecca S. Dean, Ashwini Yenamandra, Madan Jagasia, Annette S. Kim, Utpal P. Davé, Roman K. Thomas, William Pao. (2012) Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes, Chromosomes and Cancer 51:1, 54-65
CrossRef20
Stanley Cohen. (2012) Small molecular therapies for rheumatoid arthritis: where do we stand?. Expert Opinion on Investigational Drugs 21:1, 23-31
CrossRef21
D. MOKART, A. ETIENNE, B. ESTERNI, J.-P. BRUN, L. CHOW-CHINE, A. SANNINI, M. FAUCHER, J.-L. BLACHE. (2012) Critically ill cancer patients in the intensive care unit: short-term outcome and 1-year mortality. Acta Anaesthesiologica Scandinavican/a-n/a
CrossRef22
George Ansstas, Ravi Vij. (2012) Evolution of definitions of response, progression-free survival, and event-free survival in front-line studies of chronic myeloid leukemia. Leukemia and Lymphoma1
CrossRef23
Megan Cornelison, Elias J. Jabbour, Mary Alma Welch. (2012) Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner. The Journal of Supportive Oncology 10:1, 14-24
CrossRef24
Carmen Fava, Hagop Kantarjian, Jorge Cortes. (2012) Molecular Resistance: An Early Indicator for Treatment Change?. Clinical Lymphoma Myeloma and Leukemia
CrossRef25
Gopa Iyer, Matthew I. Milowsky. (2012) Fibroblast growth factor receptor-3 in urothelial tumorigenesis
. Urologic Oncology: Seminars and Original Investigations
CrossRef26
Xuelin Huang, Jorge Cortes, Hagop Kantarjian. (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancern/a-n/a
CrossRef27
Andreas Hochhaus, Andreas Reiter, Thomas Ernst, Paul La Rosée. (2012) Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders. Onkologie 35:s1, 34-41
CrossRef28
François Guilhot, Lydia Roy, Cécile Tomowiak. (2012) Current treatment strategies in chronic myeloid leukemia. Current Opinion in Hematology1
CrossRef29
Ellin Berman. (2012) Genetic mutations in chronic myelogenous leukemia. Current Opinion in Hematology1
CrossRef30
Brian L. Abbott. (2012) Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Therapeutics
CrossRef31
Carlos Alberto Pinto da Silveira, Iris Ferrari. (2011) First-line treatment with imatinib mesylate in chronic phase chronic myeloid leukemia patients: Experience of a public hospital in a developing country of South America. Leukemia & Lymphoma1-9
CrossRef32
M Schemionek, T Spieker, L Kerstiens, C Elling, M Essers, A Trumpp, W E Berdel, C Müller-Tidow, S Koschmieder. (2011) Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia
CrossRef33
Elias J. Jabbour, Alfonso Quintás-Cardama. (2011) Molecular Monitoring 101: Helping Your Patients With CML Understand the Meaning of Molecular Response. Leukemia & Lymphoma1-21
CrossRef34
Marco Mineo, Susan H. Garfield, Simona Taverna, Anna Flugy, Giacomo De Leo, Riccardo Alessandro, Elise C. Kohn. (2011) Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a src-dependent fashion. Angiogenesis
CrossRef35
A. Hamilton, G. V. Helgason, M. Schemionek, B. Zhang, S. Myssina, E. K. Allan, F. E. Nicolini, C. Muller-Tidow, R. Bhatia, V. G. Brunton, S. Koschmieder, T. L. Holyoake. (2011) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood
CrossRef36
J J W M Janssen, W Deenik, K G M Smolders, B J van Kuijk, W Pouwels, A Kelder, J J Cornelissen, G J Schuurhuis, G J Ossenkoppele. (2011) Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia
CrossRef37
H. M. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. B. Agarwal, M. S. Undurraga, J. Wang, J. J. Kassack Ipina, D.-W. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, J. H. Milone, F. E. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, M. B. Bradley-Garelik, C. Zhu, A. Hochhaus. (2011) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood
CrossRef38
S. M. Gough, C. I. Slape, P. D. Aplan. (2011) NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 118:24, 6247-6257
CrossRef39
Ramon Tiu, Matt Kalaycio. (2011) Targeted Therapy for Patients with Chronic Myeloid Leukemia: Clinical Trial Experience and Challenges in Intertrial Comparisons. Leukemia & Lymphoma1-22
CrossRef40
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology 6:4, 235-243
CrossRef41
Rina Nagao, Eishi Ashihara, Shinya Kimura, Jeffrey W. Strovel, Hisayuki Yao, Miki Takeuchi, Ruriko Tanaka, Yoshihiro Hayashi, Hideyo Hirai, Janak Padia, Kathryn Strand, Taira Maekawa. (2011) Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 – a novel Wnt/β-catenin signaling inhibitor. Cancer Letters 312:1, 91-100
CrossRef42
Seongman Kang, Sunghoi Hong. (2011) Prediction of personalized drugs based on genetic variations provided by DNA sequencing technologies. Genes & Genomics 33:6, 591-603
CrossRef43
Tze L. Lai, Philip W. Lavori. (2011) Innovative Clinical Trial Designs. Statistics in Biosciences 3:2, 145-168
CrossRef44
Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari. (2011) Hematologic toxicities of small molecule tyrosine kinase inhibitors. Targeted Oncology 6:4, 203-215
CrossRef45
A. Hochhaus. (2011) Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease. Hematology 2011:1, 128-135
CrossRef46
J. V. Melo, D. M. Ross. (2011) Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?. Hematology 2011:1, 136-142
CrossRef47
A. Kumari, C. Brendel, A. Hochhaus, A. Neubauer, A. Burchert. (2011) Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood
CrossRef48
S. Chu, T. McDonald, A. Lin, S. Chakraborty, Q. Huang, D. S. Snyder, R. Bhatia. (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118:20, 5565-5572
CrossRef49
Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus, Paul Rosée. (2011) Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of Cancer Research and Clinical Oncology
CrossRef50
Henrik ten Freyhaus, Daniel Dumitrescu, Eva Berghausen, Marius Vantler, Evren Caglayan, Stephan Rosenkranz. (2011) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs1-16
CrossRef51
T. O'Hare, M. S. Zabriskie, C. A. Eide, A. Agarwal, L. T. Adrian, H. You, A. S. Corbin, F. Yang, R. D. Press, V. M. Rivera, J. Toplin, S. Wong, M. W. Deininger, B. J. Druker. (2011) The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 118:19, 5250-5254
CrossRef52
Andrew G. Lee, David J. Beebe, Sean P. Palecek. (2011) Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels. Biomedical Microdevices
CrossRef53
Y.-F. Lu, L. C. Gavrilescu, M. Betancur, K. Lazarides, H. Klingemann, R. A. Van Etten. (2011) Distinct graft-vs-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood
CrossRef54
Noriaki Kawano, Shinya Okuda, Shuro Yoshida, Hiroko Kugimiya, Masaki Ito, Nagako Horikawa, Nobuaki Chosa, Tomoko Hisakata, Tomoko Fukudome, Ryoko Sakurai, Kiyoshi Yamashita, Akira Ueda, Yoshinobu Kanda. (2011) Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. International Journal of Hematology
CrossRef55
Shelby D. Reed. (2011) When Evaluating Parameter Uncertainty Is Not Enough: The Case of Dasatinib and Nilotinib for Imatinib-Resistant Chronic Myeloid Leukemia. Value in Health
CrossRef56
Sameek Roychowdhury, Moshe Talpaz. (2011) Managing resistance in chronic myeloid leukemia. Blood Reviews 25:6, 279-290
CrossRef57
Vincent T. DeVita. (2011) Opinion: A personal note—40 years after the signing of the Cancer Act. Nature Reviews Clinical Oncology 8:12, 693-694
CrossRef58
B G Mar, D Amakye, I Aifantis, S Buonamici. (2011) The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 25:11, 1665-1673
CrossRef59
Bhuvan Kishore, David Marin. (2011) Current opinions and controversies in chronic myeloid leukaemia. Current Opinion in Oncology 23:6, 659-664
CrossRef60
Douglas Vivona, Carolina T. Bueno, Luciene T. Lima, Rosario D.C. Hirata, Mario H. Hirata, André D. Luchessi, Maria A. Zanichelli, Carlos S. Chiattone, Elvira M. Guerra-Shinohara. (2011) ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells, Molecules, and Diseases
CrossRef61
Nóra Meggyesi, Lajos Kalmár, Sándor Fekete, Tamás Masszi, Attila Tordai, Hajnalka Andrikovics. (2011) Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. Medical Oncology
CrossRef62
R. A. Larson. (2011) CML: live long and prosper. Blood 118:17, 4499-4500
CrossRef63
J. E. Cortes, H. M. Kantarjian, T. H. Brummendorf, D.-W. Kim, A. G. Turkina, Z.-X. Shen, R. Pasquini, H. J. Khoury, S. Arkin, A. Volkert, N. Besson, R. Abbas, J. Wang, E. Leip, C. Gambacorti-Passerini. (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118:17, 4567-4576
CrossRef64
C. Hurtz, K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y.-m. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M. C. Muller, W.-K. Hofmann, A. Hochhaus, B. H. Ye, A. Agarwal, B. J. Druker, N. P. Shah, A. M. Melnick, M. Muschen. (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. Journal of Experimental Medicine 208:11, 2163-2174
CrossRef65
Hong Bing Ma, Xia Xu, Wei Ping Liu, Hong Chang, Fan Zeng, Yu Chun Wang. (2011) Successful treatment of mast cell sarcoma of the uterus with imatinib. International Journal of Hematology
CrossRef66
E. Vakana, J. K. Altman, H. Glaser, N. J. Donato, L. C. Platanias. (2011) Antileukemic effects of AMPK activators on BCR-ABL expressing cells. Blood
CrossRef67
S. Corm, L. Roche, J.-B. Micol, V. Coiteux, N. Bossard, F.-E. Nicolini, J. Iwaz, C. Preudhomme, C. Roche-Lestienne, T. Facon, L. Remontet. (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood 118:16, 4331-4337
CrossRef68
H J Khoury, M Kukreja, J M Goldman, T Wang, J Halter, M Arora, V Gupta, D A Rizzieri, B George, A Keating, R P Gale, D I Marks, P L McCarthy, A Woolfrey, J Szer, S A Giralt, R T Maziarz, J Cortes, M M Horowitz, S J Lee. (2011) Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplantation
CrossRef69
P. T. Tran, P. K. Bendapudi, H. J. Lin, P. Choi, S. Koh, J. Chen, G. Horng, N. P. Hughes, L. H. Schwartz, V. A. Miller, T. Kawashima, T. Kitamura, D. Paik, D. W. Felsher. (2011) Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation. Science Translational Medicine 3:103, 103ra99-103ra99
CrossRef70
Yanming Zhang, Janet D. Rowley. (2011) Chronic Myeloid Leukemia: Current Perspectives. Clinics in Laboratory Medicine
CrossRef71
A.L. Swampillai, P. Salomoni, S.C. Short. (2011) The Role of Autophagy in Clinical Practice. Clinical Oncology
CrossRef72
Paolo Gallipoli, Sheela A. Abraham, Tessa L. Holyoake. (2011) Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America 25:5, 951-966
CrossRef73
Theo Daniel Kim, Mareike Frick, Philipp le Coutre. (2011) Omacetaxine mepesuccinate for the treatment of leukemia. Expert Opinion on Pharmacotherapy 12:15, 2381-2392
CrossRef74
Peter C. Trask, David Cella, Nadine Besson, Virginia Kelly, Tamás Masszi, Dong-Wook Kim. (2011) Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leukemia Research
CrossRef75
Martin Hoyle, Gabriel Rogers, Tiffany Moxham, Zulian Liu, Ken Stein. (2011) Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia. Value in Health
CrossRef76
Paolo Gallipoli, Pat Shepherd, David Irvine, Mark Drummond, Tessa Holyoake. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology 155:1, 128-130
CrossRef77
Jamshid S. Khorashad, Michael W.N. Deininger. (2011) Selection of Therapy: Rational Decisions Based on Molecular Events. Hematology/Oncology Clinics of North America 25:5, 1009-1023
CrossRef78
Luke P. Akard, Y. Lynn Wang. (2011) Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners. Clinical Lymphoma Myeloma and Leukemia 11:5, 385-395
CrossRef79
Francisco Cervantes, Michael Mauro. (2011) Practical management of patients with chronic myeloid leukemia. Cancer 117:19, 4343-4354
CrossRef80
A Kreutzman, K Ladell, C Koechel, E Gostick, M Ekblom, L Stenke, T Melo, H Einsele, K Porkka, D A Price, S Mustjoki, R Seggewiss. (2011) Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:10, 1587-1597
CrossRef81
Kevin R. Kelly, Jeffrey Ecsedy, Ernest Medina, Devalingam Mahalingam, Swaminathan Padmanabhan, Steffan T. Nawrocki, Francis J. Giles, Jennifer S. Carew. (2011) The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. Journal of Cellular and Molecular Medicine 15:10, 2057-2070
CrossRef82
J.-C. Chomel, M.-L. Bonnet, N. Sorel, A. Bertrand, M.-C. Meunier, S. Fichelson, M. Melkus, A. Bennaceur-Griscelli, F. Guilhot, A. G. Turhan. (2011) Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118:13, 3657-3660
CrossRef83
N. Esposito, I. Colavita, C. Quintarelli, A. R. Sica, A. L. Peluso, L. Luciano, M. Picardi, L. Del Vecchio, T. Buonomo, T. P. Hughes, D. White, J. P. Radich, D. Russo, S. Branford, G. Saglio, J. V. Melo, R. Martinelli, M. Ruoppolo, T. Kalebic, G. Martinelli, F. Pane. (2011) SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 118:13, 3634-3644
CrossRef84
Thomas I. Peng Soh, Wei Peng Yong, Federico Innocenti. (2011) Review: Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine---
CrossRef85
A. Mukhopadhyay, S. Dasgupta, S. Mukhopadhyay, C. K. Bose, S. Sarkar, F. Gharami, S. Koner, J. Basak, U. K. Roy. (2011) Imatinib Mesylate Therapy in Patients of Chronic Myeloid Leukemia with Philadelphia Chromosome Positive: An Experience from Eastern India. Indian Journal of Hematology and Blood Transfusion
CrossRef86
Hagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, Carmino De Souza, Ian W Flinn, Leif Stenke, Yeow-Tee Goh, Gianantonio Rosti, Hirohisa Nakamae, Neil J Gallagher, Albert Hoenekopp, Rick E Blakesley, Richard A Larson, Timothy P Hughes. (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology 12:9, 841-851
CrossRef87
Paul L. McCormack, Susan J. Keam. (2011) Dasatinib. Drugs 71:13, 1771-1795
CrossRef88
Peter Valent, Günther Gastl, Klaus Geissler, Richard Greil, Oliver Hantschel, Alois Lang, Werner Linkesch, Thomas Lion, Andreas L. Petzer, Elisabeth Pittermann, Lisa Pleyer, Josef Thaler, Dominik Wolf. (2011) Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions. Critical Reviews in Oncology/Hematology
CrossRef89
Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli, Ayalew Tefferi. (2011) Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology 86:9, 811-819
CrossRef90
Lonneke Timmers, Jan Jacob Beckeringh, Myrthe P. P. Herk-Sukel, Epie Boven, Jacqueline G. Hugtenburg. (2011) Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef91
Roberto Latagliata, Massimo Breccia, Fausto Castagnetti, Fabio Stagno, Luigiana Luciano, Antonella Gozzini, Stefano Ulisciani, Francesco Cavazzini, Mario Annunziata, Federica Sorà, Antonella Russo Rossi, Patrizia Pregno, Enrico Montefusco, Elisabetta Abruzzese, Elena Crisà, Pellegrino Musto, Mario Tiribelli, Gianni Binotto, Ubaldo Occhini, Costanzo Feo, Paolo Vigneri, Valeria Santini, Carmen Fava, Giannantonio Rosti, Giuliana Alimena. (2011) Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research 35:9, 1164-1169
CrossRef92
D Marin, I H Gabriel, S Ahmad, L Foroni, H de Lavallade, R Clark, S O'Brien, R Sergeant, C Hedgley, D Milojkovic, J S Khorashad, M Bua, A Alsuliman, A Khoder, K Stringaris, N Cooper, J Davis, J M Goldman, J F Apperley, K Rezvani. (2011) KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia
CrossRef93
P J Shami, M Deininger. (2011) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy. Leukemia
CrossRef94
S. Anand, F. Stedham, E. Gudgin, P. Campbell, P. Beer, A. R. Green, B. J. P. Huntly. (2011) Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood 118:6, 1610-1621
CrossRef95
Massimo Breccia, Giuliana Alimena. (2011) The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. Critical Reviews in Oncology/Hematology 79:2, 135-143
CrossRef96
Edgar Faber, Jan Mužík, Vladimír Koza, Eva Demečková, Jaroslava Voglová, Ĺudmila Demitrovičová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Tomáš Kozák, Elena Tóthová, Marie Jarošová, Ladislav Dušek, Karel Indrák. (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry. European Journal of Haematology 87:2, 157-168
CrossRef97
Anat Gafter-Gvili, Avi Leader, Ronit Gurion, Liat Vidal, Ron Ram, Adi Shacham-Abulafia, Isaac Ben-Bassat, Michael Lishner, Ofer Shpilberg, Pia Raanani. (2011) High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients-Systematic review and meta-analysis. American Journal of Hematology 86:8, 657-662
CrossRef98
Yanmin Zhao, Yamin Tan, Gongqiang Wu, Lizhen Liu, Yingjia Wang, Yi Luo, Jimin Shi, He Huang. (2011) Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. International Journal of Hematology 94:2, 156-162
CrossRef99
Rui Chen, Bin Ma, Kehu Yang, Jinhui Tian, Yali Liu, Li Zhao. (2011) Interferon Alfa Versus Interferon Alfa Plus Cytarabine Combination Therapy for Chronic Myeloid Leukemia: A Meta-Analysis of Randomized Controlled Trials. Current Therapeutic Research 72:4, 150-163
CrossRef100
Aylin Camgoz, Emel Basak Gencer, Ali Ugur Ural, Ferit Avcu, Yusuf Baran. (2011) Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloidleukemia cells. Leukemia & Lymphoma 52:8, 1574-1584
CrossRef101
Edel Kavanagh, Bertrand Joseph. (2011) The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:1, 50-56
CrossRef102
Evgenios Goussetis, Pantelis Constantoulakis, Vasiliki Kitra, Ioulia Peristeri, Minas Mastrominas, Margarita Baka, Miltiadis Papadimitropoulos, Christos Karamolegos, Anna Paisiou, Helen Vasilatou-Kosmidis, Stelios Graphakos. (2011) Successful bone marrow transplantation in a pediatric patient with chronic myeloid leukemia from a HLA-identical sibling selected by preimplantation HLA testing. Pediatric Blood & Cancer 57:2, 345-347
CrossRef103
Margherita Maffioli, Mireia Camós, Anna Gaya, Juan-Carlos Hernández-Boluda, Alberto Álvarez-Larrán, Abel Domingo, Miquel Granell, Vicent Guillem, Rolando Vallansot, Dolors Costa, Beatriz Bellosillo, Dolors Colomer, Francisco Cervantes. (2011) Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leukemia Research 35:8, 1014-1019
CrossRef104
L. Rubinstein, M. LeBlanc, M. A. Smith. (2011) More Randomization in Phase II Trials: Necessary but not Sufficient. JNCI Journal of the National Cancer Institute 103:14, 1075-1077
CrossRef105
Martin A. Champagne, Cecilia H. Fu, Myron Chang, Helen Chen, Robert B. Gerbing, Todd A. Alonzo, Linda D. Cooley, Nyla A. Heerema, Vivian Oehler, Charlotte Wood, Mary Ellen French, Robert J. Arceci, Franklin O. Smith, Mark L. Bernstein. (2011) Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer 57:1, 56-62
CrossRef106
Wenyue Hu, Qing Zong, Annette John-Baptiste, Bart Jessen. (2011) Transient knock down of checkpoint kinase 1 in hematopoietic progenitors is linked to bone marrow toxicity. Toxicology Letters 204:2-3, 141-147
CrossRef107
P. La Rosée. (2011) Tyrosinkinaseinhibitoren. Der Onkologe 17:7, 641-650
CrossRef108
Yun Liang, Xi Qiu, Rong-zhen Xu, Xiao-ying Zhao. (2011) Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity. Journal of Zhejiang University SCIENCE B 12:7, 568-574
CrossRef109
Katayoon Kasaian, Steven JM Jones. (2011) A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology 7:7, 873-894
CrossRef110
Karl J. Aichberger, Susanne Herndlhofer, Gerit-Holger Schernthaner, Martin Schillinger, Gerlinde Mitterbauer-Hohendanner, Christian Sillaber, Peter Valent. (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. American Journal of Hematology 86:7, 533-539
CrossRef111
G. Marzocchi, F. Castagnetti, S. Luatti, C. Baldazzi, M. Stacchini, G. Gugliotta, M. Amabile, G. Specchia, M. Sessarego, U. Giussani, L. Valori, G. Discepoli, A. Montaldi, A. Santoro, L. Bonaldi, G. Giudici, A. M. Cianciulli, F. Giacobbi, F. Palandri, F. Pane, G. Saglio, G. Martinelli, M. Baccarani, G. Rosti, N. Testoni, . (2011) Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 117:25, 6793-6800
CrossRef112
K. Shide, T. Kameda, V. Markovtsov, H. K. Shimoda, E. Tonkin, S. Fang, C. Liu, M. Gelman, W. Lang, J. Romero, J. McLaughlin, S. Bhamidipati, J. Clough, C. Low, A. Reitsma, S. Siu, P. Pine, G. Park, A. Torneros, M. Duan, R. Singh, D. G. Payan, T. Matsunaga, Y. Hitoshi, K. Shimoda. (2011) R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood 117:25, 6866-6875
CrossRef113
S.-J. Chen, G.-B. Zhou, X.-W. Zhang, J.-H. Mao, H. de The, Z. Chen. (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117:24, 6425-6437
CrossRef114
Thomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, Sandra Cauwenberghs, Peter Fraisl, Christa Maes, Bart Jonckx, Kim De Keersmaecker, Maria Kleppe, Marc Tjwa, Thomas Schenk, Stefan Vinckier, Rita Fragoso, Maria De Mol, Karolien Beel, Sérgio Dias, Catherine Verfaillie, Richard E. Clark, Tim H. Brümmendorf, Peter Vandenberghe, Shahin Rafii, Tessa Holyoake, Andreas Hochhaus, Jan Cools, Michael Karin, Geert Carmeliet, Mieke Dewerchin, Peter Carmeliet. (2011) Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. Cancer Cell 19:6, 740-753
CrossRef115
Susan Branford, Jodi Prime. (2011) Chronic Myelogenous Leukemia: Monitoring Response to Therapy. Current Hematologic Malignancy Reports 6:2, 75-81
CrossRef116
J. Rudzki, D. Wolf. (2011) What's new in CML? Highlights of ASH 2010. memo - Magazine of European Medical Oncology 4:2, 124-126
CrossRef117
Yukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, Kiyoshi Ando, Kazuhito Yamamoto, Masaya Okada, Kenichi Ishizawa, Tadashi Nagai, Syuichi Miyawaki, Toshiko Motoji, Noriko Usui, Shinsuke Iida, Masafumi Taniwaki, Nobuhiko Uoshima, Taku Seriu, Ryuzo Ohno. (2011) Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. International Journal of Hematology 93:6, 745-749
CrossRef118
James E. Signorovitch, Eric Q. Wu, Keith A. Betts, Kejal Parikh, Evan Kantor, Amy Guo, Vamsi K. Bollu, Denise Williams, L.J. Wei, Daniel J. DeAngelo. (2011) Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Current Medical Research and Opinion 27:6, 1263-1271
CrossRef119
Devendra K Hiwase, David T Yeung, Deborah L White. (2011) Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Review of Hematology 4:3, 285-299
CrossRef120
Prasanth Ganesan, Tenali Gnana Sagar, Biswajit Dubashi, Rejiv Rajendranath, Krishnarathinam Kannan, Sanju Cyriac, Manjunath Nandennavar. (2011) Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. American Journal of Hematology 86:6, 471-474
CrossRef121
Sang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, Hun Mo Ryoo, Joo Seop Chung, Young Don Joo, Soo Mee Bang, Chul Won Jung, Dong Hwan Kim, Sung Soo Yoon, Ho Kim, Hong Ghi Lee, Jong Ho Won, Yoo Hong Min, June Won Cheong, Joon Seong Park, Ki Seong Eom, Myung Soo Hyun, Min Kyoung Kim, Hawk Kim, Moo Rim Park, Jinny Park, Chul Soo Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Eun Kyung Park, Dae Young Zang, Deog Yeon Jo, Joon Ho Moon, Seon Yang Park. (2011) Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leukemia & Lymphoma 52:6, 1024-1029
CrossRef122
Robert P. Hasserjian. (2011) Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase. Journal of Hematopathology 4:2, 81-92
CrossRef123
A. Megan Cornelison, Hagop Kantarjian, Jorge Cortes, Elias Jabbour. (2011) Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure. Clinical Lymphoma Myeloma and Leukemia 11, S101-S110
CrossRef124
Mathew Thomas, Wei-Sheng Huang, David Wen, Xiaotian Zhu, Yihan Wang, Chester A. Metcalf, Shuangying Liu, Ingrid Chen, Jan Romero, Dong Zou, Raji Sundaramoorthi, Feng Li, Jiwei Qi, Lisi Cai, Tianjun Zhou, Lois Commodore, Qihong Xu, Jeff Keats, Frank Wang, Scott Wardwell, Yaoyu Ning, Joseph T. Snodgrass, Marc I. Broudy, Karin Russian, John Iuliucci, Victor M. Rivera, Tomi K. Sawyer, David C. Dalgarno, Tim Clackson, William C. Shakespeare. (2011) Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant. Bioorganic & Medicinal Chemistry Letters 21:12, 3743-3748
CrossRef125
Richard Champlin, Elias Jabbour, Partow Kebriaei, Paolo Anderlini, Borje Andersson, Marcos de Lima. (2011) Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma and Leukemia 11, S96-S100
CrossRef126
Rui Chen, Wei Xiao, Ding Li, Shijie Mu. (2011) Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Medical Oncology 28:2, 528-531
CrossRef127
Lisa M. Lima, Keeran Sampat, Sarit Assouline, Debra Saxe, Sharron Nault, Mourad Tighiouart, Morgan Mclemore, Martha Arellano, Elliott Winton, Leon Bernal-Mizrachi, Jorge Cortes, Hanna Jean Khoury. (2011) Does pretreatment fluorescence in situ hybridization for BCR–ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?. Leukemia & Lymphoma 52:6, 1010-1016
CrossRef128
Zeshaan A. Rasheed, Jeanne Kowalski, B. Douglas Smith, William Matsui. (2011) Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells. STEM CELLS 29:6, 883-887
CrossRef129
Ramon V. Tiu, Valeria Visconte, Fabiola Traina, Anita Schwandt, Jaroslaw P. Maciejewski. (2011) Updates in Cytogenetics and Molecular Markers in MDS. Current Hematologic Malignancy Reports 6:2, 126-135
CrossRef130
Lucia Brilli, Furio Pacini. (2011) Targeted therapy in refractory thyroid cancer: current achievements and limitations. Future Oncology 7:5, 657-668
CrossRef131
Takaaki Ono, Shuichi Miyawaki, Fumihiko Kimura, Heiwa Kanamori, Shigeki Ohtake, Kunio Kitamura, Hiroyuki Fujita, Isamu Sugiura, Kensuke Usuki, Nobuhiko Emi, Shigehisa Tamaki, Yasutaka Aoyama, Hiroyasu Kaya, Tomoki Naoe, Kenichi Tadokoro, Toshikazu Yamaguchi, Ryuzo Ohno, Kazunori Ohnishi. (2011) BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leukemia Research 35:5, 598-603
CrossRef132
Jane L. Liesveld. (2011) CML: Defining the efficacy of targeted therapy with the TARGET system. Leukemia Research 35:5, 575-576
CrossRef133
Konrad Aumann, Silke Lassmann, Anja Schöpflin, Annette M. May, Franziska U. Wöhrle, Robert Zeiser, Cornelius F. Waller, Dieter Hauschke, Martin Werner, Tilman Brummer. (2011) The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Human Pathology 42:5, 719-726
CrossRef134
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Michele Baccarani. (2011) Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Critical Reviews in Oncology/Hematology
CrossRef135
Curt Peterson. (2011) Drug therapy of cancer. European Journal of Clinical Pharmacology 67:5, 437-447
CrossRef136
Carlos E. Vigil, Elizabeth A. Griffiths, Eunice S. Wang, Meir Wetzler. (2011) Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Reviews 25:3, 139-146
CrossRef137
Anna Brózik, Csilla Hegedüs, Zsuzsa Erdei, Tamás Hegedűs, Csilla Özvegy-Laczka, Gergely Szakács, Balázs Sarkadi. (2011) Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?. Expert Opinion on Drug Metabolism & Toxicology 7:5, 623-642
CrossRef138
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef139
Denise A. Chan, Amato J. Giaccia. (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery 10:5, 351-364
CrossRef140
Tetsuzo Tauchi, Masahiro Kizaki, Shinichiro Okamoto, Hideo Tanaka, Mitsune Tanimoto, Koiti Inokuchi, Tohru Murayama, Yoshio Saburi, Masayuki Hino, Mitsuru Tsudo, Taizo Shimomura, Yasushi Isobe, Kazuo Oshimi, Kazuo Dan, Kazuma Ohyashiki, Yasuo Ikeda. (2011) Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leukemia Research 35:5, 585-590
CrossRef141
R. V. Tiu, L. P. Gondek, C. L. O'Keefe, P. Elson, J. Huh, A. Mohamedali, A. Kulasekararaj, A. S. Advani, R. Paquette, A. F. List, M. A. Sekeres, M. A. McDevitt, G. J. Mufti, J. P. Maciejewski. (2011) Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117:17, 4552-4560
CrossRef142
Eric Padron, Lori A. Hazlehurst, Javier Pinilla-Ibarz. 2011. Molecular Pathogenesis of BCR-ABL in Chronic Myeloid Leukemia. , 62-70.
CrossRef143
Elias Jabbour, Jorge Cortes, Hagop Kantarjian. 2011. Standard Management of Patients with Chronic Myeloid Leukemia. , 71-85.
CrossRef144
Joon Ho Moon, Sang Kyun Sohn, Shi Nae Kim, Seon Yang Park, Sung Soo Yoon, In ho Kim, Hyeoung Joon Kim, Yeo Kyeoung Kim, Yoo Hong Min, June Won Cheong, Jin Seok Kim, Chul Won Jung, Dong Hwan Kim. (2011) Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Medical Oncology
CrossRef145
C. Gambacorti-Passerini, L. Antolini, F.-X. Mahon, F. Guilhot, M. Deininger, C. Fava, A. Nagler, C. M. Della Casa, E. Morra, E. Abruzzese, A. D'Emilio, F. Stagno, P. le Coutre, R. Hurtado-Monroy, V. Santini, B. Martino, F. Pane, A. Piccin, P. Giraldo, S. Assouline, M. A. Durosinmi, O. Leeksma, E. M. Pogliani, M. Puttini, E. Jang, J. Reiffers, M. G. Valsecchi, D.-W. Kim. (2011) Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. JNCI Journal of the National Cancer Institute 103:7, 553-561
CrossRef146
Su Jin Lee, Chul Won Jung, Dae-Young Kim, Kyoo-Hyung Lee, Sang Kyun Sohn, Jae-Yong Kwak, Hyeoung-Joon Kim, In Ho Kim, Seonyang Park, Dong Hwan Dennis Kim. (2011) Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. American Journal of Hematology 86:4, 346-350
CrossRef147
Sammy Pak-lam Chen, Wing-tat Poon, Chloe Miu Mak, Ching-wan Lam, Yok-lam Kwong, Albert Yan-wo Chan, Sidney Tam. (2011) Application of pharmacogenetics: UGT1A1*28 and nilotinib-induced unconjugated hyperbilirubinaemia in a patient with chronic myeloid leukaemia. Pathology 43:3, 273-274
CrossRef148
Theresia M Westers, Willemijn van den Ancker, Hetty J Bontkes, Jeroen JWM Janssen, Arjan A van de Loosdrecht, Gert J Ossenkoppele. (2011) Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy 3:4, 569-576
CrossRef149
Christopher S Hourigan, Judith E Karp. (2011) New considerations in the design of clinical trials for the treatment of acute leukemia. Clinical Investigation 1:4, 509-517
CrossRef150
Paul Workman, Paul A. Clarke. (2011) Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR. Cancer Cell 19:4, 437-440
CrossRef151
Wayne W. Chan, Scott C. Wise, Michael D. Kaufman, Yu Mi Ahn, Carol L. Ensinger, Torsten Haack, Molly M. Hood, Jennifer Jones, John W. Lord, Wei Ping Lu, David Miller, William C. Patt, Bryan D. Smith, Peter A. Petillo, Thomas J. Rutkoski, Hanumaiah Telikepalli, Lakshminarayana Vogeti, Tony Yao, Lawrence Chun, Robin Clark, Peter Evangelista, L. Cristina Gavrilescu, Katherine Lazarides, Virginia M. Zaleskas, Lance J. Stewart, Richard A. Van Etten, Daniel L. Flynn. (2011) Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036. Cancer Cell 19:4, 556-568
CrossRef152
John J. Powers, Jason A. Dubovsky, P. K. Epling-Burnette, Lynn Moscinski, Ling Zhang, Satu Mustjoki, Eduardo M. Sotomayor, Javier A. Pinilla-Ibarz. (2011) A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma 52:4, 668-679
CrossRef153
Jakob Rudzki, Dominik Wolf. (2011) Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?. Expert Review of Hematology 4:2, 153-159
CrossRef154
Deping Wang, Zhang Zhang, Xiaoyun Lu, Yubing Feng, Kun Luo, Jirong Gan, Liu Yingxue, Junting Wan, Xiang Li, Fengxiang Zhang, Zhengchao Tu, Qian Cai, Xiaomei Ren, Ke Ding. (2011) Hybrid compounds as new Bcr/Abl inhibitors. Bioorganic & Medicinal Chemistry Letters 21:7, 1965-1968
CrossRef155
Lisa Lima, Leon Bernal-Mizrachi, Debra Saxe, Karen P. Mann, Mourad Tighiouart, Martha Arellano, Leonard Heffner, Morgan McLemore, Amelia Langston, Elliott Winton, Hanna Jean Khoury. (2011) Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 117:6, 1245-1252
CrossRef156
A. Burchert, A. Neubauer. (2011) Chronische myeloische Leukämie. Der Internist 52:3, 283-296
CrossRef157
Elias Jabbour, Jorge Cortes, Hagop Kantarjian. (2011) Long-term outcomes in the second-line treatment of chronic myeloid leukemia. Cancer 117:5, 897-906
CrossRef158
Tetsuichi Yoshizato, Yasuhito Nannya, Yumiko Yoshiki, Fumihiko Nakamura, Yoichi Imai, Motoshi Ichikawa, Mineo Kurokawa. (2011) Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. International Journal of Hematology 93:3, 400-402
CrossRef159
Milena Soriano Marcolino, Antonio Luiz Ribeiro, Nelma C.D. Clementino, Maria do Carmo P. Nunes, Márcia M. Barbosa, Maria Helena C.R. Silva, Henrique N.S. Bittencourt, Marcel L. Geleijnse, Eric Boersma. (2011) The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. Leukemia Research 35:3, 317-322
CrossRef160
Miki Takeuchi, Eishi Ashihara, Yohko Yamazaki, Shinya Kimura, Yoko Nakagawa, Ruriko Tanaka, Hisayuki Yao, Rina Nagao, Yoshihiro Hayashi, Hideyo Hirai, Taira Maekawa. (2011) Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cancer Science 102:3, 591-596
CrossRef161
Michael Deininger. (2011) Hematology: Curing CML with imatinib—a dream come true?. Nature Reviews Clinical Oncology 8:3, 127-128
CrossRef162
Tatsuo Furukawa, Miwako Narita, Tadashi Koike, Kazue Takai, Koichi Nagai, Masashi Kobayashi, Satoru Koyama, Yoshinobu Seki, Hoyu Takahashi, Masahiro Fujiwara, Kenji Kishi, Koji Nikkuni, Noriatsu Isahai, Wataru Higuchi, Nobuhiko Nomoto, Souichi Maruyama, Masayoshi Masuko, Takashi Kuroha, Takashi Abe, Ken Toba, Masuhiro Takahashi, Yoshifusa Aizawa, Akira Shibata. (2011) Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study. International Journal of Hematology 93:3, 336-343
CrossRef163
Ross A Okimoto, Richard A Van Etten. (2011) Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Current Opinion in Hematology 18:2, 89-97
CrossRef164
Jennifer G Gaultney, Enrique Sanhueza, Jeroen J Janssen, William K Redekop, Carin A Uyl-de Groot. (2011) Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics 12:3, 411-421
CrossRef165
Javier Pinilla-Ibarz, Jorge Cortes, Michael J. Mauro. (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 117:4, 688-697
CrossRef166
Mohammed Awad Alkhatib. (2011) Pattern of Pediatric Chronic Myeloid Leukemia in Sudan and Hematological Response to Imatinib. Pediatric Hematology-Oncology 28:2, 100-105
CrossRef167
Xia Yuan, Yi Zhang, Haijing Zhang, Jing Jin, Xiangyan Li, He Liu, Zhiqiang Feng, Xiaoguang Chen. (2011) Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr–Abl positive cell lines in vitro and in vivo. Leukemia Research 35:2, 237-242
CrossRef168
Masaya Okada, Atsushi Satake, Katsuji Kaida, Kyoko Taniguchi, Satoshi Yoshihara, Kazuhiro Ikegame, Hiroya Tamaki, Toshihiro Soma, Yoshihiro Fujimori, Hiroyasu Ogawa. (2011) Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. International Journal of Hematology 93:2, 243-246
CrossRef169
Jorge Cortes, Alfonso Quintás-Cardama, Dan Jones, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Charles Koller, Jody Hiteshew, Jenny Shan, Susan O'Brien, Hagop Kantarjian. (2011) Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. Cancer 117:3, 572-580
CrossRef170
E Jabbour, M Deininger, A Hochhaus. (2011) Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:2, 201-210
CrossRef171
Bjoern Chapuy, Nikolai Schuelper, Melanie Panse, Andrea Dohm, Elisabeth Hand, Roland Schroers, Lorenz Truemper, Gerald G. Wulf. (2011) Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. British Journal of Haematology 152:4, 401-412
CrossRef172
Birgitta Mitchell, Michael Deininger. (2011) Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia. Leukemia & Lymphoma 52:S1, 4-11
CrossRef173
Katsuya Sakai, Yuichi Ishikawa, Yumiko Mori, Miki Kobayashi, Chisako Iriyama, Yukiyasu Ozawa, Tatsuya Suzuki, Yosuke Minami, Kazuhiro Ishikawa, Norio Kaneda, Tomoki Naoe, Hitoshi Kiyoi. (2011) A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. International Journal of Hematology 93:2, 237-242
CrossRef174
H Modi, L Li, S Chu, J Rossi, J-K Yee, R Bhatia. (2011) Inhibition of Grb2 expression demonstrates an important role in BCR–ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia 25:2, 305-312
CrossRef175
Hideki Muramatsu, Yoshiyuki Takahashi, Hirotoshi Sakaguchi, Akira Shimada, Nobuhiro Nishio, Asahito Hama, Sayoko Doisaki, Hiroshi Yagasaki, Kimikazu Matsumoto, Koji Kato, Seiji Kojima. (2011) Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. International Journal of Hematology 93:2, 186-191
CrossRef176
A.A. Leitner, R. Hehlmann. (2011) Moderne Therapie der chronisch myeloischen Leukämie. Der Internist 52:2, 209-217
CrossRef177
Gui-Sheng Zhou, Zheng Hu, Hai-Tong Fang, Feng-Xiang Zhang, Xiao-Fen Pan, Xiao-Qin Chen, An-Mei Hu, Ling Xu, Guang-Biao Zhou. (2011) Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leukemia Research 35:2, 214-218
CrossRef178
Era L. Pogosova-Agadjanyan, Wenhong Fan, George E. Georges, Jeffrey L. Schwartz, Crystal M. Kepler, Hana Lee, Amanda L. Suchanek, Michelle R. Cronk, Ariel Brumbaugh, Julia H. Engel, Michi Yukawa, Lue P. Zhao, Shelly Heimfeld, Derek L. Stirewalt. (2011) Identification of Radiation-Induced Expression Changes in Nonimmortalized Human T Cells. Radiation Research 175:2, 172-184
CrossRef179
Feero, W. Gregory, Guttmacher, Alan E., , McDermott, Ultan, Downing, James R., Stratton, Michael R., . (2011) Genomics and the Continuum of Cancer Care. New England Journal of Medicine 364:4, 340-350
Full Text180
J. Pavlu, R. M. Szydlo, J. M. Goldman, J. F. Apperley. (2011) Three decades of transplantation for chronic myeloid leukemia: what have we learned?. Blood 117:3, 755-763
CrossRef181
Ayalew Tefferi. (2011) Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia. Cancer 117:2, 234-237
CrossRef182
Aref Al-Kali, Hagop Kantarjian, Jianqin Shan, Roland Bassett, Alfonso Quintás-Cardama, Gautam Borthakur, Elias Jabbour, Srdan Verstovsek, Susan O'Brien, Jorge Cortes. (2011) Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117:2, 327-335
CrossRef183
Alexander Perl, Martin Carroll. (2011) BCR-ABL kinase is dead; long live the CML stem cell. Journal of Clinical Investigation 121:1, 22-25
CrossRef184
Amie S. Corbin, Anupriya Agarwal, Marc Loriaux, Jorge Cortes, Michael W. Deininger, Brian J. Druker. (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation 121:1, 396-409
CrossRef185
Jae Wook Lee, Nack Gyun Chung. (2011) The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean Journal of Pediatrics 54:3, 111
CrossRef186
Hao Jiang, Shan-Shan Chen, Bin Jiang, Qian Jiang, Ya-Zhen Qin, Yue-Yun Lai, Xiao-Jun Huang. (2011) Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. Annals of Hematology 90:1, 41-46
CrossRef187
Jacopo Olivieri, Sabrina Coluzzi, Imma Attolico, Attilio Olivieri. (2011) Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside. TheScientificWorldJOURNAL 11, 1908-1931
CrossRef188
Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes, Hagop Kantarjian. (2011) Suboptimal responses in chronic myeloid leukemia. Cancern/a-n/a
CrossRef189
Stacie Holloway, Katharine Lord, Beverly Bethelmie-Bryan, Marian W. Shepard, Jessica Neely, Morgan McLemore, Satyanarayan K. Reddy, Aldemar Montero, William S. Jonas, Sara Pierson Gladney. (2011) Managing Chronic Myeloid Leukemia: A Coordinated Team Care Perspective. Clinical Lymphoma Myeloma & Leukemia
CrossRef190
Alfonso Quintás-Cardama, Jorgé E. Cortes, Hagop M. Kantarjian. (2011) Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase. Cancern/a-n/a
CrossRef191
D Bixby, M Talpaz. (2011) Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25:1, 7-22
CrossRef192
Jae Wook Lee, Nack Gyun Chung. (2011) The treatment of pediatric chronic myelogenous leukemia in the imatinib era. Korean Journal of Pediatrics 54:3, 110
CrossRef193
Anthony Oyekunle, Evgeny Klyuchnikov, Sunday Ocheni, Nicolaus Kröger, Axel R. Zander, Michele Baccarani, Ulrike Bacher. (2011) Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Acta Haematologica 126:1, 30-39
CrossRef194
Suzanne George, Jonathan C. Trent. (2011) The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology 67:S1, 45-50
CrossRef195
Ramon Tiu, Matt Kalaycio. (2011) Targeted Therapy for Patients with Chronic Myeloid Leukemia: Clinical Trial Experience and Challenges in Intertrial Comparisons. Leukemia and Lymphoma1
CrossRef196
Takeru Nambu, Akinobu Hamada, Reiko Nakashima, Misato Yuki, Tatsuya Kawaguchi, Hiroaki Mitsuya, Hideyuki Saito. (2011) Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia. Biological & Pharmaceutical Bulletin 34:1, 114-119
CrossRef197
Yaoyu Chen. (2011) Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?. Leukemia Research 35:1, 27-29
CrossRef198
David W. Woessner, Carol S. Lim, Michael W. Deininger. (2011) Development of an Effective Therapy for Chronic Myelogenous Leukemia. The Cancer Journal 17:6, 477-486
CrossRef199
Fabio P. S. Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, Jorge Cortes. (2011) Evolution of Therapies for Chronic Myelogenous Leukemia. The Cancer Journal 17:6, 465-476
CrossRef200
Stefan Knop. (2011) Continuous Treatment in Multiple Myeloma – Ready for Prime Time?. Onkologie 34:8, 461-466
CrossRef201
Jill E. Larsen, Tina Cascone, David E. Gerber, John V. Heymach, John D. Minna. (2011) Targeted Therapies for Lung Cancer : Clinical Experience and Novel Agents. The Cancer Journal 17:6, 512
CrossRef202
David A. Fenstermacher, Robert M. Wenham, Dana E. Rollison, William S. Dalton. (2011) Implementing Personalized Medicine in a Cancer Center. The Cancer Journal 17:6, 528-536
CrossRef203
Anna M Eiring, Jamshid S Khorashad, Kimberly Morley, Michael W Deininger. (2011) Advances in the treatment of chronic myeloid leukemia. BMC Medicine 9:1, 99
CrossRef204
Mario Tiribelli, Marta Medeot. (2011) Cardiotoxicity of imatinib: At the heart of the problem. Leukemia Research 35:1, 36-37
CrossRef205
Muhammad Mansoor Alam, Moshe Talpaz. 2011. .
CrossRef206
Susannah O’Sullivan, Dorit Naot, Karen E. Callon, Maureen Watson, Greg D. Gamble, Marianne Ladefoged, Morten A. Karsdal, Peter Browett, Jillian Cornish, Andrew Grey. (2011) Imatinib Mesylate Does Not Increase Bone Volume In Vivo. Calcified Tissue International 88:1, 16-22
CrossRef207
Eun Ho Choo, Sang-Hyun Ihm, Ok-Ran Kim, Sung-Won Jang, Chan-Seok Park, Hee-Yeol Kim, Kiyuk Chang, Ho-Joong Youn, Wook Sung Chung, Ki-Bae Seung, Jae-Hyeong Kim. (2011) Imatinib Mesylate Attenuates Cardiac Fibrosis in Spontaneously Hypertensive Rats. Journal of the Korean Society of Hypertension 17:2, 48
CrossRef208
Chad V. Pecot, George A. Calin, Robert L. Coleman, Gabriel Lopez-Berestein, Anil K. Sood. (2011) RNA interference in the clinic: challenges and future directions. Nature Reviews Cancer 11:1, 59-67
CrossRef209
Mark D. Vincent. 2011. Cancer: Beyond Speciation. , 283-350.
CrossRef210
Franck E. Nicolini, Sandrine Hayette, Laurence Legros, Philippe Rousselot, Frédéric Maloisel, Michel Tulliez, Agnès Guerci, Aude Charbonnier, Thomas Prébet, Françoise Rigal-Huguet, Kaddour Chabane, Jean-Pierre Magaud, Carole Paillet, Christine Pivot, Mauricette Michallet. (2011) Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leukemia Research 35:1, 80-86
CrossRef211
Darlize Hübner Martins, Sandrine Comparsi Wagner, Tamyris Vianna dos Santos, Lilian de Lima Feltraco Lizot, Marina Venzon Antunes, Marcelo Capra, Rafael Linden. (2011) Monitoring imatinib plasma concentrations in chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia 33:4, 302-306
CrossRef212
Naoto Takahashi, Masatomo Miura. (2011) Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase. Pharmacology 87:5-6, 241-248
CrossRef213
G Büsche, HH Kreipe. 2011. Chronic myelogenous leukemia. , 361-370.
CrossRef214
Preudhomme, Claude, Guilhot, Joëlle, Nicolini, Franck Emmanuel, Guerci-Bresler, Agnès, Rigal-Huguet, Françoise, Maloisel, Frederic, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Rea, Delphine, Jourdan, Eric, Allard, Christian, Delmer, Alain, Rousselot, Philippe, Legros, Laurence, Berger, Marc, Corm, Selim, Etienne, Gabriel, Roche-Lestienne, Catherine, Eclache, Virginie, Mahon, François-Xavier, Guilhot, François, . (2010) Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. New England Journal of Medicine 363:26, 2511-2521
Full Text215
E. Jabbour, J. Cortes, F. P. S. Santos, D. Jones, S. O'Brien, G. Rondon, U. Popat, S. Giralt, P. Kebriaei, H. Kantarjian, R. Champlin, M. De Lima. (2010) Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood
CrossRef216
Eric Q. Wu, Annie Guerin, Andrew P. Yu, Vamsi K. Bollu, Amy Guo, James D. Griffin. (2010) Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Current Medical Research and Opinion 26:12, 2861-2869
CrossRef217
Tim Luetkens, Phillipe Schafhausen, Frederike Uhlich, Tim Stasche, Ruken Akbulak, Britta M. Bartels, York Hildebrandt, Arthur Gontarewicz, Sebastian Kobold, Sabrina Meyer, Maja Gordic, Katrin Bartels, Nesrine Lajmi, Yanran Cao, Nicolaus Kröger, Carsten Bokemeyer, Tim H. Brümmendorf, Djordje Atanackovic. (2010) Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leukemia Research 34:12, 1647-1655
CrossRef218
Koichiro Suemori, Hiroshi Fujiwara, Seiichiro Watanabe, Taichi Azuma, Masaki Yasukawa. (2010) A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months. International Journal of Hematology 92:5, 777-778
CrossRef219
E. Ardini, P. Magnaghi, P. Orsini, A. Galvani, M. Menichincheri. (2010) Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Letters 299:2, 81-94
CrossRef220
Francis J Giles, Gianantonio Rosti, Photis Beris, Richard E Clark, Philipp le Coutre, Francois-Xavier Mahon, Juan-Luis Steegmann, Peter Valent, Giuseppe Saglio. (2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology 3:6, 665-673
CrossRef221
Giuseppe Saglio, Hagop Kantarjian, Tessa Holyoake, Aarati Ranganathan, Jorge E. Cortés. (2010) Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 10:6, 443-451
CrossRef222
Friedrich Grimminger, Ralph T. Schermuly, Hossein A. Ghofrani. (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery 9:12, 956-970
CrossRef223
Maria Alessandra Santucci, Manuela Mancini, Valentina Corradi, Ilaria lacobucci, Giovanni Martinelli, Maurizio Botta, Silvia Schenone. (2010) New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells. Investigational New Drugs 28:6, 876-878
CrossRef224
M. Suttorp, F. Millot. (2010) Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation. Hematology 2010:1, 368-376
CrossRef225
Ram-Shankar Mani, Arul M. Chinnaiyan. (2010) Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nature Reviews Genetics 11:12, 819-829
CrossRef226
Youngil Koh, Dae-Young Kim, Sung-Hyo Park, Seung-Hyun Jung, Eunkyung Park, Hyeoung-Joon Kim, Sang Kyun Sohn, Young Don Joo, Seok Jin Kim, Ho-Jin Shin, Sung-Hyun Kim, Hong Suk Song, Jooseop Chung, Inho Kim, Sung-Soo Yoon, Byoung Kook Kim, Seung-Hun Shin, Yeun-Jun Chung, Seonyang Park. (2010) GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. Cancer Genetics and Cytogenetics 203:2, 215-221
CrossRef227
Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong, Andrew Spencer. (2010) Deactylase inhibition in myeloproliferative neoplasms. Investigational New Drugs 28:S1, 50-57
CrossRef228
J. P. Radich. (2010) Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go?. Hematology 2010:1, 122-128
CrossRef229
Devendra K. Hiwase, Timothy P. Hughes. 2010. Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. , 281-295.
CrossRef230
Andreas Hochhaus. 2010. Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia. , 271-280.
CrossRef231
Agnes S. M. Yong, Junia V. Melo. 2010. Pathophysiology of Chronic Myeloid Leukemia. , 259-270.
CrossRef232
A. Rizo, S. J. Horton, S. Olthof, B. Dontje, A. Ausema, R. van Os, V. van den Boom, E. Vellenga, G. de Haan, J. J. Schuringa. (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 116:22, 4621-4630
CrossRef233
Jin Zhang, Jing Zhou, Xiaomei Ren, Yanyan Diao, Honglin Li, Hualiang Jiang, Ke Ding, Duanqing Pei. (2010) A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. Investigational New Drugs
CrossRef234
T. P. Hughes, A. Hochhaus, S. Branford, M. C. Muller, J. S. Kaeda, L. Foroni, B. J. Druker, F. Guilhot, R. A. Larson, S. G. O'Brien, M. S. Rudoltz, M. Mone, E. Wehrle, V. Modur, J. M. Goldman, J. P. Radich, . (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:19, 3758-3765
CrossRef235
Jean-Claude Chomel, Nathalie Sorel, Marie-Laure Bonnet, Angelina Bertrand, Françoise Brizard, Lydia Roy, François Guilhot, Ali G. Turhan. (2010) Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leukemia & Lymphoma 51:11, 2103-2111
CrossRef236
Roberto Latagliata, Massimo Breccia, Ida Carmosino, Laura Cannella, Rosa De Cuia, Daniela Diverio, Anna Frustaci, Giuseppina Loglisci, Marco Mancini, Michelina Santopietro, Caterina Stefanizzi, Paola Volpicelli, Federico Vozella, Giuliana Alimena. (2010) “Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leukemia Research 34:11, 1472-1475
CrossRef237
Peter Valent. (2010) Exploring the curative potential of BCR–ABL1-targeting drugs for chronic myeloid leukaemia. The Lancet Oncology 11:11, 1010-1011
CrossRef238
Peter Rohon, Kimmo Porkka, Satu Mustjoki. (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. European Journal of Haematology 85:5, 387-398
CrossRef239
A. J. Olaharski, H. Bitter, N. Gonzaludo, R. Kondru, D. M. Goldstein, T. S. Zabka, H. Lin, T. Singer, K. Kolaja. (2010) Modeling Bone Marrow Toxicity Using Kinase Structural Motifs and the Inhibition Profiles of Small Molecular Kinase Inhibitors. Toxicological Sciences 118:1, 266-275
CrossRef240
François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet, Gabriel Etienne, Josy Reiffers, Philippe Rousselot. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology 11:11, 1029-1035
CrossRef241
Emma Scott, Elizabeth Hexner, Alexander Perl, Martin Carroll. (2010) Targeted Signal Transduction Therapies in Myeloid Malignancies. Current Oncology Reports 12:6, 358-365
CrossRef242
Dong Hwan Dennis Kim, Lakshmi Sriharsha, Chul Won Jung, Suzanne Kamel-Reid, Jerald P. Radich, Jeffrey H. Lipton. (2010) Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter?. American Journal of Hematology 85:11, 856-862
CrossRef243
Butrynski, James E., D'Adamo, David R., Hornick, Jason L., Dal Cin, Paola, Antonescu, Cristina R., Jhanwar, Suresh C., Ladanyi, Marc, Capelletti, Marzia, Rodig, Scott J., Ramaiya, Nikhil, Kwak, Eunice L., Clark, Jeffrey W., Wilner, Keith D., Christensen, James G., Jänne, Pasi A., Maki, Robert G., Demetri, George D., Shapiro, Geoffrey I., . (2010) Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine 363:18, 1727-1733
Full Text244
John M Goldman, Tariq I Mughal. 2010. Chronic Myeloid Leukaemia. , 483-502.
CrossRef245
D. W. Sherbenou, O. Hantschel, I. Kaupe, S. Willis, T. Bumm, L. P. Turaga, T. Lange, K.-H. Dao, R. D. Press, B. J. Druker, G. Superti-Furga, M. W. Deininger. (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116:17, 3278-3285
CrossRef246
J. R. Engler, A. Frede, V. Saunders, A. Zannettino, D. L. White, T. P. Hughes. (2010) The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 116:15, 2776-2778
CrossRef247
Irene Colavita, Nicola Esposito, Rosanna Martinelli, Francesca Catanzano, Junia V. Melo, Fabrizio Pane, Margherita Ruoppolo, Francesco Salvatore. (2010) Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1804:10, 1974-1987
CrossRef248
Paul La Rosée, Michael W. Deininger. (2010) Resistance to Imatinib: Mutations and Beyond. Seminars in Hematology 47:4, 335-343
CrossRef249
CIG Media Group. (2010) The Annual Meeting of the American Society of Clinical Oncology. Clinical Lymphoma, Myeloma & Leukemia 10:5, 323-330
CrossRef250
Xin An, Amit K. Tiwari, Yibo Sun, Pei-Rong Ding, Charles R. Ashby, Zhe-Sheng Chen. (2010) BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leukemia Research 34:10, 1255-1268
CrossRef251
Stefan Schmidt, Dominik Wolf, Josef Thaler, Sonja Burgstaller, Wolfgang Linkesch, Andreas Petzer, Michael Fridrik, Alois Lang, Hermine Agis, Peter Valent, Otto Krieger, Alois Walder, Markus Korger, Ernst Schlögl, Tamer Sliwa, Ernst Wöll, Manfred Mitterer, Wolfgang Eisterer, Michael Pober, Günther Gastl. (2010) First annual report of the Austrian CML registry. Wiener klinische Wochenschrift 122:19-20, 558-566
CrossRef252
Monica Bocchia, Marzia Defina, Lara Aprile, Micaela Ippoliti, Rosaria Crupi, Michela Rondoni, Alessandro Gozzetti, Francesco Lauria. (2010) Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination. Nature Reviews Clinical Oncology 7:10, 600-603
CrossRef253
Elias Jabbour, Hagop Kantarjian, Jorge Cortes. (2010) Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?. Seminars in Hematology 47:4, 344-353
CrossRef254
Ryuzo Ohno. (2010) Changing Paradigm of the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 5:4, 213-221
CrossRef255
Andrew L. Muranyi, Shoukat Dedhar, Donna E. Hogge. (2010) Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leukemia Research 34:10, 1358-1365
CrossRef256
Rishard Salie, Richard T. Silver. (2010) Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 10:5, 331-335
CrossRef257
David Marin. (2010) Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia. Seminars in Hematology 47:4, 312-318
CrossRef258
Carmen Fava, Giuseppe Saglio. (2010) Can We and Should We Improve on Frontline Imatinib Therapy for Chronic Myeloid Leukemia?. Seminars in Hematology 47:4, 319-326
CrossRef259
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2010) Third-Generation Tyrosine Kinase Inhibitors and Beyond. Seminars in Hematology 47:4, 371-380
CrossRef260
Bing Z. Carter, Duncan H. Mak, Jorge Cortes, Michael Andreeff. (2010) The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?. Seminars in Hematology 47:4, 362-370
CrossRef261
Yuichi Ishikawa, Hitoshi Kiyoi, Keisuke Watanabe, Koichi Miyamura, Yasuyuki Nakano, Kunio Kitamura, Akio Kohno, Isamu Sugiura, Toshiya Yokozawa, Akitoshi Hanamura, Kazuhito Yamamoto, Hiroatsu Iida, Nobuhiko Emi, Ritsuro Suzuki, Kazunori Ohnishi, Tomoki Naoe. (2010) Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study. Cancer Science 101:10, 2186-2192
CrossRef262
X. Jiang, D. Forrest, F. Nicolini, A. Turhan, J. Guilhot, C. Yip, T. Holyoake, H. Jorgensen, K. Lambie, K. M. Saw, E. Pang, R. Vukovic, P. Lehn, A. Ringrose, M. Yu, R. R. Brinkman, C. Smith, A. Eaves, C. Eaves. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 116:12, 2112-2121
CrossRef263
Meetu Agrawal, Ravin J. Garg, Hagop Kantarjian, Jorge Cortes. (2010) Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?. Current Oncology Reports 12:5, 302-313
CrossRef264
Qingfeng Du, Li Wang, Hongqian Zhu, Song Zhang, Lulu Xu, Weiyang Zheng, Xiaoli Liu. (2010) The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia. Medical Oncology 27:3, 673-679
CrossRef265
P. T. Elder, M. F. McMullin, M. W. Humphreys, J. Hamilton, P. McGrattan. (2010) The finding of a reciprocal whole-arm translocation t(X;12)(p10;p10) in association with atypical chronic myeloid leukaemia. Medical Oncology 27:3, 760-762
CrossRef266
Y Chen, C Peng, C Sullivan, D Li, S Li. (2010) Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 24:9, 1545-1554
CrossRef267
Armin Wolf, Philippe Couttet, Min Dong, Olivier Grenet, Marcia Heron, Ursula Junker, Ulrich Laengle, David Ledieu, Estelle Marrer, Anja Nussher, Elke Persohn, Francois Pognan, Gilles-Jacques Rivière, Daniel Robert Roth, Christian Trendelenburg, Jeffrey Tsao, Danielle Roman. (2010) Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leukemia Research 34:9, 1180-1188
CrossRef268
Dariusz Kata, Katarzyna Mrówka-Kata, Marek Seweryn, Jacek Pająk, Jacek Najda, Sławomira Kyrcz-Krzemień. (2010) Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature. Leukemia Research 34:9, e229-e231
CrossRef269
Kamakshi V Rao, Andrea Iannucci, Elias Jabbour. (2010) Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia. Pharmacotherapy 30:9, part 2, 77S-101S
CrossRef270
Giuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, Tamas Masszi, Ricardo Pasquini, Frederic Maloisel, Philipp Erben, Jorge Cortes, Ronald Paquette, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret. (2010) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. Cancer 116:16, 3852-3861
CrossRef271
A. Kuwabara, A. Babb, A. Ibrahim, D. Milojkovic, J. Apperley, M. Bua, A. Reid, L. Foroni, K. Rezvani, J. Goldman, D. Marin. (2010) Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116:6, 1014-1016
CrossRef272
A. Kreutzman, V. Juvonen, V. Kairisto, M. Ekblom, L. Stenke, R. Seggewiss, K. Porkka, S. Mustjoki. (2010) Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:5, 772-782
CrossRef273
Charles L. Wiggins, Linda C. Harlan, Harold E. Nelson, Jennifer L. Stevens, Cheryl L. Willman, Edward N. Libby, Robert A. Hromas. (2010) Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia. The American Journal of Medicine 123:8, 764.e1-764.e9
CrossRef274
Hyun Pyo Kim, Arthur E. Frankel, Donna E. Hogge. (2010) A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia Research 34:8, 1035-1042
CrossRef275
Qiu-bai Li, Chao Chen, Zhi-chao Chen, Hong-xiang Wang, Yan-lin Wu, Yong You, Ping Zou. (2010) Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacologica Sinica 31:8, 999-1004
CrossRef276
Edwin P. Alyea, Daniel J. DeAngelo, Jeffrey Moldrem, John M. Pagel, Donna Przepiorka, Michel Sadelin, James W. Young, Sergio Giralt, Michael Bishop, Stan Riddell. (2010) NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation 16:8, 1037-1069
CrossRef277
Arne Traulsen, Jorge M. Pacheco, David Dingli. (2010) Reproductive fitness advantage of BCR–ABL expressing leukemia cells. Cancer Letters 294:1, 43-48
CrossRef278
Haiyan Liu, Wenpin Xia, Yu Luo, Wei Lu. (2010) A novel synthesis of imatinib and its intermediates. Monatshefte für Chemie - Chemical Monthly 141:8, 907-911
CrossRef279
Jagabandhu Das, Joel C. Barrish. 2010. Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia. , 493-506.
CrossRef280
N. Carayol, E. Vakana, A. Sassano, S. Kaur, D. J. Goussetis, H. Glaser, B. J. Druker, N. J. Donato, J. K. Altman, S. Barr, L. C. Platanias. (2010) Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences 107:28, 12469-12474
CrossRef281
Danilo Perrotti, Catriona Jamieson, John Goldman, Tomasz Skorski. (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. Journal of Clinical Investigation 120:7, 2254-2264
CrossRef282
Vicent M. Guillem, Francisco Cervantes, Jesús Martínez, Alberto Alvarez-Larrán, María Collado, Mireia Camós, Anna Sureda, Margherita Maffioli, Isabel Marugán, Juan-Carlos Hernández-Boluda. (2010) XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. American Journal of Hematology 85:7, 482-486
CrossRef283
Wei-Gang Tong, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Gautam Borthakur, Jianqin Shan, Sherry Pierce, Mary Beth Rios, Jorge Cortes. (2010) Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116:13, 3152-3159
CrossRef284
Michael Jansen, Stephen Yip, David N Louis. (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. The Lancet Neurology 9:7, 717-726
CrossRef285
A. Hochhaus, F. Overkamp, T. Lange, A. Mohr, O. Ottmann, P. Coutre, T. Haferlach. (2010) Empfehlungen zur Verlaufskontrolle und Zweitlinientherapie bei der chronischen myeloischen Leukämie (CML). Der Onkologe 16:7, 701-708
CrossRef286
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Francis J. Giles. (2010) Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents. Leukemia & Lymphoma 51:8, 1399-1413
CrossRef287
, Youngil Koh, Inho Kim, Sung-Soo Yoon, Byoung Kook Kim, Dae-Young Kim, Je-Hwan Lee, Kyoo-Hyung Lee, Eunkyung Park, Hyeoung-Joon Kim, Sang Kyun Sohn, Young Don Joo, Seok Jin Kim, Jooseop Chung, Ho-Jin Shin, Sung-Hyun Kim, Chul Soo Kim, Hong Suk Song, Min Kyoung Kim, Myung Soo Hyun, Jin Seok Ahn, Chul Won Jung, Seonyang Park. (2010) Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Annals of Hematology 89:7, 725-731
CrossRef288
M Takeuchi, S Kimura, J Kuroda, E Ashihara, M Kawatani, H Osada, K Umezawa, E Yasui, M Imoto, T Tsuruo, A Yokota, R Tanaka, R Nagao, T Nakahata, Y Fujiyama, T Maekawa. (2010) Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death and Differentiation 17:7, 1211-1220
CrossRef289
Tadashi Nagai, Jin Takeuchi, Nobuaki Dobashi, Yuzuru Kanakura, Shuichi Taniguchi, Koji Ezaki, Chiaki Nakaseko, Akira Hiraoka, Masaya Okada, Yasushi Miyazaki, Toshiko Motoji, Masaaki Higashihara, Norifumi Tsukamoto, Hitoshi Kiyoi, Shinji Nakao, Katsuji Shinagawa, Ryuzo Ohno, Tomoki Naoe, Kazunori Ohnishi, Noriko Usui. (2010) Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan. International Journal of Hematology 92:1, 111-117
CrossRef290
Kazuhito Naka, Takayuki Hoshii, Atsushi Hirao. (2010) Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Science 101:7, 1577-1581
CrossRef291
Kantarjian, Hagop, Shah, Neil P., Hochhaus, Andreas, Cortes, Jorge, Shah, Sandip, Ayala, Manuel, Moiraghi, Beatriz, Shen, Zhixiang, Mayer, Jiri, Pasquini, Ricardo, Nakamae, Hirohisa, Huguet, Françoise, Boqué, Concepción, Chuah, Charles, Bleickardt, Eric, Bradley-Garelik, M. Brigid, Zhu, Chao, Szatrowski, Ted, Shapiro, David, Baccarani, Michele, . (2010) Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine 362:24, 2260-2270
Full Text292
Saglio, Giuseppe, Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Lobo, Clarisse, Pasquini, Ricardo, Clark, Richard E., Hochhaus, Andreas, Hughes, Timothy P., Gallagher, Neil, Hoenekopp, Albert, Dong, Mei, Haque, Ariful, Larson, Richard A., Kantarjian, Hagop M., . (2010) Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine 362:24, 2251-2259
Full Text293
Giuseppe Saglio, Michele Baccarani. (2010) First-line Therapy for Chronic Myeloid Leukemia: New Horizons and an Update. Clinical Lymphoma, Myeloma & Leukemia 10:3, 169-176
CrossRef294
Elie Traer, Michael W. Deininger. (2010) How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 10:0, S20-S26
CrossRef295
Pratibha Sharma, Sujata Mohanty, Vinod Kochupillai, Lalit Kumar. (2010) Mutations in ABL kinase domain are associated with inferior progression-free survival. Leukemia & Lymphoma 51:6, 1072-1078
CrossRef296
Andrea Davies, Alison K. Hayes, Katy Knight, Sarah J. Watmough, Munir Pirmohamed, Richard E. Clark. (2010) Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leukemia Research 34:6, 702-707
CrossRef297
Stewart Sell. (2010) On the Stem Cell Origin of Cancer. The American Journal of Pathology 176:6, 2584-2594
CrossRef298
Z. Aziz, J. Iqbal, K. Bano, M. Faisal, M. Akram. (2010) Sustained Superior Long-Term Outcomes and Cytogenetic Responses with Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukaemia: Report from a Developing Country. Japanese Journal of Clinical Oncology 40:6, 549-555
CrossRef299
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge E. Cortés. (2010) Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 10:0, S14-S19
CrossRef300
Jane F. Apperley. (2010) Hematology: Imatinib—should we have more of a good thing?. Nature Reviews Clinical Oncology 7:6, 303-304
CrossRef301
Yuzhen Liang, Yongrong Lai, Paul Schwarzenberger, Qiaochuan Li, Jie Ma, Jun Luo, Rongrong Liu, Lingling Shi, Jicheng Zhou, Zhigang Peng, Jie Yang, Donghong Deng, Yizhen Zhou. (2010) Targeted Agents for Chronic Myelogenous Leukemia: Will That Be the End of Allogeneic Bone Marrow Transplantation for That Disease?. Biology of Blood and Marrow Transplantation 16:6, 848-853
CrossRef302
Li-Yuan Bai, Jing-Ru Weng, Chen-Hsun Tsai, Aaron Sargeant, Cheng-Wen Lin, Chang-Fang Chiu. (2010) OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways. Leukemia Research 34:6, 816-820
CrossRef303
Xinan Yang, Yong Huang, Matthew Crowson, Jianrong Li, Michael L. Maitland, Yves A. Lussier. (2010) Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. Journal of Biomedical Informatics 43:3, 376-384
CrossRef304
Francisco J. Burguillo, Javier Martin, Inmaculada Barrera, William G. Bardsley. (2010) Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia. Computational Biology and Chemistry 34:3, 184-192
CrossRef305
F Stegmeier, M Warmuth, W R Sellers, M Dorsch. (2010) Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clinical Pharmacology & Therapeutics 87:5, 543-552
CrossRef306
M. Baccarani, M. Dreyling, . (2010) Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v165-v167
CrossRef307
Stéphane Bouchet, Bernard Royer, Chantal Le Guellec, Karine Titier. (2010) Niveau de preuve du suivi thérapeutique pharmacologique des inhibiteurs de tyrosine-kinase dans le traitement des leucémies myéloïdes chroniques. Thérapie 65:3, 213-218
CrossRef308
Sara M Tinsley. (2010) Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Journal of Clinical Nursing 19:9-10, 1207-1218
CrossRef309
Maria Demestre, Jan Herzberg, Nikola Holtkamp, Christian Hagel, David Reuss, Reinhard E. Friedrich, Lan Kluwe, Andreas Deimling, Victor-F. Mautner, Andreas Kurtz. (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. Journal of Neuro-Oncology 98:1, 11-19
CrossRef310
Matthew P. Wright, John D. Shepherd, Michael J. Barnett, Stephen H. Nantel, Heather J. Sutherland, Cynthia L. Toze, Donna E. Hogge, Thomas J. Nevill, Kevin W. Song, Yasser R. Abou Mourad, Sujaatha Narayanan, Maryse M. Power, Clayton A. Smith, Donna L. Forrest. (2010) Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 16:5, 639-646
CrossRef311
M. Schemionek, C. Elling, U. Steidl, N. Baumer, A. Hamilton, T. Spieker, J. R. Gothert, M. Stehling, A. Wagers, C. S. Huettner, D. G. Tenen, L. Tickenbrock, W. E. Berdel, H. Serve, T. L. Holyoake, C. Muller-Tidow, S. Koschmieder. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115:16, 3185-3195
CrossRef312
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef313
Jonathan M. Street, James W. Dear. (2010) The application of mass-spectrometry-based protein biomarker discovery to theragnostics. British Journal of Clinical Pharmacology 69:4, 367-378
CrossRef314
Otto Krieger. (2010) Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?. memo - Magazine of European Medical Oncology 3:1, 16-18
CrossRef315
Hatem A. Azim, Nicholas Pavlidis, Fedro A. Peccatori. (2010) Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. Cancer Treatment Reviews 36:2, 110-121
CrossRef316
Sabeeha Muneer, Sy Schlager. (2010) The 51st Annual Meeting of the American Society of Hematology. Clinical Lymphoma, Myeloma & Leukemia 10:2, 90-97
CrossRef317
Alain Li-Wan-Po, Peter Farndon, Charles Craddock, Michael Griffiths. (2010) Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. European Journal of Clinical Pharmacology 66:4, 369-374
CrossRef318
Ulrich Keller, Nikolas Von Bubnoff, Christian Peschel, Justus Duyster. (2010) Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine 14:4, 805-817
CrossRef319
Maxim Norkin, Charles A. Schiffer. (2010) Molecular Monitoring of BCR-ABL Transcripts in Patients With Chronic Myelogenous Leukemia: Is High Sensitivity of Clinical Value?. Current Hematologic Malignancy Reports 5:2, 88-94
CrossRef320
Meetu Agrawal, Ravin J. Garg, Jorge Cortes, Alfonso Quintás-Cardama. (2010) Tyrosine Kinase Inhibitors: The First Decade. Current Hematologic Malignancy Reports 5:2, 70-80
CrossRef321
J R Engler, A Frede, V A Saunders, A C W Zannettino, T P Hughes, D L White. (2010) Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia 24:4, 765-770
CrossRef322
Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Giovanni Martinelli, Michele Baccarani. (2010) Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’. Leukemia & Lymphoma 51:4, 583-591
CrossRef323
D K Hiwase, D L White, J A Powell, V A Saunders, S A Zrim, A K Frede, M A Guthridge, A F Lopez, R J D'Andrea, L B To, J V Melo, S Kumar, T P Hughes. (2010) Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24:4, 771-778
CrossRef324
George P Atkinson, Susan E Nozell, Etty (Tika) N Benveniste. (2010) NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics 10:4, 575-586
CrossRef325
N. B. Heaney, F. Pellicano, B. Zhang, L. Crawford, S. Chu, S. M. A. Kazmi, E. K. Allan, H. G. Jorgensen, A. E. Irvine, R. Bhatia, T. L. Holyoake. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 115:11, 2241-2250
CrossRef326
Thoas Fioretos, Bertil Johansson. 2010. Chronic Myeloid Leukemia. , 179-207.
CrossRef327
Hagop M. Kantarjian, Jorge Cortes, Paul La Rosée, Andreas Hochhaus. (2010) Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 116:6, 1419-1430
CrossRef328
E. A. Murphy, D. J. Shields, K. Stoletov, E. Dneprovskaia, M. McElroy, J. I. Greenberg, J. Lindquist, L. M. Acevedo, S. Anand, B. K. Majeti, I. Tsigelny, A. Saldanha, B. Walsh, R. M. Hoffman, M. Bouvet, R. L. Klemke, P. K. Vogt, L. Arnold, W. Wrasidlo, D. A. Cheresh. (2010) Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFR /B-RAF. Proceedings of the National Academy of Sciences 107:9, 4299-4304
CrossRef329
Vladimír Vonka. (2010) Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2:2, 227-241
CrossRef330
Paul La Rosée, Andreas Hochhaus. (2010) Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Current Opinion in Hematology 17:2, 91-96
CrossRef331
Momoko Suzuki, Akihiro Abe, Shizuka Imagama, Yuka Nomura, Ryohei Tanizaki, Yosuke Minami, Fumihiko Hayakawa, Yoshie Ito, Akira Katsumi, Kazuhito Yamamoto, Nobuhiko Emi, Hitoshi Kiyoi, Tomoki Naoe. (2010) BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. European Journal of Haematology 84:3, 229-238
CrossRef332
Doriano Fabbro, Paul W. Manley, Wolfgang Jahnke, Janis Liebetanz, Alexandra Szyttenholm, Gabriele Fendrich, Andre Strauss, Jianming Zhang, Nathanael S. Gray, Francisco Adrian, Markus Warmuth, Xavier Pelle, Robert Grotzfeld, Frederic Berst, Andreas Marzinzik, Sandra W. Cowan-Jacob, Pascal Furet, Jürgen Mestan. (2010) Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1804:3, 454-462
CrossRef333
Shigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, Yasushi Miyazaki, Hirokazu Okumura, Shin Matsuda, Tadashi Nagai, Yuji Kishimoto, Masaya Okada, Masatomo Takahashi, Hiroshi Handa, Jin Takeuchi, Shinichi Kageyama, Norio Asou, Fumiharu Yagasaki, Yasuhiro Maeda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno. (2010) Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. International Journal of Hematology 91:2, 276-283
CrossRef334
Daniel J. DeAngelo, Eyal C. Attar. (2010) Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leukemia & Lymphoma 51:3, 363-375
CrossRef335
D. Nowak, S. Ogawa, M. Muschen, M. Kato, N. Kawamata, A. Meixel, V. Nowak, H. S. Kim, S. Kang, R. Paquette, M.-S. Chang, N. H. Thoennissen, M. Mossner, W.-K. Hofmann, A. Kohlmann, T. Weiss, T. Haferlach, C. Haferlach, H. P. Koeffler. (2010) SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 115:5, 1049-1053
CrossRef336
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef337
Adriana Zámečníkova. (2010) Targeting the BCR–ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer. Expert Review of Hematology 3:1, 45-56
CrossRef338
Olivia Roth, Odile Spreux-Varoquaux, Stephane Bouchet, Philippe Rousselot, Sylvie Castaigne, Sophie Rigaudeau, Victoria Raggueneau, Patrice Therond, Philippe Devillier, Mathieu Molimard, Benjamin Maneglier. (2010) Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clinica Chimica Acta 411:3-4, 140-146
CrossRef339
Mohammad Azam, John T. Powers, William Einhorn, Wei-Sheng Huang, William C. Shakespeare, Xiaotian Zhu, David Dalgarno, Tim Clackson, Tomi K. Sawyer, George Q. Daley. (2010) AP24163 Inhibits the Gatekeeper Mutant of BCR-ABL and Suppresses In vitro Resistance. Chemical Biology & Drug Design 75:2, 223-227
CrossRef340
Hideki Muramatsu, Seiji Kojima, Ayami Yoshimi, Yoshiko Atsuta, Koji Kato, Yoshihisa Nagatoshi, Masami Inoue, Kazutoshi Koike, Takakazu Kawase, Masaki Ito, Hidemitsu Kurosawa, Akihiko Tanizawa, Chikako Tono, Kazuko Hamamoto, Noriko Hotta, Akihiro Watanabe, Yasuo Morishima, Keisei Kawa, Hiroyuki Shimada. (2010) Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program. Biology of Blood and Marrow Transplantation 16:2, 231-238
CrossRef341
Feng Chen, Lizhen Li, Daoxin Ma, Shuxin Yan, Jianzhi Sun, Maohong Zhang, Chunyan Ji, Ming Hou. (2010) Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment. Leukemia Research 34:2, e75-e77
CrossRef342
Mauricette Michallet, Michel Tulliez, Sélim Corm, Martine Gardembas, Françoise Huguet, Abderrahim Oukessou, Bruno Bregman, Anne Vekhoff, Kamel Ghomari, Nathalie Cambier, Agnès Guerci-Bresler. (2010) Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Current Medical Research and Opinion 26:2, 307-317
CrossRef343
Massimo Breccia, Giuliana Alimena. (2010) Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leukemia Research 34:2, 129-134
CrossRef344
Yuh Baba, Yasumasa Kato, Kaoru Ogawa. (2010) Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma. Cell Biology International 34:2, 171-175
CrossRef345
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef346
Angelo M. Carella, Anna Garuti, Gabriella Cirmena, Gioacchino Catania, Ilaria Rocco, Claudia Palermo, Gianmatteo Pica, Ivana Pierri, Maurizio Miglino, Alberto Ballestrero, Marco Gobbi, Franco Patrone. (2010) Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leukemia & Lymphoma 51:2, 275-278
CrossRef347
Hugues de Lavallade, Pascal Finetti, Nadine Carbuccia, Jamshid S. Khorashad, Aude Charbonnier, Letizia Foroni, Jane F. Apperley, Norbert Vey, François Bertucci, Daniel Birnbaum, Marie-Joëlle Mozziconacci. (2010) A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research 34:2, 254-257
CrossRef348
K. Vandyke, S. Fitter, A. L. Dewar, T. P. Hughes, A. C. W. Zannettino. (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115:4, 766-774
CrossRef349
Vinicio Navas, Daniel Simancas, Luis Ernesto González, Ricardo Hidalgo, Andrés Felipe Cardona, Arturo J Martí-Carvajal, Vinicio Navas. 2010. Imatinib for treating patients with chronic myelogeneous leukemia. .
CrossRef350
S. K. McWeeney, L. C. Pemberton, M. M. Loriaux, K. Vartanian, S. G. Willis, G. Yochum, B. Wilmot, Y. Turpaz, R. Pillai, B. J. Druker, J. L. Snead, M. MacPartlin, S. G. O'Brien, J. V. Melo, T. Lange, C. A. Harrington, M. W. N. Deininger. (2010) A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115:2, 315-325
CrossRef351
Hagop Kantarjian, Phillipp le Coutre, Jorge Cortes, Javier Pinilla-Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura, Oliver Ottmann. (2010) Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. CancerNA-NA
CrossRef352
Tadashi Ohtomo, Keisuke Miyazawa, Munekazu Naito, Shota Moriya, Masahiko Kuroda, Masahiro Itoh, Akio Tomoda. (2010) Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation. Biochemical and Biophysical Research Communications 391:1, 310-315
CrossRef353
Philipp Le Coutre, Petra Reinke, Ruth Neuhaus, Ralf Trappe, Frauke Ringel, Marc Lalancette, Philipp G. Hemmati, Bernd Dörken, Peter T. Daniel. (2010) BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients. European Journal of Haematology 84:1, 26-33
CrossRef354
Takeru Nambu, Norie Araki, Aiko Nakagawa, Akihiko Kuniyasu, Tatsuya Kawaguchi, Akinobu Hamada, Hideyuki Saito. (2010) Contribution of BCRâABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Science 101:1, 137-142
CrossRef355
A. Hochhaus, J. Duyster, T. Haferlach, T. Lange, A. Jakob, F. Overkamp, J. Hasford. (2010) Therapie der chronischen myeloischen Leukämie bei älteren Patienten. Der Onkologe 16:1, 67-72
CrossRef356
Makoto Saito, Masanobu Morioka. (2010) An elderly case of chronic myeloid leukemia in which BCR/ABL decreased or disappeared, following imatinib therapy after each episode of blast crisis. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 47:1, 86-91
CrossRef357
Mervat Mattar. (2010) Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. International Journal of Hematology 91:1, 104-106
CrossRef358
Mayu Isotani, Osamu Yamada, Joshua L. Lachowicz, Kyoichi Tamura, Hiroko Yagihara, Yasuhito Fujino, Kenichiro Ono, Tsukimi Washizu, Makoto Bonkobara. (2010) Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. British Journal of Haematology 148:1, 144-153
CrossRef359
Anne Hagemeijer, Carlos Graux. (2010) ABL1 rearrangements in T-Cell acute lymphoblastic leukemia. Genes, Chromosomes and CancerNA-NA
CrossRef360
Anat Gafter-Gvili, Ron Ram, Uzi Gafter, Ofer Shpilberg, Pia Raanani. (2010) Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature. Leukemia Research 34:1, 123-127
CrossRef361
Simone Fulda, Shazib Pervaiz. (2010) Apoptosis signaling in cancer stem cells. The International Journal of Biochemistry & Cell Biology 42:1, 31-38
CrossRef362
Hiroyuki Mano. (2010) Discovery of a Lung Cancer Oncogene, EML4-ALK, and Its Clinical Application. Haigan 50:7, 889-893
CrossRef363
Soley Bayraktar, Mark Goodman. (2010) Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review. Case Reports in Medicine 2010, 1-3
CrossRef364
David A. Irvine, Nicholas B. Heaney, Tessa L. Holyoake. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors – A synthesis of clinical and laboratory data. Blood Reviews 24:1, 1-9
CrossRef365
Shelagh M. Szabo, Adrian R. Levy, Catherine Davis, Tessa L. Holyoake, Jorge Cortes. (2010) A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health 13:1, 103-111
CrossRef366
Isamu Okamoto. (2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS Journal 277:2, 309-315
CrossRef367
Irena Cojbasic, Lana Macukanovic-Golubovic. (2010) Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience. Vojnosanitetski pregled 67:10, 802-806
CrossRef368
Irena Cojbasic, Lana Macukanovic-Golubovic. (2010) Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Srpski arhiv za celokupno lekarstvo 138:5-6, 305-308
CrossRef369
F. E. Nicolini, M. J. Mauro, G. Martinelli, D.-W. Kim, S. Soverini, M. C. Muller, A. Hochhaus, J. Cortes, C. Chuah, I. H. Dufva, J. F. Apperley, F. Yagasaki, J. D. Pearson, S. Peter, C. Sanz Rodriguez, C. Preudhomme, F. Giles, J. M. Goldman, W. Zhou. (2009) Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 114:26, 5271-5278
CrossRef370
Janusz M Sowadski, Robert K Suto. 2009. Protein Kinases: Signatures in Cancer. .
CrossRef371
N. Testoni, G. Marzocchi, S. Luatti, M. Amabile, C. Baldazzi, M. Stacchini, M. Nanni, G. Rege-Cambrin, E. Giugliano, U. Giussani, E. Abruzzese, S. Kerim, M. G. Grimoldi, A. Gozzetti, B. Crescenzi, C. Carcassi, P. Bernasconi, A. Cuneo, F. Albano, G. Fugazza, A. Zaccaria, G. Martinelli, F. Pane, G. Rosti, M. Baccarani. (2009) Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 114:24, 4939-4943
CrossRef372
G. Rosti, F. Palandri, F. Castagnetti, M. Breccia, L. Levato, G. Gugliotta, A. Capucci, M. Cedrone, C. Fava, T. Intermesoli, G. R. Cambrin, F. Stagno, M. Tiribelli, M. Amabile, S. Luatti, A. Poerio, S. Soverini, N. Testoni, G. Martinelli, G. Alimena, F. Pane, G. Saglio, M. Baccarani, . (2009) Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 114:24, 4933-4938
CrossRef373
M. C. Muller, J. E. Cortes, D.-W. Kim, B. J. Druker, P. Erben, R. Pasquini, S. Branford, T. P. Hughes, J. P. Radich, L. Ploughman, J. Mukhopadhyay, A. Hochhaus. (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:24, 4944-4953
CrossRef374
Jerald P. Radich. (2009) Molecular Monitoring of Patients With Chronic Myeloid Leukemia: Clinical Examples From a Non-Trial Setting. Clinical Lymphoma, Myeloma & Leukemia 9:0, S391-S394
CrossRef375
Michihiro Uchiyama, Takashi Ikeda. (2009) Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia. Leukemia Research 33:12, 1723-1724
CrossRef376
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2009) Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115:23, 5382-5393
CrossRef377
Carmen Fava, Jorge E. Cortés, Hagop Kantarjian, Elias Jabbour. (2009) Standard Management of Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S382-S390
CrossRef378
Emma Nicholson, Tessa Holyoake. (2009) The Chronic Myeloid Leukemia Stem Cell. Clinical Lymphoma, Myeloma & Leukemia 9:0, S376-S381
CrossRef379
Ulrike Bacher, Evgeny Klyuchnikov, Tatjana Zabelina, Hellmut Ottinger, Dietrich W. Beelen, Hubert Schrezenmeier, Gerhard Ehninger, Carlheinz Müller, Jürgen Berger, Meinolf Suttorp, Hans-Jochem Kolb, Nicolaus Kröger, Axel R. Zander. (2009) The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004. Annals of Hematology 88:12, 1237-1247
CrossRef380
Hermann Brenner, Adam Gondos, Dianne Pulte. (2009) Long-term survival in chronic myelocytic leukemia after a first primary malignancy. Leukemia Research 33:12, 1604-1608
CrossRef381
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef382
Ridvan Ali, Fahir Ozkalemkas, Vildan Ozkocaman, Tahsin Yakut, Hulya Ozturk Nazlioglu, Ferah Budak, Murat Pekgoz, Serhat Korkmaz, Mutlu Karkucak, Tulay Ozcelik, Ahmet Tunali. (2009) Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. International Journal of Clinical Oncology 14:6, 545-550
CrossRef383
Michael J. Burke, Jennifer Willert, Sunil Desai, Richard Kadota. (2009) The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. Pediatric Blood & Cancer 53:6, 992-995
CrossRef384
Alfonso Quintás-Cardama, Jorge E. Cortés. (2009) The Next Generation of Therapies for Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 9:0, S395-S403
CrossRef385
F. Pellicano, M. Copland, H. G. Jorgensen, J. Mountford, B. Leber, T. L. Holyoake. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C . Blood 114:19, 4186-4196
CrossRef386
Elena Campione, Laura Diluvio, Evelin J. Paternò, Dely Di Marcantonio, Arianna Francesconi, Alessandro Terrinoni, Augusto Orlandi, Sergio Chimenti. (2009) Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. Clinical Therapeutics 31:11, 2565-2569
CrossRef387
Thomas O'Hare, William C. Shakespeare, Xiaotian Zhu, Christopher A. Eide, Victor M. Rivera, Frank Wang, Lauren T. Adrian, Tianjun Zhou, Wei-Sheng Huang, Qihong Xu, Chester A. Metcalf, Jeffrey W. Tyner, Marc M. Loriaux, Amie S. Corbin, Scott Wardwell, Yaoyu Ning, Jeffrey A. Keats, Yihan Wang, Raji Sundaramoorthi, Mathew Thomas, Dong Zhou, Joseph Snodgrass, Lois Commodore, Tomi K. Sawyer, David C. Dalgarno, Michael W.N. Deininger, Brian J. Druker, Tim Clackson. (2009) AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer Cell 16:5, 401-412
CrossRef388
Moo-Kon Song, Joo-Seop Chung, Young-Mi Seol, Seong-Geun Kim, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho. (2009) Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?. Leukemia Research 33:11, 1459-1462
CrossRef389
Dominik Wolf, Holger Rumpold. (2009) A Benefit-Risk Assessment of Imatinib in Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumours. Drug Safety 32:11, 1001-1015
CrossRef390
Susannah Cooper, Francis J. Giles, Michael R. Savona. (2009) Overcoming resistance in chronic myelogenous leukemia. Leukemia & Lymphoma 50:11, 1785-1793
CrossRef391
M C Müller, N C P Cross, P Erben, T Schenk, B Hanfstein, T Ernst, R Hehlmann, S Branford, G Saglio, A Hochhaus. (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:11, 1957-1963
CrossRef392
A Davies, N E Jordanides, A Giannoudis, C M Lucas, S Hatziieremia, R J Harris, H G Jørgensen, T L Holyoake, M Pirmohamed, R E Clark, J C Mountford. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23:11, 1999-2006
CrossRef393
J. P. Radich. (2009) How I monitor residual disease in chronic myeloid leukemia. Blood 114:16, 3376-3381
CrossRef394
V. G. Oehler, K. Y. Yeung, Y. E. Choi, R. E. Bumgarner, A. E. Raftery, J. P. Radich. (2009) The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 114:15, 3292-3298
CrossRef395
F J Giles, M O'Dwyer, R Swords. (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 23:10, 1698-1707
CrossRef396
Brian J Druker. (2009) Perspectives on the development of imatinib and the future of cancer research. Nature Medicine 15:10, 1149-1152
CrossRef397
(2009) Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine. Internal Medicine Journal 39:10, 708-708
CrossRef398
J M Goldman, A R Green, T Holyoake, C Jamieson, R Mesa, T Mughal, F Pellicano, D Perrotti, R Skoda, A M Vannucchi. (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia 23:10, 1708-1715
CrossRef399
Jeroen J.W.M. Janssen, Henk W. Berendse, Gerrit-Jan Schuurhuis, Pauline A. Merle, Gert J. Ossenkoppele. (2009) A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American Journal of Hematology 84:10, 679-682
CrossRef400
Sukru Palanduz, Aysegul Bayrak, Sema Sirma, Burcak Vural, Kivanc Cefle, Ali Ucur, Sukru Ozturk, Mustafa Nuri Yenerel, Sevgi K. Besisik, Selim Yavuz, Reyhan Diz-Kucukkaya, Deniz Sargin, Meliha Nalcaci, Yuksel Pekcelen, Ugur Ozbek. (2009) Comparison of the Cytogenetic and Molecular Analyses in the Assessment of Imatinib Response in Chronic Myelocytic Leukemia. Genetic Testing and Molecular Biomarkers 13:5, 599-602
CrossRef401
Yanfeng Wang, Yen Lin Chia, Jerry Nedelman, Horst Schran, Francois-Xavier Mahon, Mathieu Molimard. (2009) A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times. Therapeutic Drug Monitoring 31:5, 579-584
CrossRef402
Koyu Hoshino, Alfonso Quintás-Cardama, Jerald Radich, Hongyui Dai, Hui Yang, Guillermo Garcia-Manero. (2009) Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leukemia Research 33:10, 1361-1366
CrossRef403
Lan-Ping Xu, Xiao-Hua Luo, Ying-Jun Chang, Dai-Hong Liu, Kai-Yan Liu, Yu-Hong Chen, Xiao-Jun Huang. (2009) High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Annals of Hematology 88:10, 1015-1024
CrossRef404
Rudin, Charles M., Hann, Christine L., Laterra, John, Yauch, Robert L., Callahan, Christopher A., Fu, Ling, Holcomb, Thomas, Stinson, Jeremy, Gould, Stephen E., Coleman, Barbara, LoRusso, Patricia M., Von Hoff, Daniel D., de Sauvage, Frederic J., Low, Jennifer A., . (2009) Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. New England Journal of Medicine 361:12, 1173-1178
Full Text405
Hagop Kantarjian, Ricardo Pasquini, Vincent Lévy, Saengsuree Jootar, Jerzy Holowiecki, Nelson Hamerschlak, Timothy Hughes, Eric Bleickardt, David Dejardin, Jorge Cortes, Neil P. Shah. (2009) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer 115:18, 4136-4147
CrossRef406
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef407
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2009) Imatinib and beyond—exploring the full potential of targeted therapy for CML. Nature Reviews Clinical Oncology 6:9, 535-543
CrossRef408
Juan Carlos Hernández-Boluda, Francisco Cervantes. (2009) Prognostic factors in chronic myeloid leukaemia. Best Practice & Research Clinical Haematology 22:3, 343-353
CrossRef409
Dongho Kim, Dong-Wook Kim, Byung-Sik Cho, Hyun-Gyung Goh, Soo-Hyun Kim, Wan-Seok Kim, Jeong Lee, Il-Young Kweon, Sa-Hee Park, Jeong Hyeok Yoon, Nam Doo Kim, Haarin Chun. (2009) Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. Leukemia Research 33:9, 1260-1265
CrossRef410
Richard E. Clark. (2009) Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. Leukemia Research 33:9, 1151-1155
CrossRef411
Lars Klemm, Cihangir Duy, Ilaria Iacobucci, Stefan Kuchen, Gregor von Levetzow, Niklas Feldhahn, Nadine Henke, Zhiyu Li, Thomas K. Hoffmann, Yong-mi Kim, Wolf-Karsten Hofmann, Hassan Jumaa, John Groffen, Nora Heisterkamp, Giovanni Martinelli, Michael R. Lieber, Rafael Casellas, Markus Müschen. (2009) The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia. Cancer Cell 16:3, 232-245
CrossRef412
Andreas Hochhaus, Thomas Schenk, Philipp Erben, Thomas Ernst, Paul La Rosée, Martin C. Müller. (2009) Cause and management of therapy resistance. Best Practice & Research Clinical Haematology 22:3, 367-379
CrossRef413
Alois Gratwohl, Dominik Heim. (2009) Current role of stem cell transplantation in chronic myeloid leukaemia. Best Practice & Research Clinical Haematology 22:3, 431-443
CrossRef414
Matthew P. Strout, David G. Schatz. (2009) Imatinib Resistance and Progression of CML to Blast Crisis: Somatic Hypermutation AIDing the Way. Cancer Cell 16:3, 174-176
CrossRef415
Alfonso Quintás-Cardama, Fabio Pires De Souza Santos, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Ahmed Awais, Gautam Borthakur, Jorge Cortes. (2009) Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115:17, 3935-3943
CrossRef416
Min Kyoung Kim, Hee Soon Cho, Young Kyung Bae, Kyung Hee Lee, Hae-Sun Chung, Soo-Youn Lee, Myung Soo Hyun. (2009) Nilotinib-induced hyperbilirubinemia: Is it a negligible adverse event?. Leukemia Research 33:9, e159-e161
CrossRef417
John M. Goldman. (2009) Treatment strategies for CML. Best Practice & Research Clinical Haematology 22:3, 303-313
CrossRef418
Nitin Jain, James M. Reuben, Hagop Kantarjian, Changping Li, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Theresa Ebarb, David A. Scheinberg, Jorge Cortes. (2009) Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease. Cancer 115:17, 3924-3934
CrossRef419
Tatiana Vidaurre, Julia Wilkerson, Richard Simon, Susan E. Bates, Tito Fojo. (2009) Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development. The Cancer Journal 15:5, 366-373
CrossRef420
Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Simona Soverini. (2009) Response definitions and European Leukemianet Management recommendations. Best Practice & Research Clinical Haematology 22:3, 331-341
CrossRef421
Michael J. Mauro, Michael W. Deininger. (2009) Management of Drug Toxicities in Chronic Myeloid Leukaemia. Best Practice & Research Clinical Haematology 22:3, 409-429
CrossRef422
Jane Apperley. (2009) CML in pregnancy and childhood. Best Practice & Research Clinical Haematology 22:3, 455-474
CrossRef423
F. Stagno, P. Vigneri, V. Del Fabro, S. Stella, M. Massimino, S. Berretta, A. Cupri, C. Consoli, L. Messina, E. Tirrò, A. Messina, F. Di Raimondo. (2009) Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR–ABL kinase domain. Leukemia Research 33:9, e157-e158
CrossRef424
Elias Jabbour, Jorge E. Cortés, Hagop Kantarjian. (2009) Second-line Therapy and Beyond Resistance for the Treatment of Patients With Chronic Myeloid Leukemia Post Imatinib Failure. Clinical Lymphoma, Myeloma & Leukemia 9:0, S272-S279
CrossRef425
Maren Rohrbacher, Joerg Hasford. (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Practice & Research Clinical Haematology 22:3, 295-302
CrossRef426
Timothy P. Hughes, Susan Branford. (2009) Measuring Minimal Residual Disease in Chronic Myeloid Leukemia: Fluorescence In Situ Hybridization and Polymerase Chain Reaction. Clinical Lymphoma, Myeloma & Leukemia 9:0, S266-S271
CrossRef427
Masayoshi Masuko, Tatsuo Furukawa, Takashi Abe, Reiko Wada, Soichi Maruyama, Toshiki Kitajima, Yasuhiko Shibasaki, Ken Toba, Masahiko Okada, Yoshifusa Aizawa. (2009) A chronic myeloid leukemia patient with atypical karyotype and BCR–ABL e13a3 transcript caused by complex chromosome rearrangement. International Journal of Hematology 90:2, 230-234
CrossRef428
Daniela Cilloni, Giuseppe Saglio. (2009) CML: a model for targeted therapy. Best Practice & Research Clinical Haematology 22:3, 285-294
CrossRef429
Alfonso Quintás-Cardama, Jorge Cortes. (2009) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?. Current Oncology Reports 11:5, 337-345
CrossRef430
Janet D. Rowley. (2009) Chromosomes in Leukemia and Beyond: From Irrelevant to Central Players. Annual Review of Genomics and Human Genetics 10:1, 1-18
CrossRef431
François-Xavier Mahon. (2009) Pharmacologic monitoring and determinants of intracytoplasmic drug levels. Best Practice & Research Clinical Haematology 22:3, 381-386
CrossRef432
A Hochhaus, M C Müller, J Radich, S Branford, H M Kantarjian, B Hanfstein, P Rousselot, D-W Kim, J H Lipton, E Bleickardt, A Lambert, T P Hughes. (2009) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23:9, 1628-1633
CrossRef433
M. S. Fernandes, M. M. Reddy, J. R. Gonneville, S. C. DeRoo, K. Podar, J. D. Griffin, D. M. Weinstock, M. Sattler. (2009) BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 114:9, 1813-1819
CrossRef434
Y. Shiotsu, H. Kiyoi, Y. Ishikawa, R. Tanizaki, M. Shimizu, H. Umehara, K. Ishii, Y. Mori, K. Ozeki, Y. Minami, A. Abe, H. Maeda, T. Akiyama, Y. Kanda, Y. Sato, S. Akinaga, T. Naoe. (2009) KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 114:8, 1607-1617
CrossRef435
Yesid Alvarado, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Gautam Borthakur, Jan Burger, William Wierda, Guillermo Garcia-Manero, Jianqin Shan, Jorge Cortes. (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115:16, 3709-3718
CrossRef436
M J Burke, B Trotz, X Luo, D J Weisdorf, K S Baker, J E Wagner, M R Verneris. (2009) Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplantation 44:3, 169-174
CrossRef437
Katherine I. Oravecz-Wilson, Steven T. Philips, Ömer H. Yilmaz, Heather M. Ames, Lina Li, Brendan D. Crawford, Alice M. Gauvin, Peter C. Lucas, Kajal Sitwala, James R. Downing, Sean J. Morrison, Theodora S. Ross. (2009) Persistence of Leukemia-Initiating Cells in a Conditional Knockin Model of an Imatinib-Responsive Myeloproliferative Disorder. Cancer Cell 16:2, 137-148
CrossRef438
M. Humbert, F. de Blay, G. Garcia, A. Prud’homme, C. Leroyer, A. Magnan, J.-M. Tunon-de-Lara, C. Pison, M. Aubier, D. Charpin, I. Vachier, A. Purohit, P. Gineste, T. Bader, A. Moussy, O. Hermine, P. Chanez. (2009) Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64:8, 1194-1201
CrossRef439
S Mustjoki, M Ekblom, T P Arstila, I Dybedal, P K Epling-Burnette, F Guilhot, H Hjorth-Hansen, M Höglund, P Kovanen, T Laurinolli, J Liesveld, R Paquette, J Pinilla-Ibarz, A Rauhala, N Shah, B Simonsson, M Sinisalo, J L Steegmann, L Stenke, K Porkka. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23:8, 1398-1405
CrossRef440
Dragan Jevremovic, David S. Viswanatha. (2009) Molecular Diagnosis of Hematopoietic and Lymphoid Neoplasms. Hematology/Oncology Clinics of North America 23:4, 903-933
CrossRef441
C. A. Maher, N. Palanisamy, J. C. Brenner, X. Cao, S. Kalyana-Sundaram, S. Luo, I. Khrebtukova, T. R. Barrette, C. Grasso, J. Yu, R. J. Lonigro, G. Schroth, C. Kumar-Sinha, A. M. Chinnaiyan. (2009) Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences 106:30, 12353-12358
CrossRef442
A. Olivieri, F. Locatelli, M. Zecca, A. Sanna, M. Cimminiello, R. Raimondi, G. Gini, N. Mordini, A. Balduzzi, P. Leoni, A. Gabrielli, A. Bacigalupo. (2009) Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114:3, 709-718
CrossRef443
Brigitte Kircher, Petra Schumacher, Andreas Petzer, Elisabeth Hoflehner, Margot Haun, Anna Maria Wolf, David Nachbaur, Günther Gastl. (2009) Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. European Journal of Haematology 83:1, 48-56
CrossRef444
Dunyaporn Trachootham, Jerome Alexandre, Peng Huang. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nature Reviews Drug Discovery 8:7, 579-591
CrossRef445
Alfonso Quintás-Cardama, Jorge E. Cortes, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, David Liu, Eric Bleickardt, Tai-Tsang Chen, Hagop M. Kantarjian. (2009) Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:13, 2912-2921
CrossRef446
Andrew J. Olaharski, Hirdesh Uppal, Matthew Cooper, Stefan Platz, Tanja S. Zabka, Kyle L. Kolaja. (2009) In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicology Letters 188:2, 98-103
CrossRef447
Flavia V. Castelino, Swati Bhattacharyya, John Varga. (2009) Tyrosine kinase inhibitors in systemic sclerosis: The case for imatinib. Current Rheumatology Reports 11:3, 161-163
CrossRef448
Massimo Breccia, Giuliana Alimena. (2009) The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. Leukemia Research 33:7, 871-875
CrossRef449
Mrinal M Patnaik, Ayalew Tefferi. (2009) Molecular diagnosis of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics 9:5, 481-492
CrossRef450
K Stegmaier. (2009) Genomic approaches to small molecule discovery. Leukemia 23:7, 1226-1235
CrossRef451
J W Tyner, M L Rutenberg-Schoenberg, H Erickson, S G Willis, T O'Hare, M W Deininger, B J Druker, M M Loriaux. (2009) Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia 23:7, 1345-1348
CrossRef452
A. Quintas-Cardama, H. Kantarjian, D. Jones, J. Shan, G. Borthakur, D. Thomas, S. Kornblau, S. O'Brien, J. Cortes. (2009) Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:25, 6315-6321
CrossRef453
Paul M. Hassoun, Luc Mouthon, Joan A. Barberà, Saadia Eddahibi, Sonia C. Flores, Friedrich Grimminger, Peter Lloyd Jones, Michael L. Maitland, Evangelos D. Michelakis, Nicholas W. Morrell, John H. Newman, Marlene Rabinovitch, Ralph Schermuly, Kurt R. Stenmark, Norbert F. Voelkel, Jason X.-J. Yuan, Marc Humbert. (2009) Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology 54:1, S10-S19
CrossRef454
Arinobu Tojo, Kensuke Usuki, Akio Urabe, Yasuhiro Maeda, Yukio Kobayashi, Itsuro Jinnai, Kazuma Ohyashiki, Miki Nishimura, Tatsuya Kawaguchi, Hideo Tanaka, Koichi Miyamura, Yasushi Miyazaki, Timothy Hughes, Susan Branford, Shinichiro Okamoto, Jun Ishikawa, Masaya Okada, Noriko Usui, Hiromi Tanii, Taro Amagasaki, Hiroko Natori, Tomoki Naoe. (2009) A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International Journal of Hematology 89:5, 679-688
CrossRef455
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Francis J. Giles. (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Targeted Oncology 4:2, 99-105
CrossRef456
Dong-Wook Kim, Yeow-Tee Goh, Hui-Hua Hsiao, Priscilla B. Caguioa, Dongho Kim, Wan-Seok Kim, Tapan Saikia, Shruti Agrawal, Amit Roy, David Dai, M. Brigid Bradley-Garelik, Jaydip Mukhopadhyay, Saengsuree Jootar. (2009) Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. International Journal of Hematology 89:5, 664-672
CrossRef457
Massimo Breccia, Anna Maria Frustaci, Laura Cannella, Simona Soverini, Caterina Stefanizzi, Vincenzo Federico, Sara Grammatico, Michelina Santopietro, Giuliana Alimena. (2009) Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. Cancer Chemotherapy and Pharmacology 64:1, 195-197
CrossRef458
F. Stagno, P. Vigneri, V. Del Fabro, S. Stella, M. Massimino, S. Berretta, A. Messina, F. Di Raimondo. (2009) Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase. Leukemia Research 33:6, e17
CrossRef459
Walid Rasheed, Brendan Flaim, John F. Seymour. (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia Research 33:6, 861-864
CrossRef460
M W Drummond, N Heaney, J Kaeda, F E Nicolini, R E Clark, G Wilson, P Shepherd, J Tighe, L McLintock, T Hughes, T L Holyoake. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 23:6, 1199-1201
CrossRef461
Federica Sorà, Silvia De Matteis, Jolanta Bajer, Francesco D’alò, Giuseppe Leone, Simona Sica. (2009) Persistence of molecular remission throughout pregnancy in CML after imatinib. Leukemia Research 33:6, e6-e7
CrossRef462
H.G. Sayer, D.W. Beelen. (2009) Hämatopoetische Stammzelltransplantation. Der Onkologe 15:6, 564-574
CrossRef463
A Hochhaus, S G O'Brien, F Guilhot, B J Druker, S Branford, L Foroni, J M Goldman, M C Müller, J P Radich, M Rudoltz, M Mone, I Gathmann, T P Hughes, R A Larson. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:6, 1054-1061
CrossRef464
Tatsuya Kawaguchi, Akinobu Hamada, Chie Hirayama, Reiko Nakashima, Takeru Nambu, Yuji Yamakawa, Hiroshi Watanabe, Kentaro Horikawa, Hiroaki Mitsuya, Hideyuki Saito. (2009) Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. International Journal of Hematology 89:5, 642-648
CrossRef465
Helena Linardou, Issa J. Dahabreh, Dimitrios Bafaloukos, Paris Kosmidis, Samuel Murray. (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology 6:6, 352-366
CrossRef466
J. W. Tyner, M. W. Deininger, M. M. Loriaux, B. H. Chang, J. R. Gotlib, S. G. Willis, H. Erickson, T. Kovacsovics, T. O'Hare, M. C. Heinrich, B. J. Druker. (2009) RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences 106:21, 8695-8700
CrossRef467
C. Fava, H. M. Kantarjian, E. Jabbour, S. O'Brien, N. Jain, M. B. Rios, G. Garcia-Manero, F. Ravandi, S. Verstovsek, G. Borthakur, J. Shan, J. Cortes. (2009) Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113:21, 5058-5063
CrossRef468
M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, L. Levato, G. Martinelli, A. Nagler, J. Lanng Nielsen, U. Ozbek, F. Palandri, F. Palmieri, F. Pane, G. Rege-Cambrin, D. Russo, G. Specchia, N. Testoni, O. Weiss-Bjerrum, G. Saglio, B. Simonsson. (2009) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113:19, 4497-4504
CrossRef469
Yu-Yan Hwang, Eric Tse, Jason C.C. So, Thomas S.K. Wan, Yok-Lam Kwong. (2009) Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. American Journal of Hematology 84:5, 302-305
CrossRef470
E K Allan, A Hamilton, S Hatziieremia, P Zhou, H G Jørgensen, P Vigneri, T L Holyoake. (2009) Nuclear entrapment of BCR–ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia 23:5, 1006-1008
CrossRef471
M. Baccarani, M. Dreyling, . (2009) Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv105-iv107
CrossRef472
Yanina Assef, Fernanda Rubio, Georgina Coló, Silvana del Mónaco, Mónica A. Costas, Basilio A. Kotsias. (2009) Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leukemia Research 33:5, 710-716
CrossRef473
Ming Hui Chen. (2009) Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Current Cardiology Reports 11:3, 167-174
CrossRef474
David Marin, Jamshid S. Khorashad, Letizia Foroni, Dragana Milojkovic, Richard Szydlo, Alistair G. Reid, Katayoun Rezvani, Marco Bua, John M. Goldman, Jane F. Apperley. (2009) Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. British Journal of Haematology 145:3, 373-375
CrossRef475
Massimo Breccia, Laura Cannella, Caterina Stefanizzi, Michelina Santopietro, Rosa De Cuia, Daniela Diverio, Giuliana Alimena. (2009) Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. Leukemia Research 33:5, 645-648
CrossRef476
Carolina Pavlovsky, Hagop Kantarjian, Jorge E. Cortes. (2009) First-line therapy for chronic myeloid leukemia: Past, present, and future. American Journal of Hematology 84:5, 287-293
CrossRef477
Srdan Verstovsek. (2009) Preclinical and clinical experience with dasatinib in philadelphia chromosome-negative leukemias and myeloid disorders. Leukemia Research 33:5, 617-623
CrossRef478
Yanmin Zhao, Lizhen Liu, Yingjia Wang, Gongqiang Wu, Xiaoyu Lai, Weijie Cao, Yi Luo, Yamin Tan, Jimin Shi, Wanzhuo Xie, Xiujin Ye, Zhen Cai, Maofang Lin, He Huang. (2009) Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. International Journal of Hematology 89:4, 445-451
CrossRef479
F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, G. Specchia, P. Galieni, F. Iuliano, F. Pane, G. Saglio, G. Alimena, G. Martinelli, M. Baccarani, G. Rosti, . (2009) Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 113:15, 3428-3434
CrossRef480
John Varga, Boris Pasche. (2009) Transforming growth factor β as a therapeutic target in systemic sclerosis. Nature Reviews Rheumatology 5:4, 200-206
CrossRef481
Mhairi Copland. (2009) Chronic myelogenous leukemia stem cells: What’s new?. Current Hematologic Malignancy Reports 4:2, 66-73
CrossRef482
Kamran Ghoreschi, Arian Laurence, John J O'Shea. (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nature Immunology 10:4, 356-360
CrossRef483
Eva Markert, Udo Siebolts, Margarete Odenthal, Karl-Anton Kreuzer, Claudia Wickenhauser. (2009) High diagnostic value of morphologic examination and molecular analysis of bone marrow biopsies in a case of BCR-ABL+ CML with clusters of blasts. International Journal of Hematology 89:3, 294-297
CrossRef484
Michele Baccarani. (2009) New Directions in the Treatment of Patients With Chronic Myeloid Leukemia: Introduction. Seminars in Hematology 46, S1-S4
CrossRef485
Matthew J Taylor, Paul A Scuffham. (2009) Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. Expert Review of Pharmacoeconomics & Outcomes Research 9:2, 117-121
CrossRef486
Jean-Claude Chomel, Nathalie Sorel, Marie-Laure Bonnet, Angelina Bertrand, Françoise Brizard, Pierre-Jean Saulnier, Lydia Roy, François Guilhot, Ali G. Turhan. (2009) Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML). Leukemia Research 33:4, 551-555
CrossRef487
Michael O'Dwyer, Ehab Atallah. (2009) Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era. Seminars in Hematology 46, S16-S21
CrossRef488
Michael J Eck, Paul W Manley. (2009) The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Current Opinion in Cell Biology 21:2, 288-295
CrossRef489
Juan-Carlos Hernández-Boluda, María Collado, Desamparados Roda, Paula Amat, Mar Tormo, Isabel Marugán. (2009) Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. Leukemia Research 33:4, 589-592
CrossRef490
Timothy Hughes, Andreas Hochhaus. (2009) Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy. Seminars in Hematology 46, S11-S15
CrossRef491
Michele Bianchini, Carlos De Brasi, Patricia Gargallo, Mariana Gonzalez, Raquel Bengió, Irene Larripa. (2009) Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. European Journal of Haematology 82:4, 292-300
CrossRef492
Hanna Jean Khoury, François Guilhot, Timothy P. Hughes, Dong-Wook Kim, Jorge E. Cortes. (2009) Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer 115:7, 1381-1394
CrossRef493
Richard M. Stone, Kathleen A. Donohue, Wendy Stock, Vera Hars, Charles A. Linker, Thomas Shea, Daniel J. DeAngelo, Guido Marcucci, Clara D. Bloomfield, Richard A. Larson, . (2009) A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemotherapy and Pharmacology 63:5, 859-864
CrossRef494
Shinichi Kobayashi, Fumihiko Kimura, Ayako Kobayashi, Ken Sato, Kazuo Motoyoshi. (2009) Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients. Annals of Hematology 88:4, 311-315
CrossRef495
Mari Sakai, Yasushi Miyazaki, Emi Matsuo, Yukiyoshi Moriuchi, Tomoko Hata, Takuya Fukushima, Yoshitaka Imaizumi, Daisuke Imanishi, Jun Taguchi, Masako Iwanaga, Hideki Tsushima, Yoriko Inoue, Yumi Takasaki, Takeshi Tsuchiya, Minori Komoda, Koji Ando, Kensuke Horio, Yuji Moriwaki, Shinya Tominaga, Hidehiro Itonaga, Kazuhiro Nagai, Kunihiro Tsukasaki, Chizuko Tsutsumi, Yasushi Sawayama, Reishi Yamasaki, Daisuke Ogawa, Yasuhisa Kawaguchi, Shuichi Ikeda, Shinichiro Yoshida, Yasuyuki Onimaru, Masayuki Tawara, Sunao Atogami, Satoshi Koida, Tatsuro Joh, Masaomi Yamamura, Yuji Matsuo, Hisashi Soda, Hiroaki Nonaka, Itsuro Jinnai, Kazutaka Kuriyama, Masao Tomonaga. (2009) Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. International Journal of Hematology 89:3, 319-325
CrossRef496
Hisashi Sakamaki, Ken-ichi Ishizawa, Masafumi Taniwaki, Shin Fujisawa, Yasuo Morishima, Kensei Tobinai, Masaya Okada, Kiyoshi Ando, Noriko Usui, Shuichi Miyawaki, Atae Utsunomiya, Nobuhiko Uoshima, Tadashi Nagai, Tomoki Naoe, Toshiko Motoji, Itsuro Jinnai, Mitsune Tanimoto, Yasushi Miyazaki, Kazunori Ohnishi, Shinsuke Iida, Shinichiro Okamoto, Taku Seriu, Ryuzo Ohno. (2009) Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 89:3, 332-341
CrossRef497
A Quintás-Cardama, J Cortes. (2009) Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT. Bone Marrow Transplantation 43:7, 579-581
CrossRef498
Yan-lin Wei, Lei Xu, Yun Liang, Xiao-hua Xu, Xiao-ying Zhao. (2009) Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. Acta Pharmacologica Sinica 30:4, 451-457
CrossRef499
Carmen Fava, Jorge Cortes. (2009) Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia. Seminars in Hematology 46, S5-S10
CrossRef500
A. E. Abrahamsson, I. Geron, J. Gotlib, K.-H. T. Dao, C. F. Barroga, I. G. Newton, F. J. Giles, J. Durocher, R. S. Creusot, M. Karimi, C. Jones, J. L. Zehnder, A. Keating, R. S. Negrin, I. L. Weissman, C. H. M. Jamieson. (2009) Glycogen synthase kinase 3 missplicing contributes to leukemia stem cell generation. Proceedings of the National Academy of Sciences 106:10, 3925-3929
CrossRef501
E. Jabbour, H. M. Kantarjian, D. Jones, J. Shan, S. O'Brien, N. Reddy, W. G. Wierda, S. Faderl, G. Garcia-Manero, S. Verstovsek, M. B. Rios, J. Cortes. (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113:10, 2154-2160
CrossRef502
Christopher A. Maher, Chandan Kumar-Sinha, Xuhong Cao, Shanker Kalyana-Sundaram, Bo Han, Xiaojun Jing, Lee Sam, Terrence Barrette, Nallasivam Palanisamy, Arul M. Chinnaiyan. (2009) Transcriptome sequencing to detect gene fusions in cancer. Nature 458:7234, 97-101
CrossRef503
David S Snyder. (2009) New approved dasatinib regimen available for clinical use. Expert Review of Anticancer Therapy 9:3, 285-292
CrossRef504
Michael G. Martin, John F. DiPersio, Geoffrey L. Uy. (2009) Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors. Oncology Reviews 3:1, 59-70
CrossRef505
Dae Young Zang, H Joachim Deeg. (2009) Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Current Opinion in Hematology 16:2, 140-146
CrossRef506
Seiichi Okabe, Tetsuzo Tauchi, Junko H Ohyashiki, Kazuma Ohyashiki. (2009) Mechanism of MK-0457 efficacy against BCR–ABL positive leukemia cells. Biochemical and Biophysical Research Communications 380:4, 775-779
CrossRef507
Toru Kiguchi, Tetsuzo Tauchi, Yoshikazu Ito, Keisuke Miyazawa, Yukihiko Kimura, Kazuma Ohyashiki. (2009) Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leukemia Research 33:3, 506-508
CrossRef508
Z. Li, G. Beutel, M. Rhein, J. Meyer, C. Koenecke, T. Neumann, M. Yang, J. Krauter, N. von Neuhoff, M. Heuser, H. Diedrich, G. Gohring, L. Wilkens, B. Schlegelberger, A. Ganser, C. Baum. (2009) High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood 113:9, 2028-2037
CrossRef509
Keisuke Ito, Rosa Bernardi, Pier Paolo Pandolfi. (2009) A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Current Opinion in Genetics & Development 19:1, 51-59
CrossRef510
JHM Schellens, JH Beijnen. (2009) Novel Clinical Trial Designs for Innovative Therapies. Clinical Pharmacology & Therapeutics 85:2, 212-216
CrossRef511
Donna L. Forrest, Shannon Trainor, Ryan R. Brinkman, Michael J. Barnett, Donna E. Hogge, Thomas J. Nevill, John D. Shepherd, Stephen H. Nantel, Cynthia L. Toze, Heather J. Sutherland, Kevin W. Song, Julye C. Lavoie, Maryse M. Power, Yasser Abou-Mourad, Clayton A. Smith. (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research 33:2, 271-275
CrossRef512
Stefan Schmidt, Dominik Wolf. (2009) Role of gene-expression profiling in chronic myeloid leukemia. Expert Review of Hematology 2:1, 93-103
CrossRef513
Vishnu Chintalgattu, Shalin S. Patel, Aarif Y. Khakoo. (2009) Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America 23:1, 97-107
CrossRef514
Kimmo Porkka, Satu Mustjoki, Bengt Simonsson. (2009) Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. Expert Review of Hematology 2:1, 81-91
CrossRef515
Alessandro M Vannucchi, Paola Guglielmelli, Lisa Pieri, Elisabetta Antonioli, Alberto Bosi. (2009) Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology 2:1, 41-55
CrossRef516
S. Haihua Chu, Donald Small. (2009) Mechanisms of resistance to FLT3 inhibitors. Drug Resistance Updates 12:1-2, 8-16
CrossRef517
Hagop M. Kantarjian, Richard A. Larson, Francois Guilhot, Stephen G. O'Brien, Manisha Mone, Marc Rudoltz, Tillmann Krahnke, Jorge Cortes, Brian J. Druker, . (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115:3, 551-560
CrossRef518
Giovanni Martinelli, Simona Soverini, Ilaria Iacobucci, Michele Baccarani. (2009) Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. Nature Clinical Practice Oncology 6:2, 68-69
CrossRef519
Ayalew Tefferi. (2009) Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Journal of Cellular and Molecular Medicine 13:2, 215-237
CrossRef520
J Dierov, P V Sanchez, B A Burke, H Padilla-Nash, M E Putt, T Ried, M Carroll. (2009) BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia 23:2, 279-286
CrossRef521
E. Jabbour, J. E. Cortes, H. M. Kantarjian. (2009) Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?. Mayo Clinic Proceedings 84:2, 161-169
CrossRef522
A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, R. Childs, A. J. Barrett. (2009) Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113:4, 875-882
CrossRef523
J. M. Goldman. (2009) Initial treatment for patients with CML. Hematology 2009:1, 453-460
CrossRef524
Monika Conchon, Sabri S. Sanabani, Israel Bendit, Carla Luana Dinardo, Lucia Dias, Dalton de Alencar Fischer Chamone, Pedro Enrique Dorlhiac-Llacer, Frederico Luiz Dulley. (2009) The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation 2009, 1-4
CrossRef525
Mike G. Martin, John F. Dipersio, Geoffrey L. Uy. (2009) Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia & Lymphoma 50:1, 14-23
CrossRef526
Fabio P. S. Santos, Farhad Ravandi. (2009) Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors. Leukemia & Lymphoma 50:s2, 16-26
CrossRef527
Satoko Oka, Kazuo Muroi, Masaki Mori, Tomohiro Matsuyama, Shin-Ichiro Fujiwara, Iekuni Oh, Kazuya Sato, Satoru Kikuchi, Masuzu Ueda, Masaki Toshima, Takahiro Suzuki, Katsutoshi Ozaki, Tadashi Nagai, Keiya Ozawa. (2009) Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes. Leukemia & Lymphoma 50:2, 290-293
CrossRef528
Manuela Mancini, Sara Petta, Giovanni Martinelli, Enza Barbieri, Maria A. Santucci. (2009) RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. Journal of Cellular Biochemistryn/a-n/a
CrossRef529
A. Frustaci, M. Breccia, L. Cannella, C. Stefanizzi, G. Alimena. (2009) Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature. Leukemia Research 33:1, 200-201
CrossRef530
Motohiro Tsuzuki, Youko Inaguma, Kousuke Handa, Akio Hasegawa, Yukiya Yamamoto, Masato Watanabe, Syuichi Mizuta, Fumio Maruyama, Masataka Okamoto, Nobuhiko Emi. (2009) Successful Pregnancy in a Patient with Chronic Myeloid Leukemia under Treatment with Imatinib. Internal Medicine 48:16, 1433-1435
CrossRef531
Jianming Zhang, Priscilla L. Yang, Nathanael S. Gray. (2009) Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer 9:1, 28-39
CrossRef532
Jonathan C. Trent, Shalin S. Patel, Jianhu Zhang, Dejka M. Araujo, Juan-Carlos Plana, Daniel J. Lenihan, Dominic Fan, Shreyaskumar R. Patel, Robert S. Benjamin, Aarif Y. Khakoo. (2009) Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. CancerNA-NA
CrossRef533
A Shimoni, M Leiba, M Schleuning, G Martineau, M Renaud, M Koren-Michowitz, E Ribakovski, P le Coutre, R Arnold, F Guilhot, A Nagler. (2009) Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia 23:1, 190-194
CrossRef534
Barbara Pieńkowska-Grela, Jolanta Rygier, Renata Woroniecka, Beata Grygalewicz, Anna Pastwińska, Paulina Krawczyk, Bernadeta Ceglerek, Ilona Seferyńska, Anna Sikorska, Lech Konopka. (2009) Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. Leukemia & Lymphoma 50:6, 952-965
CrossRef535
Lucy A. Godley. (2009) Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. Leukemia & Lymphoma 50:6, 871-872
CrossRef536
Masamitsu Yanada, Ryuzo Ohno, Tomoki Naoe. (2009) Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology 89:1, 3-13
CrossRef537
Wing Y. Au, Priscilla B. Caguioa, Charles Chuah, Szu Chun Hsu, Saengsuree Jootar, Dong-Wook Kim, Il-Young Kweon, William M. O’Neil, Tapan K. Saikia, Jianxiang Wang. (2009) Chronic myeloid leukemia in Asia. International Journal of Hematology 89:1, 14-23
CrossRef538
YaZhen Qin, Bin Jiang, Qian Jiang, Hao Jiang, JinLan Li, Yan Zhang, HongHu Zhu, LingDi Li, ShanShan Chen, YanRong Liu, XiaoJun Huang. (2009) Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Annals of Hematology 88:1, 37-41
CrossRef539
Ayalew Tefferi, Ross L. Levine, Hagop Kantarjian. (2009) Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation 15:1, 114-119
CrossRef540
Kazuhiko Kobayashi, Chiaki Takebayashi, Satoko Miyata, Hiroto Narimatsu, Masahiro Kami. (2009) Successful Delivery after Planned Discontinuation of Imatinib in a Patient with Chronic Myeloid Leukemia. Internal Medicine 48:5, 369-371
CrossRef541
Carlos A. Doti, Eduardo O. Bullorsky. (2009) Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors. Leukemia & Lymphoma 50:s2, 27-31
CrossRef542
Fabio Stagno, Paolo Vigneri, Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, Stefania Stella, Salvatore Berretta, Michele Massimino, Elena Tirrò, Angelo Messina, Francesco Di Raimondo. (2009) Uncommon long-term survival in a patient with chronic myeloid leukemia. Acta Oncologica 48:8, 1215-1216
CrossRef543
B. J. Druker. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:13, 4808-4817
CrossRef544
Connie J. Eaves. (2008) Cancer stem cells: Here, there, everywhere?. Nature 456:7222, 581-582
CrossRef545
J Cortes, D-W Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, S Corm, N Hamerschlak, J-L Tang, A Hochhaus, H J Khoury, T H Brümmendorf, M Michallet, G Rege-Cambrin, C Gambacorti-Passerini, J P Radich, T Ernst, C Zhu, J M A Van Tornout, M Talpaz. (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:12, 2176-2183
CrossRef546
Antonio Luiz Ribeiro, Milena Soriano Marcolino, Henrique N.S. Bittencourt, Márcia M. Barbosa, Maria do Carmo P. Nunes, Vitor Fonseca Xavier, Nelma C.D. Clementino. (2008) An evaluation of the cardiotoxicity of imatinib mesylate. Leukemia Research 32:12, 1809-1814
CrossRef547
Akihiro Abe, Yosuke Minami, Fumihiko Hayakawa, Kunio Kitamura, Yuka Nomura, Makoto Murata, Akira Katsumi, Hitoshi Kiyoi, Catriona H. M. Jamieson, Jean Y. J. Wang, Tomoki Naoe. (2008) Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. International Journal of Hematology 88:5, 471-475
CrossRef548
D. Marin, D. Milojkovic, E. Olavarria, J. S. Khorashad, H. de Lavallade, A. G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, J. Pavlu, M. Klammer, J. S. Kaeda, J. M. Goldman, J. F. Apperley. (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:12, 4437-4444
CrossRef549
Hiroyuki Mano. (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Science 99:12, 2349-2355
CrossRef550
S.W. Krause, A. Mackensen. (2008) Chronische myeloproliferative Erkrankungen. Der Internist 49:12, 1452-1457
CrossRef551
J. H. W. Distler, O. Distler. (2008) Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology 48:1, 2-4
CrossRef552
C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier, G. Bollag, S. Zhu, A. Weiss, J. A. Bluestone. (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proceedings of the National Academy of Sciences 105:48, 18895-18900
CrossRef553
Y. Minami, S. A. Stuart, T. Ikawa, Y. Jiang, A. Banno, I. C. Hunton, D. J. Young, T. Naoe, C. Murre, C. H. M. Jamieson, J. Y. J. Wang. (2008) BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proceedings of the National Academy of Sciences 105:46, 17967-17972
CrossRef554
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, J. Cooney, M. F. Leahy, P. Rowlings, J. Catalano, M. Hertzberg, R. Filshie, A. K. Mills, K. Fay, S. Durrant, H. Januszewicz, D. Joske, C. Underhill, S. Dunkley, K. Lynch, A. Grigg, . (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112:10, 3965-3973
CrossRef555
N C P Cross, G Q Daley, A R Green, T P Hughes, C Jamieson, P Manley, T Mughal, D Perrotti, J Radich, R Skoda, S Soverini, W Vainchenker, S Verstovsek, J-L Villeval, J M Goldman. (2008) BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 22:11, 1975-1989
CrossRef556
Francisco Cervantes. (2008) Leucemia mieloide crónica. Medicina Clínica 131:17, 658-659
CrossRef557
C H M Jamieson, C F Barroga, W P Vainchenker. (2008) Miscreant myeloproliferative disorder stem cells. Leukemia 22:11, 2011-2019
CrossRef558
Ashish Bajel, Saf Bassili, John F. Seymour. (2008) Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. Leukemia Research 32:11, 1789-1790
CrossRef559
Y Kamitsuji, J Kuroda, S Kimura, S Toyokuni, K Watanabe, E Ashihara, H Tanaka, Y Yui, M Watanabe, H Matsubara, Y Mizushima, Y Hiraumi, E Kawata, T Yoshikawa, T Maekawa, T Nakahata, S Adachi. (2008) The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death and Differentiation 15:11, 1712-1722
CrossRef560
H Bittencourt, V Funke, L Fogliatto, S Magalhães, D Setubal, A Paz, A V Macedo, J Ruiz, A P Azambuja, L Silla, N Clementino, R Pasquini. (2008) Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplantation 42:9, 597-600
CrossRef561
Masahiro Kizaki, Shinichiro Okamoto, Tetsuzo Tauchi, Hideo Tanaka, Mitsune Tanimoto, Koiti Inokuchi, Tohru Murayama, Yoshio Saburi, Masayuki Hino, Mitsuru Tsudo, Taizo Shimomura, Yasushi Isobe, . (2008) Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH. International Journal of Hematology 88:4, 409-417
CrossRef562
Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, Masahiro Kizaki, Koiti Inokuchi, Mariko Yabe, Kenji Yokoyama, Yoshikazu Ito, Yukihiko Kimura, Masaaki Higashihara, Masami Bessho, Kiyoshi Ando, Shigeru Chiba, Mineo Kurokawa, Kazuo Oshimi, Kazuo Dan, Kazuma Ohyashiki, Yasuo Ikeda, . (2008) Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?. American Journal of Hematology 83:11, 835-839
CrossRef563
Marta Albajar, Pilar Gutierrez, Carlos Richard, Manuel Rosa-Garrido, M. Teresa Gómez-Casares, Juan L. Steegmann, Javier León, M. Dolores Delgado. (2008) PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Letters 270:2, 328-336
CrossRef564
Anthony Jarkowski, Richard P Sweeney. (2008) Nilotinib: A New Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia. Pharmacotherapy 28:11, 1374-1382
CrossRef565
S. J. Lee, M. Kukreja, T. Wang, S. A. Giralt, J. Szer, M. Arora, A. E. Woolfrey, F. Cervantes, R. E. Champlin, R. P. Gale, J. Halter, A. Keating, D. I. Marks, P. L. McCarthy, E. Olavarria, E. A. Stadtmauer, M. Abecasis, V. Gupta, H. J. Khoury, B. George, G. A. Hale, J. L. Liesveld, D. A. Rizzieri, J. H. Antin, B. J. Bolwell, M. H. Carabasi, E. Copelan, O. Ilhan, M. R. Litzow, H. C. Schouten, A. R. Zander, M. M. Horowitz, R. T. Maziarz. (2008) Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112:8, 3500-3507
CrossRef566
A. Giannoudis, A. Davies, C. M. Lucas, R. J. Harris, M. Pirmohamed, R. E. Clark. (2008) Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112:8, 3348-3354
CrossRef567
Alfonso Quintás-Cardama, Jorge Cortes. (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncology 4:5, 611-621
CrossRef568
Theo Daniel Kim, Bernd Dörken, Philipp le Coutre. (2008) Nilotinib for the treatment of chronic myeloid leukemia. Expert Review of Hematology 1:1, 29-39
CrossRef569
Fei Fei, Yingzhe Yu, Anita Schmitt, Markus Thomas Rojewski, Baoan Chen, Jochen Greiner, Marlies Götz, Philippe Guillaume, Hartmut Döhner, Donald Bunjes, Michael Schmitt. (2008) Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Experimental Hematology 36:10, 1297-1308
CrossRef570
Dominik Heim, Alois Gratwohl. (2008) Role of allogeneic transplantation in chronic myeloid leukemia. Expert Review of Hematology 1:1, 41-50
CrossRef571
M Suttorp. (2008) Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplantation 42, S40-S46
CrossRef572
Juan Olazábal, Juan L. García, Norma C. Gutiérrez, Magdalena Sierra, Marcos González, Jesús M. Hernández. (2008) Transient t(11;17)(q14;q12) in patient with chronic myelogenous leukemia in complete molecular response. Cancer Genetics and Cytogenetics 186:2, 125-126
CrossRef573
C M Lucas, L Wang, G M Austin, K Knight, S J Watmough, K H Shwe, R Dasgupta, Nauman M Butt, D Galvani, C F Hoyle, J R C Seale, R E Clark. (2008) A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 22:10, 1963-1966
CrossRef574
Ahmed Aribi, Hagop Kantarjian, Charles Koller, Deborah Thomas, Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes. (2008) The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 113:6, 1338-1343
CrossRef575
Michael G. Kharas, Matthew R. Janes, Vanessa M. Scarfone, Michael B. Lilly, Zachary A. Knight, Kevan M. Shokat, David A. Fruman. (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. Journal of Clinical Investigation 118:9, 3038-3050
CrossRef576
Li Hui Xu, Henry Zheng, Daniel D Sedmak, Wolfgang Sadée. (2008) The re-emerging concept of personalized healthcare. Personalized Medicine 5:5, 457-469
CrossRef577
Yasuhito Nannya, Hiromitsu Yokota, Yumiko Sato, Go Yamamoto, Takashi Asai, Motoshi Ichikawa, Takuro Watanabe, Keiki Kumano, Akira Hangaishi, Tsuyoshi Takahashi, Shigeru Chiba, Yutaka Yatomi, Mineo Kurokawa. (2008) Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. International Journal of Hematology 88:2, 159-164
CrossRef578
Bhushan Nagar. (2008) Structural biology in the battle against BCR-Abl. Expert Opinion on Therapeutic Patents 18:9, 975-988
CrossRef579
J S Khorashad, V A De Melo, H Fiegler, G Gerrard, D Marin, J F Apperley, J M Goldman, L Foroni, A G Reid. (2008) Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. Leukemia 22:9, 1806-1807
CrossRef580
C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, B. Savoldo. (2008) Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112:5, 1876-1885
CrossRef581
K. M. Hoffmann, A. Moser, P. Lohse, A. Winkler, B. Binder, P. Sovinz, H. Lackner, W. Schwinger, M. Benesch, C. Urban. (2008) Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112:5, 1655-1657
CrossRef582
Ryuzo Ohno. (2008) Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Current Oncology Reports 10:5, 379-387
CrossRef583
Christine Dierks, Ronak Beigi, Gui-Rong Guo, Katja Zirlik, Mario R. Stegert, Paul Manley, Christopher Trussell, Annette Schmitt-Graeff, Klemens Landwerlin, Hendrik Veelken, Markus Warmuth. (2008) Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation. Cancer Cell 14:3, 238-249
CrossRef584
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef585
S. Dulucq, S. Bouchet, B. Turcq, E. Lippert, G. Etienne, J. Reiffers, M. Molimard, M. Krajinovic, F.-X. Mahon. (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:5, 2024-2027
CrossRef586
A S M Yong, K Keyvanfar, R Eniafe, B N Savani, K Rezvani, E M Sloand, J M Goldman, A J Barrett. (2008) Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22:9, 1721-1727
CrossRef587
Javier Pinilla-Ibarz, Celeste Bello. (2008) Modern approaches to treating chronic myelogenous leukemia. Current Oncology Reports 10:5, 365-371
CrossRef588
Ruriko Tanaka, Shinya Kimura. (2008) Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation. Expert Review of Anticancer Therapy 8:9, 1387-1398
CrossRef589
A. Tefferi. (2008) The Need for Adequate Coverage of Oncology Topics in Internal Medicine Journals. Mayo Clinic Proceedings 83:9, 980-982
CrossRef590
Dong Hwan (Dennis) Kim, Gizelle Popradi, Lakshmi Sriharsha, Suzanne Kamel-Reid, Hong Chang, Hans A. Messner, Jeffrey H. Lipton. (2008) No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR / ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 113:4, 772-781
CrossRef591
Fröhling, Stefan, Döhner, Hartmut, . (2008) Chromosomal Abnormalities in Cancer. New England Journal of Medicine 359:7, 722-734
Full Text592
A Koch, M Scherr, B Breyer, A Mancini, C Kardinal, K Battmer, M Eder, T Tamura. (2008) Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr–Abl transformed cells via the alteration of signaling complex and the receptor turnover. Oncogene 27:34, 4678-4689
CrossRef593
J M Goldman. (2008) Allogeneic stem cell transplantation for chronic myeloid leukemia–status in 2007. Bone Marrow Transplantation 42, S11-S13
CrossRef594
Edurne San José-Enériz, José Román-Gómez, Lucia Cordeu, Esteban Ballestar, Leire Gárate, Enrique J. Andreu, Isabel Isidro, Elizabeth Guruceaga, Antonio Jiménez-Velasco, Anabel Heiniger, Antonio Torres, Maria José Calasanz, Manel Esteller, Norma C. Gutiérrez, Angel Rubio, Ignacio Pérez-Roger, Xabier Agirre, Felipe Prósper. (2008) BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. British Journal of Haematology 142:4, 571-582
CrossRef595
T Nagamura-Inoue, S Kai, H Azuma, M Takanashi, K Isoyama, K Kato, S Takahashi, S Taniguchi, K Miyamura, K Aoki, M Hidaka, F Nagamura, A Tojo, X M Fang, S Kato. (2008) Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis. Bone Marrow Transplantation 42:4, 241-251
CrossRef596
C. S. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'Brien, F. Ravandi, J. Shan, J. Cortes. (2008) Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112:3, 516-518
CrossRef597
Alfonso Quintás-Cardama, Jorge Cortes. (2008) Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leukemia Research 32:8, 1313-1316
CrossRef598
Peter Valent. (2008) Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. British Journal of Haematology 142:3, 361-378
CrossRef599
Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, S. Grant. (2008) Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 112:3, 793-804
CrossRef600
S Fanta, M Sonnenberg, I Skorta, J Duyster, C Miething, W E Aulitzky, H van der Kuip. (2008) Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 27:31, 4380-4384
CrossRef601
Chandan Kumar-Sinha, Scott A. Tomlins, Arul M. Chinnaiyan. (2008) Recurrent gene fusions in prostate cancer. Nature Reviews Cancer 8:7, 497-511
CrossRef602
C Walz, N C P Cross, R A Van Etten, A Reiter. (2008) Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22:7, 1320-1334
CrossRef603
Jerzy Holowiecki, Sebastian Giebel, Jerzy Wojnar, Malgorzata Krawczyk-Kulis, Miroslaw Markiewicz, Aleksandra Holowiecka-Goral, Mathias Freund, Jochen Casper. (2008) Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British Journal of Haematology 142:2, 284-292
CrossRef604
F. Rollot-Trad, H. Lahjibi, C. Lazarovici, C. Bauer, O. Saint-Jean, M. Gisselbrecht. (2008) Hémopathies et sujets âgés : expérience d’un service de court séjour gériatrique. La Revue de Médecine Interne 29:7, 541-549
CrossRef605
Massimo Breccia, Fabiana Gentilini, Laura Cannella, Roberto Latagliata, Ida Carmosino, Annamaria Frustaci, Giuliana Alimena. (2008) Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leukemia Research 32:7, 1022-1025
CrossRef606
Elias Jabbour, Samih El Ahdab, Jorge Cortes, Hagop Kantarjian. (2008) Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion on Investigational Drugs 17:7, 1127-1136
CrossRef607
E. O. Hexner, C. Serdikoff, M. Jan, C. R. Swider, C. Robinson, S. Yang, T. Angeles, S. G. Emerson, M. Carroll, B. Ruggeri, P. Dobrzanski. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111:12, 5663-5671
CrossRef608
M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, A. Lopez, R. Islam, V. Valero, G. N. Hortobagyi. (2008) Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR- : clinical activity and biological correlations. Annals of Oncology 19:10, 1713-1719
CrossRef609
Swami Padmanabhan, Saritha Ravella, Tyler Curiel, Francis Giles. (2008) Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncology 4:3, 359-377
CrossRef610
Thomas O'Hare, Christopher A Eide, Michael W Deininger. (2008) New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opinion on Investigational Drugs 17:6, 865-878
CrossRef611
Simona Soverini, Giovanni Martinelli, Ilaria Iacobucci, Michele Baccarani. (2008) Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Review of Anticancer Therapy 8:6, 853-864
CrossRef612
Venkata Satya Suresh Attili, P.P. Bapsy, G. Anupama, D. Lokanatha. (2008) Irreversible sensorineural hearing loss due to Imatinib. Leukemia Research 32:6, 991-992
CrossRef613
Klaus Strebhardt, Axel Ullrich. (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer 8:6, 473-480
CrossRef614
A Quintás-Cardama, W Tong, T Manshouri, F Vega, P A Lennon, J Cools, D G Gilliland, F Lee, J Cortes, H Kantarjian, G Garcia-Manero. (2008) Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia 22:6, 1117-1124
CrossRef615
Ayalew Tefferi. (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. American Journal of Hematology 83:6, 491-497
CrossRef616
María J. Bueno, Ignacio Pérez de Castro, Marta Gómez de Cedrón, Javier Santos, George A. Calin, Juan C. Cigudosa, Carlo M. Croce, José Fernández-Piqueras, Marcos Malumbres. (2008) Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer Cell 13:6, 496-506
CrossRef617
A Hochhaus, M Baccarani, M Deininger, J F Apperley, J H Lipton, S L Goldberg, S Corm, N P Shah, F Cervantes, R T Silver, D Niederwieser, R M Stone, H Dombret, R A Larson, L Roy, T Hughes, M C Müller, R Ezzeddine, A M Countouriotis, H M Kantarjian. (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:6, 1200-1206
CrossRef618
Elias Jabbour, Jorge E. Cortes, Hagop M. Kantarjian. (2008) Molecular monitoring in chronic myeloid leukemia. Cancer 112:10, 2112-2118
CrossRef619
N. B. Heaney, M. Copland, K. Stewart, J. Godden, A. N. Parker, I. G. McQuaker, G. M. Smith, C. Crawley, P. Shepherd, T. L. Holyoake. (2008) Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood 111:10, 5252-5255
CrossRef620
Y Fukuyoshi, H Inoue, Y Kita, T Utsunomiya, T Ishida, M Mori. (2008) EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers. British Journal of Cancer 98:9, 1536-1539
CrossRef621
Michael Savona, Moshe Talpaz. (2008) Getting to the stem of chronic myeloid leukaemia. Nature Reviews Cancer 8:5, 341-350
CrossRef622
A Quintás-Cardama. (2008) Experimental non-ATP-competitive therapies for chronic myelogenous leukemia. Leukemia 22:5, 932-940
CrossRef623
Ernst Rechberger, Gerald Webersinke, Andreas L. Petzer. (2008) Chronische Myeloproliferative Erkrankungen (CMPE). Wiener klinische Wochenschrift Education 3:1, 59-77
CrossRef624
Neil P Shah. (2008) Bench to bedside: BRCA: From therapeutic target to therapeutic shield. Nature Medicine 14:5, 495-496
CrossRef625
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef626
Daniela S Krause, Richard A Van Etten. (2008) Bedside to bench: Interfering with leukemic stem cells. Nature Medicine 14:5, 494-495
CrossRef627
T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, R. D. Romero, S. K. Burley, M. W. Deininger. (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proceedings of the National Academy of Sciences 105:14, 5507-5512
CrossRef628
Joyce Ou, Jo-Anne Vergilio, Adam Bagg. (2008) Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. American Journal of Hematology 83:4, 296-302
CrossRef629
Mitch Raponi, Jean-Luc Harousseau. (2008) Development of genomic markers that predict response to molecularly targeted antileukemic therapy. Expert Opinion on Medical Diagnostics 2:4, 361-372
CrossRef630
James M. Allan. (2008) The Genetics of Cancer Survivorship. Hematology/Oncology Clinics of North America 22:2, 257-269
CrossRef631
J. Wu, F. Meng, H. Lu, L. Kong, W. Bornmann, Z. Peng, M. Talpaz, N. J. Donato. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111:7, 3821-3829
CrossRef632
Giuseppe Saglio, Stefano Ulisciani, Milena Fava, Enrico Gottardi, Daniela Cilloni. (2008) Molecular monitoring in patients with chronic myelogenous leukemia. Current Hematologic Malignancy Reports 3:2, 65-71
CrossRef633
Fabio Stagno, Stefania Stella, Salvatore Berretta, Michele Massimino, Agostino Antolino, Rosario Giustolisi, Angelo Messina, Francesco Di Raimondo, Paolo Vigneri. (2008) Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leukemia Research 32:4, 673-674
CrossRef634
Martin H Fenner, Gernot Beutel, Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, 511-522
CrossRef635
Ifat Geron, Annelie E. Abrahamsson, Charlene F. Barroga, Edward Kavalerchik, Jason Gotlib, John D. Hood, Jeffrey Durocher, Chi Ching Mak, Glenn Noronha, Richard M. Soll, Ayalew Tefferi, Ken Kaushansky, Catriona H.M. Jamieson. (2008) Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors. Cancer Cell 13:4, 321-330
CrossRef636
Alfonso Quintás-Cardama, Jorge Cortes. (2008) Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy 9:6, 1029-1037
CrossRef637
J. G. Harb, B. I. Chyla, C. S. Huettner. (2008) Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 111:7, 3760-3769
CrossRef638
Paul La Rosée, Andreas Hochhaus. (2008) Resistance to imatinib in chronic myelogenous leukemia: Mechanisms and clinical implications. Current Hematologic Malignancy Reports 3:2, 72-79
CrossRef639
Richard T Maziarz. (2008) Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?. Current Opinion in Hematology 15:2, 127-133
CrossRef640
José Baselga. (2008) Evolving options and future challenges for targeted therapies in ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 1-6
CrossRef641
C F Craddock. (2008) Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplantation 41:5, 415-423
CrossRef642
W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, P. Sonneveld, M. van Marwijk Kooy, S. Wittebol, R. Willemze, P. W. Wijermans, P. H. M. Westveer, H. B. Beverloo, P. Valk, B. Lowenberg, G. J. Ossenkoppele, J. J. Cornelissen. (2008) Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 111:5, 2581-2588
CrossRef643
Ayalew Tefferi, Hagop Kantarjian. (2008) Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia—Remarkable activity with room for improvement. American Journal of Hematology 83:3, 175-177
CrossRef644
Massimo Breccia, Laura Cannella, Enrico Montefusco, Annamaria Frustaci, Matteo Pacilli, Giuliana Alimena. (2008) Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. Leukemia Research 32:3, 519-520
CrossRef645
Georg Hess, Ralf G. Meyer, Brigitte Schuch, Katja Bechthold, Ilse El-Kholy, Christoph Huber. (2008) Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: A 5-year follow up. American Journal of Hematology 83:3, 178-184
CrossRef646
Jennifer Laudadio, Michael W.N. Deininger, Michael J. Mauro, Brian J. Druker, Richard D. Press. (2008) An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy. The Journal of Molecular Diagnostics 10:2, 177-180
CrossRef647
Tannu Sahay, Charles A Schiffer. (2008) Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. Current Opinion in Hematology 15:2, 134-139
CrossRef648
J. W. Tyner, D. K. Walters, S. G. Willis, M. Luttropp, J. Oost, M. Loriaux, H. Erickson, A. S. Corbin, T. O'Hare, M. C. Heinrich, M. W. Deininger, B. J. Druker. (2008) RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111:4, 2238-2245
CrossRef649
P. le Coutre, O. G. Ottmann, F. Giles, D.-W. Kim, J. Cortes, N. Gattermann, J. F. Apperley, R. A. Larson, E. Abruzzese, S. G. O'Brien, K. Kuliczkowski, A. Hochhaus, F.-X. Mahon, G. Saglio, M. Gobbi, Y.-L. Kwong, M. Baccarani, T. Hughes, G. Martinelli, J. P. Radich, M. Zheng, Y. Shou, H. Kantarjian. (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:4, 1834-1839
CrossRef650
Hagop Kantarjian, Susan O'Brien, Jianqin Shan, Xuelin Huang, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi-Kashani, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes. (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 112:4, 837-845
CrossRef651
H. Kantarjian, C. Schiffer, D. Jones, J. Cortes. (2008) Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111:4, 1774-1780
CrossRef652
H. Konig, T. L. Holyoake, R. Bhatia. (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111:4, 2329-2338
CrossRef653
Francis J. Giles, Daniel J. DeAngelo, Michele Baccarani, Michael Deininger, François Guilhot, Timothy Hughes, Michael Mauro, Jerald Radich, Oliver Ottmann, Jorge Cortes. (2008) Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. Seminars in Oncology 35, S1-S17
CrossRef654
Giuliana Alimena, Massimo Breccia, Luigia Luciano, Fabrizio Quarantelli, Daniela Diverio, Barbara Izzo, Biagio De Angelis, Marco Mancini, Roberto Latagliata, Ida Carmosino, Mauro Nanni, Marco Picardi, Bruno Rotoli, Franco Mandelli, Fabrizio Pane. (2008) Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. Leukemia Research 32:2, 255-261
CrossRef655
Marco Radi, Emmanuele Crespan, Giorgia Botta, Federico Falchi, Giovanni Maga, Fabrizio Manetti, Valentina Corradi, Manuela Mancini, Maria Alessandra Santucci, Silvia Schenone, Maurizio Botta. (2008) Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorganic & Medicinal Chemistry Letters 18:3, 1207-1211
CrossRef656
Jörg Distler, Oliver Distler. (2008) Novel Treatment Approaches to Fibrosis in Scleroderma. Rheumatic Disease Clinics of North America 34:1, 145-159
CrossRef657
L Wang, A Giannoudis, S Lane, P Williamson, M Pirmohamed, RE Clark. (2008) Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. Clinical Pharmacology & Therapeutics 83:2, 258-264
CrossRef658
M Bocchia, M Ippoliti, A Gozzetti, E Abruzzese, S Calabrese, M Amabile, M T Pirrotta, R Crupi, D Tozzuoli, M M Trawinska, M Defina, G Martinelli, F Lauria. (2008) CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 22:2, 426-428
CrossRef659
R. A. Larson, B. J. Druker, F. Guilhot, S. G. O'Brien, G. J. Riviere, T. Krahnke, I. Gathmann, Y. Wang, . (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:8, 4022-4028
CrossRef660
Shaoguang Li. (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leukemia & Lymphoma 49:1, 19-26
CrossRef661
Greg L Plosker, Dean M Robinson. (2008) Nilotinib. Drugs 68:4, 449-459
CrossRef662
Ingo Roeder, Ingmar Glauche. (2008) Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses. Journal of Molecular Medicine 86:1, 17-27
CrossRef663
Oliver Hantschel, Uwe Rix, Giulio Superti-Furga. (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia & Lymphoma 49:4, 615-619
CrossRef664
A Tefferi. (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:1, 3-13
CrossRef665
Enrico Orciuolo, Gabriele Buda, Sara Galimberti, Nadia Cecconi, Giulia Cervetti, Mario Petrini. (2008) Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. Leukemia Research 32:1, 188-190
CrossRef666
Gianantonio Rosti. (2008) Nilotinib. Drugs 68:4, 460-461
CrossRef667
Ayalew Tefferi. (2008) Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction. Acta Haematologica 119:4, 192-193
CrossRef668
Elias Jabbour, Jorge E Cortes, Hady Ghanem, Susan O’Brien, Hagop M Kantarjian. (2008) Targeted therapy in chronic myeloid leukemia. Expert Review of Anticancer Therapy 8:1, 99-110
CrossRef669
Shelby D Reed, Kevin J Anstrom, Yanhong Li, Kevin A Schulman. (2008) Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. PharmacoEconomics 26:5, 435-446
CrossRef670
Stefania Sarno, Lorenzo A. Pinna. (2008) Protein kinase CK2 as a druggable target. Molecular BioSystems 4:9, 889
CrossRef671
Yoshihiro Takihara. (2008) Role of Polycomb-group genes in sustaining activities of normal and malignant stem cells. International Journal of Hematology 87:1, 25-34
CrossRef672
A Pardanani. (2008) JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22:1, 23-30
CrossRef673
Stephen Yip, A. John Iafrate, David N. Louis. (2008) Molecular Diagnostic Testing in Malignant Gliomas. Journal of Neuropathology and Experimental Neurology 67:1, 1-15
CrossRef674
Peter Valent, Michael Deininger. (2008) Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leukemia & Lymphoma 49:4, 604-609
CrossRef675
Timothy Hughes. (2008) Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?. Nature Clinical Practice Oncology 5:1, 14-15
CrossRef676
Alfonso Quintás-Cardama, Jorge Cortes, Hagop Kantarjian. 2008. Biology of Chronic and Acute Myeloid Leukemia. , 371-383.
CrossRef677
C. H. Jamieson. (2008) Chronic Myeloid Leukemia Stem Cells. Hematology 2008:1, 436-442
CrossRef678
Dragana Milojkovic, Jane Apperley. (2008) State-of-the-art in the treatment of chronic myeloid leukaemia. Current Opinion in Oncology 20:1, 112-121
CrossRef679
Zainab Jagani, Amrik Singh, Roya Khosravi-Far. (2008) FoxO tumor suppressors and BCR–ABL-induced leukemia: A matter of evasion of apoptosis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:1, 63-84
CrossRef680
P.J. Loehrer. (2008) Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. Yearbook of Medicine 2008, 169-170
CrossRef681
Min-Koo CHOI, Im-Sook SONG. (2008) Organic Cation Transporters and their Pharmacokinetic and Pharmacodynamic Consequences. Drug Metabolism and Pharmacokinetics 23:4, 243-253
CrossRef682
Enrico Orciuolo, Gabriele Buda, Sara Galimberti, Giulia Cervetti, Nadia Cecconi, Federico Papineschi, Mario Petrini. (2008) Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. Leukemia Research 32:1, 190-191
CrossRef683
Gabriele Buda, Enrico Orciuolo, Sara Galimberti, Edoardo Benedetti, Francesco Caracciolo, Giulia Cervetti, Giovanni Carulli, Federico Papineschi, Mario Petrini. (2008) Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leukemia Research 32:1, 192-194
CrossRef684
Senthil Rajappa, Lalit Varadpande, Tara Paul, Rachel Jacob, Raghunadharao Digumarti. (2008) Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leukemia & Lymphoma 49:3, 554-558
CrossRef685
Ayalew Tefferi. (2008) Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leukemia & Lymphoma 49:12, 2231-2232
CrossRef686
Pierre-Jean Saulnier, Florence Dalbiès, Christian Berthou, François Guilhot, Nicolas Bourmeyster, Jean-claude Chomel, Ali Thuran. (2008) Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy. Leukemia & Lymphoma 49:4, 815-816
CrossRef687
Meir Wetzler, Kathleen A. Donohue, Olatoyosi M. Odenike, Eric J. Feldman, David D. Hurd, Richard M. Stone, Peter Westerfelt, Clara D. Bloomfield, Richard A. Larson. (2008) Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107. Leukemia & Lymphoma 49:7, 1274-1278
CrossRef688
Deborah L. White. (2008) Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?. Leukemia & Lymphoma 49:6, 1022-1023
CrossRef689
Shiro Akinaga, Yukimasa Shiotsu, Hitoshi Kiyoi, Tomoki Naoe. (2008) FLT3 tyrosine kinase inhibitors: current status and future perspectives for their development. Folia Pharmacologica Japonica 132:4, 217-220
CrossRef690
Sonali Smith. (2008) Anti-Bcl2 therapy in chronic myelogenous leukemia. Leukemia & Lymphoma 49:7, 1232-1233
CrossRef691
Hisashi Yamada. (2008) Current state and the future of molecular target drugs: lessons learned from the success of imatinib. Folia Pharmacologica Japonica 132:6, 339-342
CrossRef692
Massimo Breccia, Caterina Stefanizzi, Laura Cannella, Roberto Latagliata, Anna Maria Frustaci, Ida Carmosino, Michelina Santopietro, Giuliana Alimena. (2008) Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leukemia & Lymphoma 49:12, 2328-2332
CrossRef693
J. McLaughlin, D. Cheng, O. Singer, R. U. Lukacs, C. G. Radu, I. M. Verma, O. N. Witte. (2007) Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proceedings of the National Academy of Sciences 104:51, 20501-20506
CrossRef694
R. Hehlmann, A. Gratwohl, M. Pfirrmann, J. Hasford, A. Hochhaus, D. K. Hossfeld, H. Heimpel. (2007) Response: Drug treatment and allografting as first-line therapy in young patients with CML. Blood 110:13, 4618-4619
CrossRef695
E. Olavarria, S. Siddique, M. J. Griffiths, S. Avery, J. L. Byrne, K. P. Piper, A. L. Lennard, L. Pallan, J. M. Arrazi, J. B. Perz, D. O'Shea, J. M. Goldman, J. F. Apperley, C. F. Craddock. (2007) Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110:13, 4614-4617
CrossRef696
D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, T. Hughes. (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:12, 4064-4072
CrossRef697
Gabriele Buda, Enrico Orciuolo, Nadia Cecconi, Sara Galimberti, Giulia Cervetti, Mario Petrini. (2007) Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). Leukemia Research 31:12, 1765-1766
CrossRef698
Andreas Hochhaus. (2007) Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opinion on Pharmacotherapy 8:18, 3257-3264
CrossRef699
Junichi Sugita, Junji Tanaka, Mitsutoshi Kurosawa, Takashi Fukuhara, Satoshi Hashino, Etsuhiro Torimoto, Kazuki Koizumi, Nobuo Masauji, Susumu Nishimura, Kyuhei Koda, Masahiro Imamura, Masaharu Kasai. (2007) Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group. European Journal of Haematology 0:0, 071119190146003-???
CrossRef700
H. M. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. J. Ossenkoppele, F.-E. Nicolini, S. G. O'Brien, M. Litzow, R. Bhatia, F. Cervantes, A. Haque, Y. Shou, D. J. Resta, A. Weitzman, A. Hochhaus, P. le Coutre. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:10, 3540-3546
CrossRef701
A. D. Klion, J. Robyn, I. Maric, W. Fu, L. Schmid, S. Lemery, P. Noel, M. A. Law, M. Hartsell, C. Talar-Williams, M. P. Fay, C. E. Dunbar, T. B. Nutman. (2007) Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110:10, 3552-3556
CrossRef702
A. Chase, F. H. Grand, N. C. P. Cross. (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110:10, 3729-3734
CrossRef703
Elias Jabbour, Jorge Cortes, Francis Giles, Hagop Kantarjian. (2007) Current Perspectives on the Treatment of Patients with Chronic Myeloid Leukemia: An Individualized Approach to Treatment. The Cancer Journal 13:6, 357-365
CrossRef704
S Mustjoki, T Lundán, S Knuutila, K Porkka. (2007) Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia 21:11, 2363-2368
CrossRef705
Ying Chun Shen, Chiun Hsu, Ann Lii Cheng. (2007) Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology 2:4, 199-210
CrossRef706
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, T. Fischer, S. G. O'Brien, J. J. Reiffers, M. Mone, T. Krahnke, M. Talpaz, H. M. Kantarjian. (2007) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment. Blood 111:3, 1039-1043
CrossRef707
R. A. Mesa. (2007) Not too late for imatinib. Blood 111:3, 973-974
CrossRef708
Taira Maekawa, Eishi Ashihara, Shinya Kimura. (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. International Journal of Clinical Oncology 12:5, 327-340
CrossRef709
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef710
J. M. Goldman. (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:8, 2828-2837
CrossRef711
(2007) Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. New England Journal of Medicine 357:15, 1556-1558
Full Text712
Michael W. N. Deininger, Jorge Cortes, Ron Paquette, Byung Park, Andreas Hochhaus, Michele Baccarani, Richard Stone, Thomas Fischer, Hagop Kantarjian, Dietger Niederwieser, Carlo Gambacorti-Passerini, Charlene So, Insa Gathmann, John M. Goldman, Douglas Smith, Brian J. Druker, François Guilhot. (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110:7, 1509-1519
CrossRef713
Graeme AM Fraser, Ralph M Meyer. (2007) Biomarkers and the design of clinical trials in cancer. Biomarkers in Medicine 1:3, 387-397
CrossRef714
Jaehyuk Choi, Francine Foss. (2007) Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2:4, 272-277
CrossRef715
Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes. (2007) Flying under the radar: the new wave of BCR–ABL inhibitors. Nature Reviews Drug Discovery 6:10, 834-848
CrossRef716
K. J. Aichberger, S. Herndlhofer, H. Agis, W. R. Sperr, H. Esterbauer, W. Rabitsch, P. Knöbl, O. A. Haas, R. Thalhammer, I. Schwarzinger, C. Sillaber, U. Jäger, P. Valent. (2007) Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. European Journal of Clinical Investigation 37:10, 808-813
CrossRef717
Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman. (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:1, 95-103
CrossRef718
Pier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani. (2007) Imatinib mesylate in the treatment of hematologic malignancies. Expert Opinion on Biological Therapy 7:10, 1597-1611
CrossRef719
Enrico Orciuolo, Gabriele Buda, Sara Galimberti, Elisabetta Sordi, Giulia Cervetti, Mario Petrini. (2007) Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. Cancer Genetics and Cytogenetics 177:2, 166-167
CrossRef720
Guang-biao ZHOU, Guo LI, Sai-juan CHEN, Zhu CHEN. (2007) From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacologica Sinica 28:9, 1434-1449
CrossRef721
D P Hart, K S Peggs. (2007) Current Status of Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies. Clinical Pharmacology & Therapeutics 82:3, 325-329
CrossRef722
(2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:3, 148-155
CrossRef723
H. Kantarjian, J. Cortes. (2007) E08 New tyrosine kinase inhibitors in chronic myeloid leukemia (CML). Leukemia Research 31, S16-S19
CrossRef724
Tong Zhang, Sylvie Grenier, Bevoline Nwachukwu, Cuihong Wei, Jeffrey H. Lipton, Suzanne Kamel-Reid. (2007) Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring. The Journal of Molecular Diagnostics 9:4, 421-430
CrossRef725
F.-X. Mahon, S. Picard, G. Marit, P. Robinson, M. Molimard. (2007) Use of therapeutic drug monitoring in CML patients on imatinib. Blood 110:5, 1701-1701
CrossRef726
E. Atallah, J.-B. Durand, H. Kantarjian, J. Cortes. (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:4, 1233-1237
CrossRef727
Susan Branford, Timothy Hughes, Alvin Milner, Rachel Koelmeyer, Anthony Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Kevin Lynch, Kerry Taylor. (2007) Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α. Cancer 110:4, 801-808
CrossRef728
Edmundo A. Rodriguez-Frias, William M. Lee. (2007) Cancer Chemotherapy I: Hepatocellular Injury. Clinics in Liver Disease 11:3, 641-662
CrossRef729
Daniel W. Sherbenou, Brian J. Druker. (2007) Applying the discovery of the Philadelphia chromosome. Journal of Clinical Investigation 117:8, 2067-2074
CrossRef730
Henry H.Q. Heng. (2007) Cancer genome sequencing: The challenges ahead. BioEssays 29:8, 783-794
CrossRef731
Andreas Burchert. (2007) Roots of imatinib resistance: A question of self-renewal?. Drug Resistance Updates 10:4-5, 152-161
CrossRef732
Amy D. Klion. (2007) Approach to the Therapy of Hypereosinophilic Syndromes. Immunology and Allergy Clinics of North America 27:3, 551-560
CrossRef733
Michael J. Mauro. (2007) Mutational Analysis and Overcoming Imatinib Resistance in Chronic Myeloid Leukemia with Novel Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology 8:4, 287-295
CrossRef734
Aaron D. Schimmer. (2007) Novel Therapies Targeting the Apoptosis Pathway for the Treatment of Acute Myeloid Leukemia. Current Treatment Options in Oncology 8:4, 277-286
CrossRef735
S. Sell. (2007) Cancer and Stem Cell Signaling: A Guide to Preventive and Therapeutic Strategies for Cancer Stem Cells. Stem Cell Reviews 3:1, 1-6
CrossRef736
Schiffer, Charles A., . (2007) BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. New England Journal of Medicine 357:3, 258-265
Full Text737
Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Sergio Giralt, Borje S. Andersson, Francis Giles, Elizabeth Shpall, Partow Kebriaei, Richard Champlin, Marcos de Lima. (2007) Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Cancer 110:2, 340-344
CrossRef738
Jason Sakamoto, Ananth Annapragada, Paolo Decuzzi, Mauro Ferrari. (2007) Antibiological barrier nanovector technology for cancer applications. Expert Opinion on Drug Delivery 4:4, 359-369
CrossRef739
T Mughal, J Cortes, N C P Cross, N Donato, O Hantschel, E Jabbour, H Kantarjian, J V Melo, T Skorski, R T Silver, J M Goldman. (2007) Chronic myeloid leukemia – some topical issues. Leukemia 21:7, 1347-1352
CrossRef740
Rüdiger Hehlmann, Andreas Hochhaus, Michele Baccarani. (2007) Chronic myeloid leukaemia. The Lancet 370:9584, 342-350
CrossRef741
Shin Nakayama, Tokiko Nagamura-Inoue, Kazuaki Yokoyama, Nobuhiro Ohno, Jun Ooi, Satoshi Takahashi, Kaoru Uchimaru, Toru Iseki, Arinobu Tojo. (2007) Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. International Journal of Hematology 86:3, 208-211
CrossRef742
Junia V. Melo, David J. Barnes. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer 7:6, 441-453
CrossRef743
R. Hehlmann, U. Berger, M. Pfirrmann, H. Heimpel, A. Hochhaus, J. Hasford, H.-J. Kolb, T. Lahaye, O. Maywald, A. Reiter, D. K. Hossfeld, C. Huber, H. Loffler, H. Pralle, W. Queisser, A. Tobler, C. Nerl, M. Solenthaler, M. E. Goebeler, M. Griesshammer, T. Fischer, S. Kremers, H. Eimermacher, M. Pfreundschuh, W.-D. Hirschmann, K. Lechner, B. Wassmann, C. Falge, H. H. Kirchner, A. Gratwohl, . (2007) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109:11, 4686-4692
CrossRef744
F. Guilhot. (2007) No more transplantation in CML?. Blood 109:11, 4592-4592
CrossRef745
Elias Jabbour, Jorge E. Cortes, Francis J. Giles, Susan O'Brien, Hagop M. Kantarjian. (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109:11, 2171-2181
CrossRef746
Nina Anensen, Anne M Øyan, Sjur Huseby, Karl-Henning Kalland, Øystein Bruserud, Bjørn T Gjertsen. (2007) Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy 7:5, 741-751
CrossRef747
Robert A. Wolff. (2007) Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy. The Cancer Journal 13:3, 175-184
CrossRef748
Ronan Swords, Yesid Alvarado, Jorge Cortes, Francis J. Giles. (2007) Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Current Hematologic Malignancy Reports 2:2, 83-88
CrossRef749
Karthik Ramasamy, Janet Hayden, ZiYi Lim, Ghulam J. Mufti, Aloysius Y. L. Ho. (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. British Journal of Haematology 137:4, 374-375
CrossRef750
(2007) Imatinib in Chronic Myeloid Leukemia. New England Journal of Medicine 356:17, 1780-1780
Full Text751
Ricardo T Paniagua, William H Robinson. (2007) Imatinib for the treatment of rheumatic diseases. Nature Clinical Practice Rheumatology 3:4, 190-191
CrossRef752
Michael W.N. Deininger. (2007) Optimizing therapy of chronic myeloid leukemia. Experimental Hematology 35:4, 144-154
CrossRef753
Giovanni Martinelli, Michela Rondoni, Emanuela Ottaviani, Stefania Paolini, Michele Baccarani. (2007) Hypereosinophilic Syndrome and Molecularly Targeted Therapy. Seminars in Hematology 44, S4-S16
CrossRef754
Daniel J. DeAngelo. (2007) Role of Imatinib-Sensitive Tyrosine Kinases in the Pathogenesis of Chronic Myeloproliferative Disorders. Seminars in Hematology 44, S17-S30
CrossRef755
Nicholas Dainiak. (2007) Recent advances in radiation effects, hematopoiesis, and malignancy. Experimental Hematology 35:4, 1-4
CrossRef756
Giovanni Martinelli. (2007) Atypical Chronic Myeloproliferative Disorders: Genes and Imatinib-Sensitive Targets. Seminars in Hematology 44, S1-S3
CrossRef757
(2007) Another Look at Imatinib Mesylate. New England Journal of Medicine 356:11, 1183-1183
Full Text758
G. Martineau, L. Roy, F. Guilhot. (2007) Thérapeutiques ciblées et personnes âgées: l’exemple de la leucémie myéloïde chronique. Oncologie 9:3, 219-225
CrossRef759
C. Fozza, R.M. Szydlo, M.M. Abdel-Rehim, E. Nadal, J.M. Goldman, J.F. Apperley, F. Dazzi. (2007) Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. British Journal of Haematology 136:6, 833-836
CrossRef760
Angelo Michele Carella. (2007) Imatinib mesylate, a selective inhibitor of BCR–ABL, in chronic myeloid leukemia. Expert Review of Anticancer Therapy 7:3, 249-251
CrossRef761
Andreas Hochhaus, Philipp Erben, Thomas Ernst, Martin C. Mueller. (2007) Resistance to Targeted Therapy in Chronic Myelogenous Leukemia. Seminars in Hematology 44, 15-24
CrossRef762
Alan Hatfield, Samantha Owen, Paul Richard Pilot. (2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine 13:1, 13-13
CrossRef763
Lisa Kujawski, Moshe Talpaz. (2007) Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leukemia & Lymphoma 48:12, 2310-2322
CrossRef764
Lucio Luzzatto. (2007) David Galton and the evolution of somatic cell populations. Leukemia & Lymphoma 48:12, 2288-2289
CrossRef765
Kazunori OHNISHI. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 387-391
CrossRef766
N. P. Shah. (2007) Medical Management of CML. Hematology 2007:1, 371-375
CrossRef767
John Goldman. (2007) Chronic myeloid leukemia – Therapy in the 20 th and 21 st centuries. Leukemia & Lymphoma 48:12, 2287-2288
CrossRef768
Rolf Linke, Wolfram Dempke. (2007) Management of Imatinib-Resistant CML Patients. Onkologie 30:11, 574-580
CrossRef769
Theodore Darkow, Henry J Henk, Simu K Thomas, Weiwei Feng, Jean-Francois Baladi, George A Goldberg, Alan Hatfield, Jorge Cortes. (2007) Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs. PharmacoEconomics 25:6, 481-496
CrossRef770
Ricardo H. Alvarez, Hagop Kantarjian, Jorge E. Cortes. (2007) The Biology of Chronic Myelogenous Leukemia: Implications for Imatinib Therapy. Seminars in Hematology 44, 4-14
CrossRef771
Elias Jabbour, Hagop Kantarjian. (2007) Introduction. Seminars in Hematology 44, 1-3
CrossRef
- Letters
